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Abstract 
 
The enzyme 11β-Hydroxysteroid Dehydrogenase 1 (11β-HSD1) catalyses the 
intracellular biosynthesis of the active glucocorticoid cortisol. Tissue specific 
dysregulation of the enzyme has been implicated in the development of metabolic 
syndrome and other associated diseases. Experiments with transgenic mice and 
prototype inhibitors show that inhibition of 11β-HSD1 in visceral adipose tissue and 
liver leads to a resistance of diet-induced hyperglycemia and a favourable lipid and 
lipoprotein profile as compared to controls. 11β-HSD1 inhibition has thus been 
proposed as an effective strategy to decrease intracellular glucocorticoid levels 
without affecting circulating glucocorticoid levels that are essential for stress 
responses. The clinical development of selective and potent drugs has therefore 
become a priority. In this research, a process of virtual screening employing the 
novel algorithm UFSRAT (Ultra Fast Shape Recognition with Atom Types) was used 
to discover compounds which had specific physicochemical and spatial atomic 
parameters deemed essential for inhibition of 11β-HSD1. The top scoring compounds 
were assayed for inhibitory activity against recombinant human and mouse enzyme, 
using a fluorescence spectroscopy approach. In addition, HEK-293 cell based assays 
with either human, mouse or rat enzymes were carried out using a scintillation 
proximity assay (SPA). The most potent compound competitively inhibited human 
11β-HSD1 with a Kiapp value of 51 nM. Recombinant mouse and human enzyme were 
expressed, purified and characterised and used in a series of ligand binding assays. 
Further to this, an X-ray crystal structure of mouse 11β-HSD1 in complex with a tight 
binding inhibitor – carbenoxolone was solved. 
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CHAPTER 1: 
11-β HYDROXYSTEROID DEHYDROGENASE TYPE 1 
 
1. INTRODUCTION 
Glucocorticoids are an important class of steroid hormones essential to life. They 
play a large role in glucose homeostasis, maintenance of blood pressure and most 
importantly, regulation of stress and inflammatory responses (Tomlinson et al. 
2004). The major active glucocorticoid found in higher organisms is cortisol with 
the inactive form known as cortisone. 
The enzyme 11β-Hydroxysteroid Dehydrogenase type 1 (11β-HSD1, E.C. 1.1.1.146) 
interconverts the steroid hormone cortisone to cortisol in humans, or 
dehydrocorticosterone and corticosterone in rodents, birds and amphibians. It is a co-
factor dependent, bidirectional enzyme that is thought to act primarily as a reductase 
in vivo (i.e. cortisone → cortisol with the concurrent oxidation of NADPH to NADP) 
(Bujalska et al. 1997). However, the bidirectionality is heavily influenced by the 
surrounding cellular milieu. The basic reaction is shown below, in figure 1.1. 
 
 
Figure 1.1: Reaction catalysed by 11β-HSD1: the dehydrogenase reaction is the forward 
reaction (the reductase reaction is the reverse) where the substrate cortisol is oxidised by 
11β-HSD1 and thus transfers one proton and a pair of electrons to an acceptor; the co-factor 
NADP+.  
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The enzyme is expressed and active in skeletal muscle, white adipose tissue and the 
liver. It follows then that the principal role of 11β-HSD1 is to regulate cortisol levels 
in these key tissues; this regulation prevents cortisol binding to the intrinsically non-
selective mineralocorticoid receptor (MR), allowing binding to its endogenous 
glucocorticoid receptor (GR). 
Functionally, the enzyme 11β-HSD1 may be divided into several important regions. 
This is depicted below in figure 1.2. At the N-terminus is found the transmembrane 
domain, allowing the enzyme to attach itself to the lumen of the endoplasmic 
reticulum (ER) consisting of residues 1 – 23 in humans. Adjacent to this is the 
dinucleotide binding domain, characterized by a Rossman fold (co-factor binding 
domain in figure 1.2). This is followed by a cluster of catalytic residues which 
constitute the active site. Finally, the C-terminal domain, which plays a key role in 
dimerisation of the enzyme.  
Each of these regions are discussed in further detail in this chapter. Structurally, it is 






Figure 1.2: The functional regions of 11β-HSD1: (from left to right) the transmembrane 
domain (residues 1 – 23), the nucleotide binding domain, the catalytic site (showing the 
catalytic triad of residues) and the C-terminal domain which plays an important role in 
oligomerisation of the enzyme. 
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1.1 Steroid Hormones 
There are five classes of steroid hormones, the precursor for all of which is 
cholesterol. Briefly, these five classes are: Glucocortocoids (e.g. cortisone), 
mineralocorticoids (e.g. aldosterone) and the sex steroids – the androgens, 
oestrogens and progestins. These are depicted below in figure 1.3. Synthesis and 
secretion of the glucocorticoids and mineralocorticoids occurs from the adrenal 
cortex, from where they are transported humorally to their target sites. As the 
steroids are hydrophobic in nature they must be transported in complex with a 




Figure 1.3: A: the basic structure of steroids: cyclopentanoperhydrophenanthrene, showing 
the ring nomenclature. B: the molecular structures of: the steroid precursor cholesterol, 
progesterone (a progestin, C-21), cortisol (a glucocorticoid, C-21), aldosterone 
(mineralocorticoid, C-21), testosterone (an androgen, C-19) and estradiol (an estrogen, C-
18). 
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There is diurnal variation in the plasma concentration of endogenous glucocorticoids 
with the levels higher in the morning (~450 nmol/L) and lower (~110 nmol/L) in the 
evening (Rang et al. 2005).  
The steroids are not stored in vivo, but are produced as required; self-regulated by a 
negative feedback loop. This is part of the hypothalamic-pituitary-adrenal axis 
(HPA); the system that regulates glucocorticoid plasma levels in the body. 
 
1.2 Two Isoforms of 11β-HSD 
There are two isozymes of 11β-HSD  in human; types 1 and 2 (Rusvai, Naray-Fejes-
Toth 1993) which despite nearly identical enzymatic actions share a low homology; a 
sequence identity of 14 % (Stewart, Krozowski 1999). This can be seen below in the 
sequence alignment in figure 1.5. There are also several splice variants that have been 
identified in numerous species (known as 11β-HSD1 A-C; not shown below).  
Structurally, the enzymes differ significantly, with the type 2 isoform having 3 
membrane insertions as opposed to one for isoform 1. This is depicted in figure 1.4, 
in an image taken from Odermatt et al, 2006. 
 
Figure 1.4: circle model of the N-terminal membrane anchor sequences of 11β-HSD2 (left) 
and 11β-HSD1 (right). The amino acids are indicated in single letter code, with positively 
charged residues in white on black background. The residues Lys 5 and Glu 25, Glu 26 
determine the lumenal orientation of 11β-HSD1, and are indicated by arrows. 
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Figure 1.5: A multiple amino acid sequence alignment of the human 11β-HSD type 1 and 
11β-HSD type 2 (denoted HSD1 and HSD2 respectively in the alignment below). The 
colours represent amino acids of similar properties: 
 
 
Residue: Colour:  Property: 
AVFPMILW RED  Small (small+ hydrophobic (incl.aromatic -Y)) 
DE BLUE  Acidic 
RK MAGENTA  Basic 
STYHCNGQ GREEN  Hydroxyl + Amine + Basic - Q 
Others GREY    
 
 
Legend of characters used on the bottom row: 
* indicates identical residues, 
: indicates semi-conserved residues in accordance with the colour chart described above, 
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The two isozymes are different gene products and differ in their regulation and 
tissue distribution. Isoform 1 is highly expressed in many glucocorticoid target 
tissues, such as liver, adipose tissue, skeletal muscle and macrophages. Isoform 2 is 
located in kidney, colon, placenta and inflamed tissue. This is summarised in table 
1.2.  
The major difference between the two isozymes aside from their amino acid 
sequences is the cellular location of their catalytic domain. The type 1 enzyme is 
found in the lumen of the endoplasmic reticulum, anchored by an N-terminal 
transmembrane domain, however the type 2 isoform faces into the cytosolic space. 
This is potentially one reason behind the differing catalytic predispositions of the 
two enzymes and co-factor recruitment; 11β-HSD1 takes NADPH as a co-factor for 
reduction of cortisone whereas 11β-HSD2 will utilise NAD for the reaction of 
dehydrogenating cortisol. 
Table 1.2: A summary of the main characteristics of the two human 11β-HSD isoforms, 
adapted from Sandeep and Walker, 2001. 
 







Reductase; NADPH as co-factor 
Faces the ER lumen; N-terminus 







Dehydrogenase; NADH as co-
factor; Faces the ER cytoplasm; 





Liver, adipose tissue, brain, lung, 
pituitary, gonads, skeletal 







Kidney, colon, salivary glands, 
sweat glands, placenta, vascular 





∙ 34 KDa 
∙ 292 amino acids 
∙ Chromosome 1 
∙ >20 kb cDNA 






∙ 44 KDa 
∙ 405 amino acids 
∙ Chromosome 16 
∙ 5.3 kb cDNA 
∙ 5 exons 
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The type 2 isoform is not thought to be highly regulated and is seemingly a 
constitutive enzyme (Sandeep, Walker 2001). In contrast, the type 1 isoform of 11β-
HSD is tightly regulated by several complex factors including glucocorticoids, sex 
steroids, growth hormones, cytokines and stress (Seckl, Walker 2001;Stewart, 
Krozowski 1999).  
The current paradigm states that 11β-HSD1 is responsible for providing and 
regulating the levels of active glucocorticoid, i.e. cortisol, in GR-abundant tissue 
(Arampatzis et al. 2005;Atanasov, Odermatt 2007;Odermatt et al. 2006). On the other 
hand, the primary role of 11β-HSD2 is to oxidise free cortisol to produce inactive 
cortisone, preventing it interacting with the MR and thus the enzyme is located in 
MR rich tissues (Albiston et al. 1994). 
1.3 Protein family: The Short Chain Dehydrogenases/ Reductases 
The enzyme 11β-HSD types 1 and 2 are members of the Short-chain 
Dehydrogenases/ Reductases (SDR) family of proteins. This family of enzymes is 
known to be NADP(H) or NAD(H) dependent oxidoreductases (defined as an 
enzyme which will catalyse the transfer of electrons from one molecule – the 
reductant - to another – the oxidant) and convert secondary alcohols to ketones (and 
vice versa). They generally possess two binding domains – one for the co-factor and 
another for substrate. The overall sequence similarity is typically 10 – 30 %, but all 
members share a high degree of secondary structure conservation (Benyajati et al. 
1981). The active site cavities for all enzymes in the SDR family are unique which is 
in accordance with the wide range of substrate specificities observed.  
Overall, little sequence similarity is found within members of the SDR protein 
family, with the exception of the Rossman fold and two conserved motifs which are 
detailed in the following sections.  
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1.4 The Rossmann Fold 
The Rossmann fold is a structural motif of β-sheets interconnected by α-helices first 
observed by Rossmann (Rao, Rossmann 1973). It is an arrangement that forms a cleft 
for nucleotide co-factors to bind and has a unique topology. 
In 11β-HSD1, this is represented by a central seven-stranded parallel β-sheet, 
sandwiched between three alpha helices on either side. The seven beta strands 
(named β-A to β-G) twist by 90o and it is the first six of these (β-A to β-F) that 
comprise the principal end of the Rossmann fold. The carboxyl ends of the β-strands 
β-A, β-B and β-C along with the α-helices α –2 and α-3 (figure 1.6B) bind the AMP 
portion of NADP. The remaining structural components (β-D, β-E, β-F and α–5 and 
α-6/7) bind the nicotinamide moiety of the dinucleotide co-factor. The strands of the 
β-sheet are ordered 3-2-1-4-5-6. 
 
 
Figure 1.6: (A) A 3-dimensional representation of 11β-HSD1 from PDB entry 3CH6 
showing the α-helices in red and the β-sheets in yellow. The N- and C- termini are labeled 
as are several of the structural components. The Rossmann fold consists of 6 of the 7 β-
strands and 4 of the 11 α-helices. (B) 2-dimensional representation is shown in a simpler 
format with each component labeled.  
 
This is also depicted in figure 1.7A and B.  
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Figure 1.7: (A) A recent crystal structure of a human 11β-HSD1 monomer, showing the 
Rossman fold and the orientation of NADPH in the protein. The beta-sheets and alpha-
helices are colour-coded to correspond to figure 1.4B. This particular structure is 3CH6 
(Wang et al. 2008) deposited in the PDB in 2008 by Bristol-Myers Squibb and shown with a 
novel pyridine inhibitor (stick format, green) and co-factor NADPH (stick format, purple). 
The monomer is shown here is a double mutant (L262R, F278E). (B): A two dimensional 
representation of the enzyme 11β-HSD1 showing the beta-sheets labeled βA to βF, which 
form part of the Rossmann fold. Noted in the figure are residues involved in binding the 
co-factor and substrate (Ser 170 and Tyr 183); and the two sequence motifs (which start at 
Gly 41 and Tyr 183) and the start and finish residues (Glu 24 and Asp 287 respectively). 
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All dehydrogenases of known structure utilise NAD(H) or NADP(H) as co-factors 
and almost all have a similar dinucleotide binding domain formed by the Rossmann 
fold prompting speculation as to the evolutionary convergence or divergence of 
these enzymes (Creighton 1984). Inhibitors exist which competitively inhibit 
dinucleotide binding to the Rossmann fold; in clinical use is Gossypol (Vander Jagt et 
al. 2000) which is a polyphenol compound derived from the Gossypium cotton plant 
and was initially developed as a male anti-fertility agent.  
The enzyme 11β-HSD1 confers a specificity for NADP(H) and not NAD(H) through 
an electrostatic interaction between the guanidine moiety of an arginine residue at 
position 66 and the ribose 2’-phosphate of NADP(H) (Hosfield et al. 2005). As may be 
expected, this arginine residue is not seen in the NAD(H)-dependent type 2 isoform. 
Turn-over of cortisol to cortisone and vice versa will occur in the presence of 
NAD(H) (Bush et al. 1968) however at a much reduced rate. 
1.5 Overall Structure and Functionally Important Regions of 11β-HSD1 
In addition to displaying the typical SDR architecture of a Rossman fold, 11β-HSD1 
possesses two conserved motifs which are also observed within SDR families. Of the 
two conserved sequences, one is located within the N-terminal nucleotide binding 
domain (section 1.5.1) and the other within the catalytic site (section 1.5.2). 
 
1.5.1 SDR Conserved Sequences: The Dinucleotide Binding P-Loop 
The first SDR-typical motif is the phosphate binding loop – a P-Loop; the primary 
structure of which typically consists of a glycine-rich loop proceeded by a Lys, Ser or 
Thr residue (Saraste et al. 1990). In 11β-HSD1 this conserved sequence is located in 
the N-terminal nucleotide binding domain between the β-sheet ‘β-A’, and the α-helix 
‘α-2’ (figure 1.6B). This P-loop directly contacts the ribose sugar and pyrophosphate 
(Hosfield et al. 2005). It consists of the sequence motif: Gly-X-X-X-Gly-X-Gly (X = any 
residue, but typically ‘Gly-Ala-Ser-Lys-Gly-Ile-Gly’) which confers specificity to 
NADPH, but with only Ser 43 and Ile 46 making any polar interactions, as illustrated 
in figure 1.8.  
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1.5.2 SDR Conserved Sequences: The Catalytic Triad of Residues  
In the central active site the amino acid sequence Tyr-X-X-X-Lys (Tyr 183, Lys 187) is 
often combined with a conserved serine (Ser 170). These three residues orient the 
substrate, catalyse the proton transfer to and from reaction intermediates (Hosfield et 
al. 2005) and are thought of as the ‘catalytic triad’ when found as Ser-Tyr-Lys.  
The Tyr 183 residue forms hydrogen bonds with the cortisone keto-group at position 
C-11 (figure 1.10). The conserved lysine (Lys 187) residue forms hydrogen bonds 
with the nicotinamide ribose hydroxyls from NADP(H) and also lowers the pKa of 
the neighbouring tyrosine hydroxyl group through electrostatic interactions. This 
lowered pKa of Tyr 183 (which is ~ 9.7 in model peptides but may range from 9 to 12 
in proteins) promotes proton transfer to the reactive keto-oxygen of bound cortisone. 
In addition to this, a hydride is donated from NADPH, and the reduced 
glucocorticoid is produced; cortisol (Filling et al. 2002;Hosfield et al. 2005). The 
catalytic residues are arranged in a suitable assembly for carrying out a similar 
mechanism in cortisol oxidation. These are pictured in figure 1.8, in a diagram 
depicting overall co-factor binding. Substrate binding is shown in figure 1.10. 
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Figure 1.8: A 1-dimensional, simplified diagram showing the polar interactions involved in 
binding NADPH. Importantly, Tyr 183 and Lys 187 interact with the nicotinamide ribose 
hydroxyl groups as described. These residues are highlighted in red. This crucial 
interaction facilitates electron transfer. Also important are residues Ser 67 and Arg 66 
which confer the specificity for NADPH over NADH. Co-factor binding also entails 
stacking interactions with Arg 66 on one face of the purine ring and His 120 on the 
opposite face (not shown).  
 
Also pictured in figure 1.8 is an SDR conserved water molecule, ligated to the 
carbonyl backbone of Asn 143. This water plays a role in the proton relay system 
with bulk solvent when re-protonating Tyr 183. 
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1.5.3 Binding in the Catalytic Site: Additional Residues Involved 
The catalytic triad and other residues involved in substrate binding are shown in 
figure 1.9.  
 
 
Figure 1.9: Diagram showing the principal residues in the human 11β-HSD1 active site 
involved in binding substrate and ligands. On the steroid beta-face (bold bonds) are Ile 
121, Thr 124, Ser 170, Val 171, Ala 172, Tyr 177, Val 180 and Tyr 183. On the alpha-face 
(dashed bonds) are Lei 217, Ala 223, Ala 226, Val 227, Val 231 and Met 233.  Two of the 
catalytic residues – Ser 170 and Tyr 183 - interact with the substrate cortisone (shown in 
blue). There are also interactions between the ribose hydroxyl and the hydroxyl at the 17 
position of the steroid. 
 
The substrate binding pocket and the co-factor binding site are situated closely 
enough to allow stabilising interactions between co-factor - primarily the 
nicotinamide of NADPH - and substrate. This is illustrated in figure 1.10A. The 
presence and proximity of NADPH is essential for catalysis of the substrate; it is 
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necessary as an electron acceptor for the dehydrogenase reaction and an electron 
donor in the reductase reaction. The short distance between the NADP(H) 
nicotinamide ring and the substrate allows for π-stacking between ring structures, 
further enhancing stabilisation. The interactions between substrate and the catalytic 
site are principally hydrophobic; indeed the substrate binding site is a hydrophobic 
tunnel as shown in figure 1.10B. The hydrophobic tunnel connects to the co-factor 
binding site; NADP(H) enters the tunnel from the opposite end to the substrate. 
 
 
Figure 1.10 (A) Cartoon representation of crystal structure of human 11β-HSD1 (PDB 
accession 2BEL). One subunit is shown, NADPH is pink and carbenoxolone blue. (B) 3D3E  
monomer, NADPH (pink, only just seen) and benzamide inhibitor (blue). A surface has 
been applied to the structure to allow a clearer envisagement of the tunnel.  
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Figure 1.11 shows the interactions of bound substrate as seen from the opening of the 
catalytic pocket. 
 
Figure 1.11: A 3-dimensional model of cortisol binding in the human active site, taken 
from crystal structure 1XU7 (Hosfield et al. 2005) prepared with Pymol. The hydrogen 
atoms are shown in white. 
 
The residue Tyr 177 was also thought to play a role in substrate binding through 
polar interactions (shown in figure 1.9 and 1.11) however a recent mutagenesis study 
with Y 177 (to either Y177Q or Y177A) suggested that it did not participate in 
hydrogen bonding but instead in hydrophobic interactions with the substrates 
cortisone and cortisol (Kim et al. 2006). An exchange to phenylalanine (Y177F) did 
not significantly alter the Km of 11β-HSD1 for cortisone; both Y 177 and F 177 have a 
Km of ~600 nM (Kim et al. 2006). These mutations resulted in increased Km values for 
cortisone: from ~ 600 nM to ~ 4.5 μM and ~ 8.3 μM respectively. As the mutations 
Y177Q or Y177A would effectively remove the hydrophobic character at this 
position, the increase in Km values supports the hypothesis that Tyr 177 is more likely 
to be involved in substrate binding through its hydrophobic side chain as opposed to 
hydrogen bonding.  Interestingly, the mutation of Y 177 to a glutamine or alanine 
residue altered the affinity of 11β-HSD1 for selected inhibitors, such as glycyrrhetinic 
acid (C30H46O4, GA), substantially increasing the IC50 from ~ 55 nM (wild-type) to        
~ 425 nM (Y177Q) and 275 nM (Y177A) (Kim et al. 2006). 
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Interestingly, the residue Tyr 280 (a serine residue in mouse 11β-HSD1) which is 
found in the C-terminal domain, is thought to play a role in the selectivity of the 
enzyme toward ligands (Kim et al. 2007) but its direct involvement in inhibitor 
binding is dependent on the overall structure of the inhibitor. For example, it is not 
essential in carbenoxolone binding (as seen in the crystal structure 2BEL (Hale et al. 
2008)) although it is a vital point of interaction with another non-selective 11β-HSD1 
inhibitor glychyrrhitinic acid (GA) as determined by a mutagenesis study, where the 
mutation of Y280 to A280 or F280 caused drastic changes in the IC50 of GA (Kim et al. 
2007). 
  
1.6 Species Variation in the Catalytic Site 
There are several important differences between the rodent and human catalytic 




Figure 1.12: (A) corticosterone, the active glucocorticoid in rodents, birds and amphibians. 
B: Cortisol, the active glucocorticoid in higher organisms. Both are reduced by 11β-HSD1 
to yield 11-dehydrocorticosterone (from compound A) and cortisone (from B). The only 
difference between the two compounds is the presence of a hydroxyl group at position 17 
in the cortisol and cortisone, as indicated by the red arrow. 
  
The single difference between the rodent and human substrate is the additional 
hydroxyl group found at position 17 of the steroid molecule in humans. Position 17 
of the steroid molecule is anticipated at to bind deep within the catalytic site, close to 
NADP(H).  
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The most important difference between the rodent and human active site residues is 
the replacement of tyrosine (Y 177) in human to glutamine (Q 177) in rodents. This is 
shown in figure 1.13. Interestingly, mutations of Q 177 to alanine or glutamate do not 
affect the affinity of the human 11β-HSD1 enzyme for the rodent substrate: 11-




Figure 1.13: Overlay of human and mouse 11β-HSD1 monomers from 1Y5M (mouse, in 
blue ribbon) and 2RBE (human, in green ribbon). Overall, the structures are strikingly 
similar. A close-up of the active site of this overlay reveals a 2-anilinothiazolone inhibitor 
(shown in pink) NADPH can be seen to the bottom right.  
 
There exist 17 crystallographic structures of 11β-HSD1 currently in the protein data 
bank (PDB). These are summarised in table 6.1, and discussed in chapter 6. 
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1.7 Bidirectionality of 11β -HSD1 
In vivo, the catalytic domain of 11β-HSD1 faces the lumen of the endoplasmic 
reticulum. This surrounding oxidising environment allows the enzyme to function 
primarily as a reductase (Odermatt et al. 1999;Ozols 1995) and provides a degree of 
hydrophobic active site sheltering. It also allows for the hydrophobic substrate, the 
inactive cortisone, to freely diffuse across the membrane and into the catalytic site 
(Odermatt et al. 2006) although the mechanisms behind steroid entry into target cells 
remains poorly understood. 
Although the enzyme is reported to favour the reductase reaction in vivo, it has been 
observed during this research and previously that this activity is reduced after cell 
lysis (Lakshmi, Monder 1988) which may be an effect of local in vitro conditions. As 
the reaction has a relatively low free enthalpy change, the enzyme activity greatly 
depends on the [NADPH]/[NADP+] ratio in the ER lumen (Atanasov et al. 2004). 
Furthermore, an excess of approximately 10-fold NADPH is required to induce the 
functioning of 11β-HSD1 as a reductase. There is a significant increase in the activity 
starting at a 9 [NADPH]: 1 [NADP+] ratio (Dzyakanchuk et al. 2009). 
In addition to the local environment conditions, current research has pointed 
towards the presence of a second enzyme; hexose-6-phosphate dehydrogenase 
(Hewitt et al. 2005) as a prime determinant of 11β-HSD1 activity. Hexose-6-
phosphate dehydrogenase (H6PD) is an enzyme which catalyses the first two steps of 
the pentose phosphate pathway. It regenerates reduced NADPH in the lumen of the 
endoplasmic reticulum, supplying its neighbouring enzyme - 11β-HSD1 – with a 
constant replenishment of reductase co-factor. Certainly, this has proven to be the 
case in intact culture cells (HEK293 cells) as the co-expression of H6PD stimulated 
reductase activity 5-fold and decreased the dehydrogenase activity six-fold, as 
compared to controls without co-expression of H6PD (Atanasov et al. 2004). 
 
1.8 Alternate Roles of 11β -HSD1 
There are secondary, additional roles that 11β-HSD1 has in vivo, which are not fully 
understood or documented. Evidence exists for a role for 11β-HSD1 in the 
detoxification of several non-steroidal carbonyl compounds; the enzyme reduces 
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these compounds to their corresponding hydroxyl derivatives (Maser, Oppermann 
1997). This is in addition to detected 11β-HSD1 activity reducing neurosteroids 7-
keto-, 7-α-hydroxy- and 7-β-hydroxy-dehydroepiandrosterone, DHEA (Nashev et al. 
2007). The non-steroidal carbonyl compounds reduced by 11β-HSD1 include a 
tobacco derivative; nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone 
(NNK) (Maser 1998;Maser et al. 2003) the most potent carcinogenic agent in cigarette 
smoke (Maser et al. 2006) as well as a new anticancer drug oracin (Wsol et al. 2004). 




Figure 1.14 Structure of non-steroidal substrates of 11β-HSD1 (A) NKK (B) Oracin. 
Illustration prepared with Chemdraw 11.0. 
 
This xenobiotic carbonyl compound-reducing activity is typical of many 
hydroxysteroid dehydrogenase enzymes from the SDR family and from the aldo-
keto reductase family of enzymes. There is evidence to suggest that it is a 
bidirectional activity which is heavily influenced by hexose-6-phosphate 
dehydrogenase (H6PD) (Nashev et al. 2007) as with endogenous substrate.  
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1.8 Oligomerisation State of 11β-HSD1 
The active form of 11β-HSD1 has been shown to be homodimeric and tetrameric in 
solution, initially evidenced through gel filtration chromatography (Kim et al. 2007) 
in addition to the more definitive crystal structures of the enzyme (table 6.1). 
The overall organisation and topology of the homodimer as seen in figure 1.15B, is 
very similar to other Short-Chain Dehydrogenase / Reductase (SDR) family member 
species and consists of the C-terminal helix of one monomer and the C-terminal helix 
of the other to face each other in an anti-parallel manner. Each C-terminal helix will 
face its dimer partners’ substrate binding pocket, and several residues act as a ‘cap’ 
structure over the substrate pocket. The interactions are hydrophobic and involve 
residues located on helices α-4 and α-5 (nomenclature from figure 1.3). Residues Arg 
273, Lys 274 and Glu 277 on the C-terminal helix from one monomer interact with 
core residues on its dimer partner: Asp 191, Arg 198, Lys 199, Glu 254 and Glu 255. 
These interactions anchor the macromolecules together. The total buried surface area 
of the dimer interface is large at around 5129 Å (Zhang et al. 2005). 
The C-terminal tail of 11β-HSD1 is relatively flexible, approximately 15 amino acids 
in length, and is not always well resolved in crystal structure refinements.  
Tetramer formation involves pairs of C-termini in anti-parallel directions, generating 
a central four helix bundle of the C-terminal helices and a localization of active sites 
(figure 1.15D). Mutagenesis studies have shown that in the absence of the C-terminal 
(an 11β-HSD1 mutant lacking the last 28 amino acids), the enzyme cannot form a 
tetramer (Hosfield et al. 2005) verifying that this domain mediates tetramer 
assembly.  
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Figure 1.15: Oligomeric structures of 11β-HSD1: (A) monomer subunit (green) (B) 
Homodimer: the monomer from 1.14A in the same position (green) and a second monomer 
(blue) pictured. NADP(H) is visible in stick format. (C) Homo-tetramer: as 1.14B but with 
their tetrameric partners (pale green and teal). NADP(H) is visible in the Rossmann fold, in 
stick format. (D) Re-orientation of the tetramer showing the central four helix bundle of C-
terminal helices and the positions of all four active sites. Pictures from the crystal structure 
3D3E, prepared using Pymol. 
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1.9 Post-Translational Modifications of 11β-HSD1 
The local cellular microenvironment of 11β-HSD1 has a knock-on effect not only on 
the bidirectionality of the enzyme but also its topology and post-translational 
modifications (PTMs). The lumen of the ER is an oxidising environment and 
therefore may facilitate formation of intra-chain sulphide bonds (Ozols 1995) 
particularly between Cys 77 and Cys 212.  
Other PTMs of 11β-HSD1 include glycosylation, initially thought to affect the activity 
of the enzyme. More recent mutagenesis research indicates that glycosylation is 
important for preventing aggregation of the protein and stabilisation, but does not 
affect the activity or protein folding (Blum et al. 2000). Glycosylation sites include 
Asn 123, Asn 162, and Asn 207 (Arampatzis et al, 2005) for the human enzyme, 
however Asn 123 is located in a variable region of the enzyme and so is exchanged 
for Gln (in rat and mouse variants) and Tyr (in hamster and guinea-pig variants).  
1.10 Pre-receptor Regulation of Glucocorticoid Activity 
Glucocorticoids act through binding to the glucocorticoid receptor (GR), a nuclear 
hormone receptor which causes the transactivation or transrepression of numerous 
genes. These genes are involved in processes such as immune and stress responses, 
maturation and differentiation of cells, and the regulation of bone, carbohydrate, 
amino acid and lipid metabolism (Barnes 2005). Indeed, cortisol is one of the 
strongest known endogenous suppressors of the immune system but plays a 
modulatory role during inflammation and infection. The effects of cortisol are 
modulated by two mediators; (a) the glucocorticoid receptor and (b) the local tissue 
concentration of cortisol which is regulated by the ‘pre-receptor metabolism’ activity 
carried out by 11β-HSD1 and 11β–HSD2 (Classen-Houben et al. 2009). 
Excessive glucocorticoid activity results in “Cushing’s Syndrome”, a disease with 
phenotypical characteristics such as high blood pressure, osteoporosis, abdominal 
obesity and a higher cardiovascular mortality risk. While Cushing’s syndrome is 
rare, it does exemplify the pathological effects associated with imbalances in 
circulating cortisol levels.  
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Although the exact role of 11β-HSD1 in metabolic disease still remains to be fully 
elucidated, it is clear that it exerts an effect on the local glucocorticoid receptor 
activation; after all it has the role of metabolising cortisol in significant metabolic 
physiological locations, such as adipose tissue and liver. 
 
1.10.1 Metabolic Syndrome 
The metabolic syndrome can be broadly defined as a collective of medical disorders 
that includes type 2 diabetes, high blood pressure, central obesity, low HDL (high 
density lipoprotein) cholesterol, elevated triglycerides and uric acid levels and non-
alcoholic fatty liver disease (NAFLD). Each of these symptoms alone can cause a 
higher risk of cardiovascular disease, but when combined increase the risk even 
further. The symptoms of metabolic syndrome are not always consistently defined 
but it is estimated that over 20 % of the U.S.A population currently live with the 
condition and its prevalence is strongly and unfailingly age-dependent (Eckel et al. 




Figure 1.16: Flow chart indicating the risk factors for metabolic syndrome, and the 
disorders that this syndrome envelops. 
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The majority of current research focuses on the role of 11β-HSD1 inhibitors as a 
prophylactic treatment for complications associated with the metabolic syndrome; 
primarily in the prevention or reduction of obesity and type 2 diabetes. Disease 
models for obesity or insulin resistance are readily available and well-developed. For 
example, genetically obese Zucker rats are homozygous for the fatty (fa) allele which 
results in leptin receptor defects and leads to hyperphagia and obesity. Koletsky rats 
are obese and hypertensive, and Wistar Ottawa Karlsburg W rats are a new strain 
which exhibit many metabolic syndrome characteristics (Aleixandre de Artinano, 
Miguel 2009).  
 
1.10.2 11β-HSD1 and Type 2 Diabetes 
One potential therapeutic area for 11β-HSD1 is type 2 diabetes and its precursor: 
insulin resistance. Currently the 6th leading cause of death in the U.S.A, it has been 
estimated that by 2010, diabetes will exceed both heart disease and cancer as the 
leading cause of death through complications. Type 2 diabetes is closely associated 
with obesity and is characterised by an initial phase of progressive insulin resistance 
followed by the ensuing β–cell exhaustion (β–cells are the insulin producing 
pancreatic islet cells). This results in an unusually high blood glucose level through a 
lack of blood glucose control usually regulated by insulin. 
A key feature in insulin resistance and the subsequent development of type 2 
diabetes is postulated to be abnormal hepatic 11β-HSD1 reductase activity. 
Glucocorticoids are involved in the transcriptional control of several genes involved 
in the regulation of hepatic glucose production, such as the gene encoding PEPCK – 
an enzyme which catalyses the rate limiting step in gluconeogenesis. An excess of 
glucocorticoids may thus result in glucose intolerance and insulin resistance. It 
follows that inhibition of 11β-HSD1 would decrease the level of cortisol available, 
thus decreasing excessive hepatic glucose production in hyperglycemia and so 
potentially type 2 diabetes. Indeed, this hypothesis has been tested in several mouse 
models of type 2 diabetes which were given a small, non-steroidal selective inhibitor 
of 11β-HSD1 known as “BVT.2733” over a period of seven days (Alberts et al. 2003). 
BVT.2733 (synthesised by Biovitrum, Sweden) derives from the 
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arylsulfonamidothiazole class of inhibitors and is shown in figure 1.21. The results of 
this study showed a significant reduction in blood glucose and serum insulin levels 
in mice treated with BVT.2733 compared to mice treated with a placebo. The drug 
also improved insulin sensitivity, supporting the notion of 11β-HSD1 as a target for 
the treatment of type 2 diabetes.  
It is noteworthy however, that administration of carbenoxolone - a non-selective 11β-
HSD inhibitor - was found not to improve insulin sensitivity or glucose tolerance in 
lean or obese Zucker rats (Livingstone, Walker 2003). This was due to the liver-
specific nature of carbenoxolone, which did not penetrate adipose layers and so did 
not inhibit adipose 11β-HSD1. Thus, a successful 11β-HSD1-inhibiting treatment for 
type 2 diabetes would require improved pharmacokinetic parameters.  
 
1.10.3 11β-HSD1 and Obesity 
Obesity is a condition which affects up to 300 million individuals globally according 
to World Health Organisation (WHO) statistics from 2003. A third of the U.S.A 
population was declared obese in 2004 (WHO) using criteria based on the number of 
individuals with a body mass index (BMI) of over 30 kg / m2. Problems can then stem 
not only from the associative chronic diseases (as shown in figure 1.16) but also with 
financial drain on health care resources. 
Overall there is a well-documented increase in 11β-HSD1 reductase activity (and 
thus cortisol) in visceral adipose tissue in obese patients and rodent models 
(Livingstone et al. 2000;Mericq et al. 2009;Rask et al. 2002;Wake et al. 2003) and 
reports of increased urinary free cortisol metabolite excretion (Livingstone et al. 
2000;Andrew et al. 1998;Wajchenberg 2000;Marin et al. 1992) however the circulating 
cortisol levels remain constant. This increase in 11β-HSD1 activity (through an 
increase in enzyme expression) is thought to be regulated by glucocorticoids and 
insulin (Bujalska et al. 1997). When reproduced in transgenic mouse models 
overexpressing 11β-HSD1, the phenotypic results mimic those seen in patients with 
idiopathic obesity; the transgenic mice are found to have visceral obesity, 
hyperglycemia, hypertension, hyperlipidaemia, hyperphagia (and thus an increased 
sensitivity to weight gain) and insulin-resistant diabetes (Kotelevtsev et al. 1997). 
  - 26 - 
When fed a high fat diet (45% fat) the transgenic mice were found to be 
approximately 16% heavier in weight than non-transgenic mice on the same diet 
(Masuzaki et al. 2001). When 11β-HSD1 is over-expressed in the liver only, mice 
show a mild insulin resistance, dyslipidaemia, hypertension and fatty liver.  
Furthermore, cortisol is required for adipocyte differentiation (Liu et al. 2007) and 
accordingly is found in adipose tissue in vivo. Interestingly, there is an increase in the 
expression of H6PD during preadipocyte differentiation to adipocytes (Odermatt et 
al. 2006) suggesting a high local requirement for NADPH, potentially for the purpose 
of funding 11β-HSD1 with co-factor to enable cortisone reduction. 
These studies show that there is clearly a role for 11β-HSD1 in obesity and insulin 
resistance. This raises more specific questions about the possible effects of 11β-HSD1 
inhibition and whether the enzyme would make an effective drug target. This has 
been studied; in rodent obesity models, removing glucocorticoids will tend to reverse 
obesity and its metabolic abnormalities. In addition, mice given a daily 
administration of carbenoxolone - a non-selective 11β-HSD inhibitor – show a 
reverse in the effects of high-fat diet induced obesity and insulin resistance (Nuotio-
Antar et al. 2007;Taylor et al. 2008) with no change in feeding habits. 
By far the best example of the potential of 11β-HSD1 inhibition is observed in 11β-
HSD1 knock-out mice which show improved glucose tolerance, reduced weight gain, 
reduced visceral fat accumulation (with chronic high-fat feeding) and a ‘diabetes-
resistant’ phenotype (Kotelevtsev et al. 1997). This is summarised in figure 1.17. 
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Figure 1.17: Cartoon mouse models illustrating the effects of excess 11β-HSD1 (on left, in a 
transgenic mouse model over-expressing 11β-HSD1 in visceral adipose tissue) and the 
absence of 11β-HSD1 (mouse on right, an 11β-HSD1 knock-out mouse). 
 
Selective inhibition of 11β-HSD1 has therefore been proposed as a novel drug target 
for treatment of disorders associated with cortisol excess such as obesity, insulin 
resistance and type 2 diabetes with additional benefits in dyslipidaemia and 
hypertension.  
Also, 11β-HSD1 inhibitors have been postulated to have a beneficial effect on 
cognitive impairment and other associated conditions. 
 
1.11 11β-HSD1 and Cognitive Function 
The role of 11β-HSD1 is less well documented for cognitive function compared to 
metabolic syndrome. Importantly, a rare polymorphism in the gene encoding 11β-
HSD1 (HSD11B1) has recently been linked with increased risk of developing 
Alzheimer’s disease; rs846911-C/A (Deary et al. 2006;de Quervain et al. 2004). Several 
other polymorphisms of the HSD11B1 gene have been identified; interestingly some 
are associated with a cardiometabolic phenotype.  
In addition to metabolic tissue, 11β-HSD1 mRNA has been localized to the human 
hippocampus, frontal cortex and cerebellum (Sandeep et al. 2004). Elevated cortisol 
levels in elderly humans and rodents correlate with hippocampus-dependent 
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memory impairments (Yau et al. 2007) and chronic glucocorticoid excess can have 
detrimental effects in the brain. These deleterious effects include psychosis, 
depression, neuroendocrine dysfunction, structural deterioration and cognitive 
impairment (Seckl, Walker 2004).  
In the hippocampus specifically, an excess of glucocorticoids can potentiate 
excitatory neurotransmission, which has a knock-on effect on other 
electrophysiological brain functions such as long-term potentiation (LTP) – the 
process underlying memory formation and learning (McEwen et al. 1999). Indeed, 
mild cognitive impairment has been linked in the past with variations in 
glucocorticoid exposure (Lupien et al. 1998). Studies on rats with controlled low 
glucocorticoid levels throughout life (i.e. through neonatal handling or an 
adrenalectomy) show attenuation of certain deficits associated with ageing, such as 
hippocampal atrophy and cognitive decline, when compared to controls (Landfield 
et al, 1981, Meaney et al, 1988). 
Human parallels have been carried out in small scale clinical trials. It has been 
observed that administration of carbenoxolone to healthy elderly men (55 – 75 years 
of age) or to elderly men with type 2 diabetes showed improved verbal fluency and 
verbal memory, respectively (Sandeep et al. 2004). When combined with the - albeit 
rare - polymorphism, an apparent role for 11β-HSD1 in cognitive decline and other 
age related mental deterioration emerges. However, the underlying biological 
complexities, intricacies and mechanisms involved in cognitive function and 
dysfunction mean that further detailed research is required in this area. A further 
challenge would be the design of CNS specific 11β-HSD1 inhibitors. 
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1.12 11β-HSD1 is a Pre-receptor Drug Target 
It is apparent from the published evidence that it is the effects of excess cortisol in 
specific tissues which cause varying degrees of the metabolic syndrome. Therefore 
the objective in investigating treatments for these interventions is to target and 
antagonise receptors and enzymes involved in the production of cortisol, for 
example, certain key adrenal steroidogenic enzymes and the GR. Indeed there are 
clinically available GR antagonists (e.g. dexamethasone) and drugs which inhibit key 
enzymes involved in adrenal steroidogenesis (e.g. ketoconazole). The caveats of 
cortisol antagonism through these methods are the systemic side effects, particularly 
in times of physiological stress when an increase in glucocorticoids is necessary to 
elicit correct immune response but also interference with the negative feedback loop. 
Therefore a clear advantage of targeting 11β-HSD1 lies in the natural tissue 
selectivity presented by the enzyme, which has a high expression in white adipose 
tissue and the liver, allowing circumvention of the majority of systemic side effects. It 
is also a well defined and characterised protein with good quality structural data 
available and much documented evidence as to the benefits of its inhibition. The 
enzyme 11β-HSD1 is therefore an attractive therapeutic venture as a means of 
controlling local tissue concentrations of cortisol: a pre-receptor target. 
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1.13 Inhibitors of 11β-HSD1: Clinical and Preclinical 
1.13.1 Selectivity 
The selectivity of new inhibitors is of supreme importance to prevent any side effects 
associated with the ligand binding non-selectively to 11β–HSD2 or indeed other 
hydroxysteroid dehydrogenase enzymes such as 17β-HSD.  
The isoform 11β–HSD2 will preferentially produce the inactive glucocorticoid in 
specific tissues in order to prevent the activation of the mineralocorticoid receptor 
(MR) by active glucocorticoid. Mineralocorticoid receptor activation by cortisol is, for 
unknown reasons, preferential to activation by its endogenous ligand – aldosterone 
(structure shown in figure 1.3). Inhibition of 11β–HSD2 would lead to an over-
activated MR resulting in hypokalemia (potassium deficiency) and hypernatremia 
(elevated sodium levels) which would lead to hypertension. 
Binding of inhibitors to alternative hydroxysteroid dehydrogenase enzymes would 
interfere with the sex steroid metabolism, for example, 17β-HSD inhibition would 
affect local estrogen metabolism. Therefore selectivity is the ultimate criteria in the 
development of new inhibitors for 11β -HSD1. 
 
1.13.2 Endogenous Inhibitors of 11β-HSD1 
Several endogenous substances have been reported to display inhibition of either 
isoform of 11β-HSD. Coined ‘Glycyrrhetinic Acid-Like Factors’ (GALFs)(Morris et al. 
1992) they are endogenous substances initially detected in urine known to non-
selectively inhibit 11β-HSD1. Further investigation is required to fully elucidate the 
mechanism and regulation of these substances, some of which are derivatives of 
cortisol and corticosterone. Those which inhibit 11β-HSD1 and 11β-HSD2 
dehydrogenase are 3α-5α-tetrahydrocorticosterone, a derivative 3α-5α-tetrahydro-
11β-hydroxyprogesterone, and 3α-5α-tetrahydro-11β-hydroxytestosterone. The 
compounds found to preferentially inhibit 11β-HSD1 reductase are 11-keto-3α-5α-
tetrahydro-derivatives (Latif et al. 2005;Morris et al. 2007).  
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1.13.3 Clinically Available Inhibitors: Carbenoxolone 
Currently there is one clinically available inhibitor for 11β -HSD1: carbenoxolone. It 
is a steroidal compound with an extended acidic chain on the A ring (figure 1.17). 
This extension protrudes from the mouth of the active site when bound, the 
remainder of the molecule is held in position by Leu 217, Ser 170 and Tyr 183 (the last 
two form part of the catalytic triad). In addition, polar interactions occur between the 
nicotinamide ring nitrogens and the carboxyl group of the 5th ring (figure 1.18).   
 
Figure 1.18: The 2-D and 3-D molecular structure of carbenoxolone, a clinically used 
inhibitor of 11β-HSD1 and 11β–HSD2, derived from the natural compound glycyrrhizin 
(GA). Figure prepared with Pymol. 
 
There are also several major hydrophobic interactions and π-stacking keeping the 
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Figure 1.19: Carbenoxolone binding. (A) 3-D model of carbenoxolone (magenta) binding in 
the active site of the enzyme (blue), showing the 3 main interactions with Leu 217, Ser 170 
and Tyr 183 and co-factor (yellow). (B) Simplified model of the interactions between 
carbenoxolone and co-factor NADP(H). Prepared with Pymol. 
 
Crucially, carbenoxolone is a non-selective compound and inhibits both 11β-HSD1 
and 11β–HSD2. Clinically it has been in use for almost 50 years, and is prescribed as 
a treatment for gastric ulcers in combination with other drugs to supplement the 
subsequently decreased potassium levels brought about by over-stimulation of the 
mineralocorticoid receptor. Carbenoxolone displays a liver-specific inhibition of 11β-
HSD1, observed in both obese Zucker rats (Livingstone, Walker 2003) and humans 
with type 2 diabetes (Andrews et al. 2003). This has been postulated to be a 
pharmacokinetic challenge rather than one relating to experimental design or non-
selective inhibition of other pathways. 
Interestingly, carbenoxolone is a derivative of the natural product glycyrrhizin (GE) – 
a compound derived from liquorice root Glycyrrhizia glabra. Other derivatives from 
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this source have been harvested and analysed successfully for 11β-HSD1 selective 
inhibition such as 18α-glycyrrhetinic acid (18α-GA) and 18β-glycyrrhetinic acid (18β-
GA) (Classen-Houben et al. 2009) which are discussed later in the text.  
Pertinently, carbenoxolone appears to be several-fold more effective in inhibiting the 
mouse, rat and human enzymes as compared to dog, hamster and guinea-pig 
enzymes (Arampatzis et al, 2005) highlighting important cross species differences 
between the active sites of  11β-HSD1. 
 
1.14 Preclinical Inhibitors: A Brief Introduction 
In the interest of this project, the pre-clinical inhibitors covered in this section will be 
only those which have a corresponding 11β-HSD1 published crystal structure 
complex. This allows a detailed and more accurate analysis of the binding 
mechanistics for each inhibitor compound, expounding the available data for a 
rational drug design project such as this. Thus, it is by no means an exhaustive list of 
all current pre-clinical inhibitors, simply those that are most relevant. The 
compounds cited are summarised in table 1.5 at the end of this section for clarity. 
Despite the enzyme being effectively characterised in the 1960s, it is only recently 
that patents have been filed for compounds inhibiting 11β-HSD1. In 2001 the first 
patent was claimed, and there has been a swift growth in the number of patents 
claimed since 2004. It is estimated that there are over 60 patents currently filed 
(Webster, Pallin 2007). As of 2007, there were three compounds in clinical 
development: INCB-13739, AMG-221, and PF-915275, with many more in pre-clinical 
stages. All of the compounds in clinical development are reportedly targeting type 2 
diabetes rather than any other element of the metabolic syndrome, as it has the most 
validated research. 
Numerous other pharmaceutical companies have filed for patents; a recent report 
documented over 14 individual pharmaceutical companies filing for patent 
applications for 11β-HSD1 inhibiting compounds, with many filing more than one 
patent. The principal players were Incyte and Biovitrum (these compounds were 
subsequently sold to Amgen in 2003) (Norman 2007).  
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1.14.1 Liquorice Root Derivatives  
Although these compounds do not share a co-crystal structure, liquorice root 
derivatives such as glycyrrhizin (GE), 18β-glycyrrhetinic acid (18β-GA, shown in 
figure 1.20A) and subsequent derivatives - such as carbenoxolone (CBX) – are known 
potent inhibitors of 11β-HSD1. This has led to a dynamic search for the development 
of more active and selective natural-product derived inhibitors for 11β-HSD1.  
 
 
Figure 1.20: (A) Chemical structure of 18β-glycerrhetinic acid (18β-GA) (B) The chemical 
structure of the 11-exo-methylene derivative of 18β-GA demonstrating the importance of 
the hydrogen acceptor suitability of the 11-position (Su et al. 2007).  
 
The compound 18β-GA is a potent, non-selective inhibitor of 11β-HSD with an IC50 
value in the nano-molar range (Buhler et al. 1991;Monder et al. 1989).  Although non-
selective, it has been trialled clinically, and 18β-GA has even reportedly been shown 
to reduce subcutaneous thigh fat after topical application (Armanini et al. 2005). 
Furthermore, several 18β-GA derivatives have been discovered to be selective 11β-
HSD1 inhibitors (Su et al. 2007) as shown by inhibition assays using homogenous 
time resolved fluorescence (HTRF) on human liver microsome fractions. 
Modifications made to the parent compound at positions 11 and 30 (see figure 1.3 for 
carbon numbering in steroids) conferred selectivity against the rat enzyme. These 
assays also confirmed the importance of a hydrogen bond acceptor group at position 
11 by demonstrating the loss of potency of the compound when a methylene group is 
substituted, as shown in figure 1.20B. 
Further development is currently underway with compounds similar to 18β-GA 
(Classen-Houben et al. 2009) however concerns regarding the cell membrane 
permeability of this class of compounds have been raised. 
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1.14.2 β-keto Sulfone Inhibitors 
The β-keto sulfones are a class of selective inhibitors developed by Wyeth with a 




Figure 1.21: Skeleton structure of β-keto sulfone class of inhibitors. The highest potency is 
found when R1 = 3-MeO-Ph. 
 
However the β-keto sulfone series hold a drawback: the potential for 11β-HSD1 to 
turn-over this compound, producing potentially ineffective hydroxyl sulfones (Xiang 
et al. 2005, Xiang et al. 2007). Similar in nanomolar IC50 potency are the 
arylsulfonamidothiazole and arylsulfonamidooxazole compounds shown in figure 
1.22, apparently circumventing the metabolic challenges faced by the β-keto sulfone 
class by the addition of an amido substituent from the central sulfur atom. 
 
1.14.3 Sulfonamides 
The sulfonamide moiety is an important central scaffold for inhibitors of 11β-HSD1, 
as it provides a hydrogen bond acceptor group which then interacts with Tyr 183 and 
Ser 170 of the catalytic triad. Understandably then, this scaffold has been repeatedly 
seen in reports of potent inhibitors, typically unearthed using pharmacophore 
models of existing potent inhibitors and also through structure based drug design 
(Barf et al. 2002;Yang et al. 2009). Indeed this scaffold can be seen in INCB-13739 
(Incyte) which is one of the three 11β-HSD1 inhibitors currently undergoing clinical 
trials. The compound INCB-13739 has been reported to markedly enhance hepatic 
and peripheral insulin sensitivity in a trial of 30 patients with type 2 diabetes 
(Hawkins M et al. 2008). It was also a feature of BVT 3498 (Biovitrum) which entered 
clinical trials in 2003 but was a phase II failure. 
Currently in development by Amgen (Tu et al. 2008) are a class of sulfonamides 
reported to be selective nanomolar inhibitors. The original skeleton structure of this 
series is shown in figure 1.22A, with the most potent drug in this class (figure 1.22B) 
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which has been co-crystallised with the human enzyme. The class of inhibitors 
consisted of the sulfonamide core, with additional substitutions on and off the 
benzamide ring. The addition of a long chain with one additional hydrogen acceptor 
and one hydrogen donor group (1.22B) was found to very slightly enhance binding 
to the human enzyme, from an IC50 of 2.1 nM to 1.2 nM. 
 
 
Figure 1.22: (A) the chemical structure of sulfonamide skeleton (B) the most potent 
compound in the sulfonamide series. 
 
The sulfonamide compound B (figure 1.22B) binds in a competitive manner in the 
active site as demonstrated by scintillation proximity assays (described in chapter 5) 
using recombinant full-length human enzyme, with an approximate Ki of 1 nM for 
the reductase reaction. A crystal structure of a tetrameric 11β-HSD1 in complex with 
the highly potent sulfonamide compound B was subsequently deposited in 2008 
(PDB accession 3D4N (Tu et al. 2008)) and demonstrates inhibitor binding in the 
catalytic site, reproduced simplistically in figure 1.23A. It is interesting to note that 
despite predictions of interaction with the catalytic triad, there are no direct contacts 
between the central sulfonyl group and these residues, simply a hydrogen bond 
between the backbone of Ala 172 and the oxygen from the sulfonyl group. 
 
 
Figure 1.23: (A) Depiction of sulfonamide inhibitor binding in the active site of 11β-HSD1. 
(B) 3-D model of the molecule. 
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The 3-dimensional structure of the molecule (1.23B) shows it exists and binds in a V-
shape. When bound the cyclopropane carboxamide group points toward the exterior 
of the protein (and the C-terminal dimer interface of the adjoining dimer). 
Other sulfonamide scaffolds in development by Biovitrum (Barf et al. 2002) are the 
arylsulfonamides. These were discovered through a high-through put screen of the 
in-house compound database then a lead optimisation process.  
 
Figure 1.24: Chemical structure of two arylsulfonamide compounds; BVT 14255 (left), and 
BVT 2733 (right), Biovitrum. 
 
These compounds showed a good metabolic profile and were selective for 11β-HSD1. 
However, they were not as potent as the competitor compounds, with IC50 values of 
52 nM and 3341 nM for BVT 14225 and BVT 2733 respectively.  
With regards to this project, the relevance of these inhibitors is the different affinity 
in human and mouse recombinant 11β-HSD1. As seen in figure 1.24, the single 
difference between the two compounds is the nature of the substitution – one 
diethylamide and the other N-methylpiperazinamide. The bulky piperazinamide 
(BVT 2733) is not tolerated well in the human enzyme, thus reducing the affinity of 
binding for human enzyme. In mouse enzyme assays this bulky group appears to 
enhance binding affinity, giving an IC50 of 96 nM (compared to a human assay IC50 
3.3 nM). A smaller, more flexible substituent in BVT 14255 produces better binding in 
human (IC50 52 nM) compared to mouse (IC50 284 nM). The authors suggest that it is 
this solvent-facing end of the molecule which can dictate the extent of inhibition in 
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1.14.4 Benzamides 
An additional series of inhibitors developed by Amgen stemmed from the core 
sulfonamide structure BVT 14225 (figure 1.24) replacing the sulfonyl group with an 
amide defining the benzamide class (figure 1.25, Julian et al. 2008). 
 
 
Figure 1.25: Chemical structure of core benzamide compound.  
 
One of the principal aims of employing this new class of inhibitors was to attain a 
drug with an improved metabolic profile, therefore substitutions made at R1 and R2 
were initially based not only on potency but also on metabolic stability in cultured 
rat and human liver microsomes. Improved in vitro human metabolic stability was 
explored when R1 = N-cyclopropyl, which, when combined with R2 = a trans-aryl, 
hetero-aryl or alkyl group demonstrated a set of three corresponding compounds 
with the most promising in vitro and in vivo pharmacokinetic profiles. In particular, 
the substitution of R1 = N-cyclopropyl and R2 = hetero-aryl displayed an IC50 of 1.4 
nM with recombinant human enzyme as determined by scintillation proximity assay 
(SPA). This compound is seen in a complex with the enzyme in PDB deposition 3D3E 
(Julian et al. 2008) and is observed to bind in a V-shape with the pyridine ring toward 
the exterior and the trifluoromethyl tertiary alcohol buried within the active site in 
close proximity to the co-factor. This can be seen in figure 1.26B. 
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Figure 1.26: The most promising compound from the benzamide series, (A) A 2-D drawing 
of the benzamide ligand binding. (B) Benzamide compound bound to enzyme (one 3D3E 
monomer shown in purple). The ligand can be seen on the left hand side forming a V-
shape, with the piperazine ring facing out of the binding pocket. The trifluoromethyl 
tertiary alcohol is buried into the pocket in close proximity to co-factor which can also be 
seen on the right hand side. Illustration prepared with Pymol. 
 
1.14.5 Triazoles 
The triazole class of 11β-HSD1 inhibitors have been developed  by Amgen (Tu et al. 
2008) with a subsequent X-ray crystallography structure deposited in the PDB in 
May 2008 (3D5Q). The triazole compound shown in figure 1.27 is the most potent, 
with a mixed inhibition profile. 
 
 
Figure 1.27: Chemical structure of Amgen triazole compound seen in the co-crystal 
structure 3D5Q. On the right hand side is a 3-D model of the molecule, to demonstrate the 
V-shape formed. This illustration prepared with Pymol. 
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The calculated IC50 value for this selective compound is 1.6 ± 0.5 nM for the reductase 
reaction, as determined by SPA in full-length recombinant 11β-HSD1. The 
compound binds to 11β-HSD1 in an L-shape through two members of the catalytic 
triad, Tyr 183 and Ser 170 acting as hydrogen bond donors to the nitrogen atoms in 
the triazole ring. Several Van der Waals interactions between the fluoro-phenyl 
group, buried into the active site, exist between the phenyl ring and Thr 124, Leu 126; 
and the fluoride atom and Ser 125, Leu 126. The presence and bulk of this compound 
forces not only Ser 170 to rotate 180o but also Tyr 177 to arc away from its usual 
position at the mouth of the enzyme due to the presence of the trifluoromethyoxy 
phenyl group. This is demonstrated in a 1-dimensional format in figure 1.28A and a 




Figure 1.28: (A) Residues involved in Amgen triazole inhibitor binding (B) enzyme 
complexed with triazole compound.  
 
1.14.6 Adamantanes 
Abbott (Sorensen et al. 2006) developed a series of adamantane amide inhibitors 
which were reportedly long-acting, dually potent (against human and mouse), with 
good metabolic profiles.  
The adamantane scaffold is shown in figure 1.29, with three of the highest potency 
compounds, labeled 2-4. Due to the lipophilicity of the steroid binding site of 11β-
HSD1, potential inhibitors must have several hydrophobic features, but also 
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maintain a good metabolic stability. To this end, the addition of polar groups at 
either end of the inhibitor molecule may improve metabolic stability but may equally 
reduce permeability. 
A year later a new series of adamantyl inhibitors emerged from Abbott (Sorensen et 
al. 2007) with a sulfone group off the adamantane (figure 1.29, compound 5). This 
appeared to help resolve issues with metabolic stability and consequently a crystal 
structure of human 11β-HSD1 in complex with an adamantane sulfone compound 
(compound 6 in figure 1.29) emerged (PDB 2ILT). From this structure it is possible to 
observe that the adamantyl sulfones bind in a manner similar to the sulfones; that is 
to say that the central carbonyl group acts as a hydrogen bond acceptor from Tyr 183 
and Ser 170 in the catalytic site. This particular compound (compound 6 in figure 
1.29) was also found to strongly inhibit liver, fat and brain 11β-HSD1 and was a long-
acting inhibitor. 
In addition to these adamantane containing compounds are a series of adamantyl 
amides developed at the University of Edinburgh (Webster et al. 2007), one of which 
is depicted in figure 1.29, compound 7. Replacement of the adamantyl moiety with 
smaller substituents resulted in a decrease in potency suggesting the importance of a 
bulky, lipophilic group. Also noted was that the addition of larger phenyl or benzyl 
groups from the piperazine structure resulted in a loss of potency. Keeping this 
substituent small and relatively hydrophobic increased potency (in compound 7 it is 
an ethyl). Potentially it is this region of the molecule which is in close contact with 
the co-factor deep within the pocket where space and hydrophobicity is at a 
premium.  
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Figure 1.29: Overview of adamantane inhibitors. (1) is the adamantane scaffold molecule, 
compounds (2), (3) and (4) (Sorensen et al. 2006) are the most potent variations of the 
scaffold molecule with differing substituents. Compounds (2) and (3) were potent against 
human and mouse enzyme but (4) was less potent. For compounds (2), (3) and (4) the 
human Ki values were: 8 nM, 9 nM and 7 nM respectively. For mouse 11β-HSD1, the Ki 
values are: 15 nM, 5 nM and 500 nM respectively. In human 11β-HSD1 expressing HEK-293 
based assays, the IC50 values are 22 nM, 45 nM and 45 nM, respectively. Compounds (5) 
and (6) (Sorensen et al. 2007) are adamantyl sulfones, (5) is the scaffold of this series, (6) is 
one of the more potent inhibitors from this series (Ki 7 nM with human recombinant 
protein, 4 nM with mouse recombinant enzyme and an IC50 of 98 nM in HEK-293 cells 
over-expressing human 11β-HSD1). (7) (Webster et al. 2007)  shows an IC50 of 82 nM for 
human enzyme. 
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Further to this, Merck-Serono have used the adamantine series of inhibitors as lead 
compounds and by using a structure activity relationship (SAR) methodology have 
designed structurally divergent inhibitors currently in pre-clinical development 
(Roche et al. 2009). 
 
1.14.7 Thiazolones 
Another class of compounds in complex with a published crystal structure of 11β-
HSD1 are the thiazolones. The 2-anilinothiazolones are a novel class of inhibitors 
designed in a collaborative effort by Amgen and Biovitrum (Yuan et al. 2007). These 
compounds were designed using a systematic structure-activity relationship (SAR) 
based approach. The compound shown in complex in the published crystal structure 
2RBE is shown in figure 1.30. 
 
Figure 1.30: A: 2-anilinothiazolone scaffold from (Yuan et al. 2007), B: thiazolone inhibitor 
in complex with human 11β-HSD1 in 3BZU. 
 
A SAR approach was taken in the design of these compounds initially replacing the 
isopropyl group with lipophilic substituents, followed by systematic replacement of 
the aryl group with various heteroaromatic groups. The most potent substitution at 
this point was isoquinolinyl which gave a Ki of 32 nM (compared to 110 nM for an 
aryl group). However, this substituent was thought to affect membrane permeability 
of the compound as the cell-based IC50 value was significantly higher.  
Subsequently the C-5 substituent was varied (‘X’ in figure 1.30A). The most potent 
substituent at this location was a fluorine or a chlorine atom, which gave a Ki of 17 
nM and 7.2 nM respectively and it is the 2-fluoro structure that is seen in 2RBE. This 
binds in a manner similar to the sulfones; there are interactions of the imine-like and 
endocyclic nitrogens with Ser 170 and Tyr 183 of the catalytic triad. In addition the 
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Tyr 177 phenyl ring and the thiazolone core are both perpendicularly planar 
allowing for π-stacking interactions.  
Another 11β-HSD1 inhibiting compound which has a co-crystal structure published 
with the enzyme (3BYZ) is (5S)-2-(cyclooctylamino)-5-methyl-5-propyl- 1,3-thiazol-
4(5H)-one, a member of a thiazolone class of compounds from Amgen/Biovitrum 
(Johansson et al. 2008). This particular compound (figure 1.31A) has a Ki of 28 ± 9 nM 
in human enzyme assays. Binding is shown in figure 1.31C.  
This set of ligands was a continuation from the previous set, the anilinothiazolones; 
where the same scaffold structure is maintained and compounds were assessed via 
their SAR and correspondingly optimised. It is surprising then, to discover that this 
compound binds differently to that observed in 2RBE and 3BYZ with the 
fluorophenylthiazolone compounds (shown in figure 1.30A and B).  
 
 
Figure 1.31 (A) (5S)-2-(cyclooctylamino)-5-methyl-5-propyl-1,3-thiazol-4(5H)-one: the 




Figure 1.31 (C) An illustration of the binding site from 3BYZ.  
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The main differences in binding are a direct interaction between the carbonyl of the 
thiazolone group with the backbone NH proton of Ala 172, in 3BYZ, whereas in 
2RBE there is an indirect interaction: the backbone NH proton of Ala 172 interacts 
instead with Ser 170, and the OH proton of the Ser 170 then forms an interaction with 
the exocyclic nitrogen lone pair on the inhibitor. The varying tautomeric states of 
both ligands (from 3BYZ and 2RBE) allow for different interactions in the binding 
site. This applies also to the Tyr 177 residue near the mouth of the binding pocket; 
the phenyl ring of this residue π-stacks with the planar thiazolone ring of the 
inhibitor in 2RBE. However in 3BYZ this does not occur: the Tyr 177 swings away 
from the inhibitor and subsequently the neighbouring residue Leu 171 forms contacts 
with the propyl moiety from the thiazolone ring (Johansson et al. 2008;Yuan et al. 
2007). 
Following the publication of 3BYZ, further SAR carried out yielded a far more potent 
inhibitor shown in figure 1.31B, which has a 5-membered ring replacing the propyl 
chain at position 5 of the thiazolone and a noradamantyl function replacing the 
cyclo-octyl ring. This added bulkiness on the left hand side of the molecule (this is 
the part of the molecule which is buried into the hydrophobic pocket), appears to 
enhance potency in human enzyme as observed with the adamantine series. The 
potency is increased to yield a Ki of 3 ± 1 nM in human enzyme assays and displays 




In 2008, Amgen put forward another series of inhibitors: the arylsulfonyl 
piperazines, as potent and selective inhibitors of 11β-HSD1 (Sun et al. 2008;Sun et al. 
2009) and in addition published the co-crystal structures (PDB accession 3CZR and 
3D4N). Previous 11β-HSD1 inhibitor series’ from Amgen have also included 
compounds with a central sulfonyl group, which was found to be important for 11β-
HSD1 inhibition. This was determined using a SAR approach and varying each 
moiety systematically. This is demonstrated in figure 1.32A which is the chemical 
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structure of the most potent inhibitor from this series and is the compound seen in 
the crystal structure 3CZR (Sun et al. 2008).  
Indeed, the development of these inhibitors is an exquisite example of employing 
SAR to significantly improve the potency and pharmacokinetic properties of a 
compound. Initially the sulfonyl group was replaced with urea, amides or methylene 
groups, finding the original sulfonyl compounds to be most potent. Subsequently, 
the sulfonyl aryl group was varied and investigated (figure 1.32A, area 2) followed 
by substitutions and replacements at the pyridyl ring (figure 1.32A, part 3 and 4), 
substitutions from this and finally the piperazine ring (figure 1.32A, part 5). However 
the most potent compound from this series (shown in figure 1.32, A and B) displayed 
a poor oral bioavailability in rodents and was water-insoluble. Further SAR was 




Figure 1.32: Overview of the arylsulfonylpiperazines. (A) and (B) Chemical structure of the 
most potent compound from the arylsulfonylpiperazine series, the 3-D model structure 
shows that it forms a V-shape similar to previous 11β-HSD1 inhibitor series’. (C) and (D) 
Further SAR yielded a compound with higher potency which co-crystallised with human 
11β-HSD1. 
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The tert-butylphenyl group of the initial compound (1.32A: on the left hand side of 
the molecule) is located in close proximity to the co-factor and the backbone of Ala 
172. The hydroxyl of Ser 170 forms a polar contact with the sulfonyl group oxygen 
atoms. The second compound (figure 1.32C) was found to bind to the enzyme in the 
same manner but exhibited improved kinetics: the IC50 of A was 10 nM, of B was 0.7 
nM in recombinant human enzyme SPA. In HEK293 cells overexpressing 11β-HSD1, 
the IC50 values were: for B = 14 nM, A = 247 nM. 
 
1.14.9 Pyridine Amides 
This class of compounds were developed by Bristol-Myers Squibb (Wang et al. 2008) 
and have a co-crystal structure which was deposited in March 2008 (3CH6). A SAR 
approach concluded that meta-substituted regio-isomers showed higher potency 
than para-substituted analogues on the central pyridine ring. Lipophilic substituents 
such as 3,3-dimethylpiperidyl amide enhanced potency. In addition, linear isomers 
tended to exhibit weaker potency as compared to V-shaped molecules.  
 
Figure 1.33: Chemical structure of the most potent compound from the pyridine amide 
series, in a 2-dimensional drawing (A, left) and a three-dimensional model (B, right). 
 
The compound observed in the X-ray crystal structure 3CH6 is shown in figure 1.33, 
and forms polar interactions with Ser 170 and Tyr 183; while the dimethylpiperidyl 
substituent is buried further into the binding pocket; the central pyridine core forms 
contacts with Tyr 177. In SPA this compound exhibited one of the highest potencies 
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1.15 An 11β-HSD1 Inhibitor Summary 
There are currently several classes of 11β-HSD1 inhibitors under investigation, many 
with nanomolar inhibition kinetics and reasonable metabolic profiles. These 
investigations allow for a SAR analysis across many different compound classes, 
allowing for the improvement of existing inhibitors and an excellent starting point 
and comparison in the development of new inhibitors; as in the case of this PhD 
project. The major classes of 11β-HSD1 inhibitors which are relevant to this project 
have been tabulated for comparison in table 1.5.  
Inhibitor binding is mediated by a group of 8 to 10 amino acids in the active site; the 
residues involved differ depending on the structural features of the 11β-HSD1 
inhibiting compounds. An overview and further analysis of each inhibitor class 
binding is shown in figure 1.34. 
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Figure 1.34: Illustration of the active site of 11β-HSD1 (each residue shown in blue) and 
five important classes of inhibitors superimposed in the binding site. These are identified 
by their differing colours and are labeled. The compounds shown are those which 
exhibited the highest potency of their compound class in 11β-HSD1 inhibition assays and 
are discussed in the text. Final image is a superimposition of all 5 inhibitors onto the 11β-
HSD1 active site. NADPH is shown at the bottom, in green, distances are not to scale. 
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An additional analysis of the 11β-HSD1 binding pocket was carried out by 
examining existing ligand orientation and position in crystal structures and 




Figure 1.35: Superimposition of various ligands from crystal structures 2BEL 
(carbenoxolone, blue), 2RBE (2-anilinothiazolone, magenta), 3BYZ (a thiazolone, yellow), 
and 2IRW (adamantyl ether, blue), 3CH6 (pyridine amide, pink). Superimposing the 
ligands in this manner allows an insight into the regions of the binding pocket and the 
potential substituents which will interact with them. Illustration adapted from (Lee et al. 
2008). The orange arrow points toward the entrance of the pocket.  
 
The majority of potent inhibitors appear to have a slight V-shape enabling a better fit 
in the active site. It can be seen from figure 1.35 that there are 4 parts to be taken into 
consideration when designing potential ligands for this active site. These are: 
 A solvent exposed region at the opening of the binding site. Importantly, a 
tyrosine residue (Tyr 177) situated at the entrance often interacts 
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hydrophobically with extended molecules - the phenyl ring has been observed to 
π-stack with the thiazolone in the co-crystal structure 2RBE (Yuan et al. 2007). 
 A region for co-factor interaction; the close proximity of the nicotinamide ring 
allows for hydrophobic interactions between the ligand and co-factor as 
observed with carbenoxolone (figure 1.18). 
 A buried hydrophobic pocket, divided into two sections: a deeply buried 
hydrophobic pocket and a second section closer to the entrance of the pocket. A 
hydrophobic group would be necessary here as seen with the sulfone adamantyl 
class of inhibitors. 
This simple analysis of the binding site allows predictions for the types of atoms or in 
fact substituents necessary in specific positions for potential inhibitors. It suggests 
that an ideal potential inhibitor molecule would have to be overall hydrophobic with 
a lipophilic group located near the buried hydrophobic pocket and an aromatic 
group with a hydrogen acceptor substituent located close to the nicotinamide ring of 
the NADPH to allow interactions.  
Further analysis of the residues involved in binding show that a central hydrogen 
acceptor is crucial for tight binding following interactions with Ser 170 and Tyr 183 
as depicted in figure 1.34. This is seen with the majority of inhibitors currently in 
development. 
Several of the inhibitors covered in this chapter will be used as ‘template’ or query 
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Compound Class Structure Ki / IC50 PDB Code Comment 
Carbenoxolone 
 




IC50 1.2 nM 3D4N 
Selective and potent competitive inhibition; 





IC50 1.4 nM 3D3E, 3FRJ, 3FCO 
Selective, potent and metabolically stable, 
competitive inhibition; Interaction of central 




IC50 1.6 nM 3D5Q 
Selective, potent, mixed inhibition; Tyr 183 and 
Ser 170 act as hydrogen bond donors to the 




Ki 7 nM 2ILT, 2IRW 
Selective, potent, competitive inhibition; 
Highlights the importance of a bulky, lipophilic 
group in compound; central carbonyl interacts 
with Ser 170, Tyr 183; 
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Ki 7.2 nM 2RBE, 3BZU, 
3BYZ, 3EY4 
Potent, selective, competitive inhibition; Binding 
similar to sulfonamide class; binding enhanced 





IC50 0.7 nM 3CZR 
Potent, selective; initial difficulties with 




IC50 0.1 nM 3CH6 
Potent, selective; V-shape enhances potency as 
does lipophilicity and position (meta > para) of 
substituents from central pyridine;  
 
Table 1.5: A summary of 11β-HSD1 inhibitors currently in development and with a co-crystal structure in the PDB. 
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CHAPTER 2 
EXPRESSION AND PURIFICATION OF 
11β–HYDROXYSTEROID DEHYDROGENASE TYPE I 
 
2.1 Expression 
2.1.1 DNA and Cloning of Mouse, Rat and Human 11β-HSD1 
The human cDNA of 11β-HSD1was first isolated and cloned in 1991 (Tannin et al 
1991) from a human testis cDNA library, using hybridization with the previously 
isolated rat cDNA (Agarwal et al 1989b). The mouse variant followed soon after 
(Oppermann et al 1995; Rajan et al 1995) along with several new 11β-HSD1 
constructs engineered with and without tags for expression and purification of the 
enzyme (Odermatt et al 1999).  
The DNA plasmids used in this instance for human and murine 11β-HSD1 were 
kindly provided by Dr. Scott Webster from the Endocrinology Unit at the 
University of Edinburgh. In both cases, a truncated 11β-HSD1 gene had been 
cloned into the bacterial expression vector pET-28b. The pET system (Novagen) 
has been developed for the cloning and expression of recombinant proteins in 
Escherichia coli (E. coli), under the transcriptional control of the T7 promoter. The 
expression vector pET-28b encodes a hexa-histidine tag upstream of the inserted 
gene, resulting in an N-terminal His-tag when the protein is expressed. The 
inclusion of a His-tag on the C-terminus has shown to affect solubility and activity 
of the enzyme (Walker et al 2001). The His-tag is linked to the 11β-HSD1 gene 
through a short peptide sequence of 9 residues, 6 of which encode the thrombin 
cleavage site (underlined): 
Ser Ser Gly Leu Val Pro Arg Gly Ser
This expression vector has been employed previously to successfully express the 
catalytic domain of  human 11β-HSD1 (Walker et al 2001b). 
  
The final construct and sequences used are shown in figures 2.1A and B; the 
methods for cloning and cell transformation are described in Chapter 7 (Materials 
and Methods). 
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Figure 2.1(A) Simplified vector map of pET28-b depicting the location of the 11β-HSD1 
gene, the lac operon, Kmr (kanamycin resistance gene), the F1 origin, and the pBR322 
origin of replication. The T7 promoter and terminator are located within the multiple 




Figure 2.1(B) Alignment of the amino acid sequences of human, mouse and rat 
 
11β-
HSD1. The sequence commences with the hexa-His tag (green) with linker sequence. 
The first 23 (or 19 in rat) residues from the N-termini (orange) were truncated so the 
sequence starts with ‘NEE…’ (black). Alignment prepared using the ClustalW server. 
The 11β-HSD1 gene has been deliberately truncated so that the first 23 amino acids 
are deleted, in both the human and mouse gene (19 in the rat variant) as seen in 
figure 2.1B. This region of the protein has a high percentage of hydrophobic 
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residues which are used to anchor the protein into the membrane in vivo. 
Removing these residues results in a more soluble protein product, as described 
previously (Kim et al 2006b) with no adverse effects on activity.  
The rat DNA was synthesized and optimized by Codon Devices, a biotechnology 
company which specializes in construction of synthetic (and E. coli codon-
optimised) cDNA clones. Biased codon usage can result in a lower rate of 
mammalian protein production in E. coli cells. Optimising the codons used can 
overcome this problem - now more cost-effectively than before - without the need 
for rare codon tRNAs in specific cell lines (e.g. the E. coli RosettaTM strain) or 
targeted mutagenesis to remove rare codons (Burgess-Brown et al 2008).  
 
The synthesized rat DNA product was supplied in a pUC19 plasmid, which was 
subsequently exchanged for pET-28b as this has been successfully used to express 
the mouse enzyme (materials and methods are in chapter 7). The plasmids are 
depicted in figure 2.2. 
 
 
Figure 2.2 (A) Expression plasmid pUC-19 (Fermentas) and position of the rat 11β-HSD1 
gene (Codon Devices). (B) Expression plasmid pET28-b (Novagen) showing position of 
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2.1.2 Three Species of 11β-HSD1: Human, Mouse and Rat 
The significance of selecting mouse and rat 11β-HSD1 genes to express in addition 
to the human enzyme gene was three-fold: 
1. to complement the novel inhibitor studies carried out on the human enzyme; 
2. to draw conclusions from the variation in ligand binding between the species 
through analysis of amino acid differences, enabling a more detailed 
structure activity analysis to be developed; 
3. to pre-empt problems in pre-clinical development with rodent models. 
The three forms of 11β-HSD1 all share a high amino acid sequence identity as 
detailed in table 2.1.  
 
Table 2.1: The isoelectric point (pI), the molecular weight, the number of residues and 
similarity to each species homolog and the number of published crystal structures are 





Rat Mouse Human 
Predicted pI 
(native form) 
8.36 9.16 8.71 
Predicted pI 
(Δ1-19 / 23 truncated) 7.88 8.35 8.3 
Predicted weight 
(native form) 
31883 Da 37396.6 Da 32400.9 Da 
Predicted weight 
(Δ1-19 / 23 truncated) 
29633.4 Da 29591.5 Da 29620.5 Da 
Number of residues 
(native form) 288 a.a 292 a.a 292 a.a 
Number of residues 
(Δ1-19 / 23 truncated) 
269 a.a 269 a.a 269 a.a 
Sequence homology to 
human 
76% 78% - 
Sequence homology to 
mouse 87% - - 
Crystal Structures 0 2 11 
 
 
The most significant differences between the three forms of 11β-HSD1 lie in five 
distinct areas, as previously described by Arampatzis (Arampatzis et al 2005) and 
are apparent from an amino acid sequence alignment of all three full-length 
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sequences. These are shown in figure 2.3, labelled I - V. Of the five variable regions 
(in order of N-terminus toward C-terminus); the first is a site of potential 
glycosylation; the second and most important is a highly conserved tyrosine 
residue at position 177, which is replaced with glutamine in rodent forms. The 
third is downstream of the catalytic site and involves several residues (human: Tyr 
201, Ser 202). The fourth and fifth regions (the fifth region having the highest level 
of changeability) exist in the C-terminal region but do not include the residues 
involved in dimerisation (Arampatzis, Kadereit, Schuster, Balazs, Schweizer, Frey, 
Langer, and Odermatt 2005; Hult et al 2006c). 
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Figure 2.3: A multiple amino acid sequence alignment of sequences from human, mouse 
and rat 11β-HSD1. Overlaid are the five distinct regions of the enzyme as described by 
Arampatzis et al., 2005 (regions labelled I –V). The colours represent amino acids of 
similar properties, as shown in the legend. 
 
Residue Colour Property 
A, V, F, P, M, I, L, W Red Small + hydrophobic (incl. aromatic Y) 
D, E Blue Acidic 
R, K Magenta Basic 
S, T, Y, H, C, N, G, Q Green Hydroxyl + amine + basic -Q 
Others Grey  
 
Legend of characters used on the bottom row: 
* indicates identical residues, 
: indicates semi-conserved residues in accordance with the colour chart described above, 
. indicates no conservation. The sequence alignment was performed using ClustalW 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html). 
 
2.2 Aims of 11β-HSD1 Expression 
The main objectives of the expression protocol were to produce a large quantity of 
each of human, mouse and rat enzyme, which must be soluble and active. This was 
to be produced from a bacterial expression system as opposed to previous more 
frequently employed mammalian and yeast expression systems. 
To optimise conditions of the expression, small scale expression trials were 
systematically carried out, in addition to testing co-expression with bacterial 
chaperone proteins to promote correct folding of the enzyme. 
Furthermore, the 11β-HSD1 enzyme produced must also be of a sufficient activity 
for use in enzyme assays and biophysical characterisation, an effort that has been 
rarely achieved in prokaryotic expression systems. A successful bacterial 
expression system would allow for a large quantity of protein to be expressed, 
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2.3 Expression System for 11β -HSD1 
Previous studies with 11β-HSD1 have employed many different cell types for the 
expression of 11β-HSD1. These have typically included mammalian cell lines such 
as; Human Embryonic Kidney (HEK293) (Arampatzis, Kadereit, Schuster, Balazs, 
Schweizer, Frey, Langer, and Odermatt 2005), Chinese Hamster Ovary (CHO cells) 
(Agarwal et al 1989c), and Rat hepatic cells (2S-FAZA) (Voice et al 1996). In 
addition to these, yeast (Pichia pastoris) has proven to be a successful expression 
system (Hult et al 1998; Hult et al 2001a; Nobel et al 2002a) but fewer have 
successfully employed bacterial expression systems until more recently. This was 
predominantly due to the low yield of soluble protein expressed which would be 
principally found as multimeric aggregates or insoluble and packed into inclusion 
bodies, regardless of the N-terminal truncation (Blum et al 2000b; Elleby et al 
2004a).  
There are many advantages to utilizing a bacterial system for expression of 
recombinant proteins such as: potentially high expression of protein; simplicity; 
the cost-effectiveness; and the speed of production. However this expression 
system also poses several caveats - for example a lack of certain post-translational 
modifications – which can ultimately lead to the formation of inclusion bodies and 
protease-mediated degradation of the protein expressed.  
 
2.3.1 Full-Length 11β-HSD1 Expression 
The majority of 11β-HSD1 constructs that have been successfully expressed have 
been truncated versions, notably N-terminal truncations (Elleby et al 2004b; 
Walker et al 2001c) and occasionally C-terminal. The expression of full-length 11β-
HSD1 with retained enzymatic activity is notoriously difficult but not impossible 
as demonstrated in more recent years by Hult et al. and Nobel et al. - both research 
groups based in Sweden (Hult et al 2001b; Nobel et al 2002b). In each case the 
enzyme was expressed in the yeast strain Pichia pastoris.  
In 2006 during the period of this research, 11β-HSD1 (residues 24 – 292) expression 
was achieved in E. coli cells (Kim et al 2006a) by Amgen Inc., and a further 
publication emerged (Castro et al 2007c) the following year from Pfizer, also 
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expressing human 11β-HSD1 (residues 24 – 292) in E. coli BL21(DE3) cells. 
Experimental reproduction of the brief methods detailed in the published articles 
(which made no mention of any specialised methods to aid expression such as co-
expression of chaperones or supplements to the media) resulted in the enzyme 
being detected in inclusion bodies, in the insoluble fraction, of the lysed cell pellets.  
This indicated that further experimental adjustments were to be made, for example 
the co-expression of GroEL and GroES (the bacterial chaperone proteins) alongside 
11β-HSD1 as demonstrated previously (Elleby et al 2004c). Consequently, co-
expression was explored and is discussed in section 2.4. 
 
2.4 Co-Expression of Chaperonins with 11β-HSD1 to Improve Yield 
Initial expression protocols of 11β-HSD1 in E. coli resulted in the majority of the 
enzyme being present in the insoluble fraction of the bacterial cell pellet in 
inclusion bodies. Frequently, this is a result of the misfolding or lack of folding of 
nascent polypeptides in the cell, which are subsequently sequestered into inclusion 
bodies in the cell.  
Subsequent experimental work attempting to solubilise and potentially refold the 
enzyme was avoided in order to prevent possible loss of enzyme activity, 
following previous research (Blum et al 2000a). Instead, the molecular chaperones 
GroEL and GroES were simultaneously co-overexpressed with all species’ 11β-
HSD1 enzyme in E. coli (Elleby et al 2004d). This enabled soluble protein to be 
expressed and purified however, it emerged that a large part of the protein 
preparation remained in complex with the chaperone proteins once extracted from 
the cells and purified. 
 
2.4.1 Background to Chaperonins 
Molecular chaperones are ubiquitous proteins, identified in the majority of micro-
organism and cellular components to date. Their major role is to enable proteins to 
form the correct tertiary structure and oligomeric form whilst preventing 
aggregation and without themselves forming part of the structure in doing so. 
Many of the molecular chaperones are heat-shock proteins – proteins which are 
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constitutively expressed at a level of 1 – 2% of the total cell protein when 
unstressed and more abundantly so upon induction with temperature (an increase 
to 12 % at 46 oC) (Thomas and Baneyx 1996). GroEL and its co-chaperonin GroES 
are the heat-shock proteins of the bacteria E. coli, and are the archetypal members 
of this family of protein folding engines. They are oligomeric proteins of 58 KDa 
and 11 KDa in size, respectively. GroEL is organised into a double stack of 
heptameric rings, forming a molecular cylinder, GroES forms a single heptameric 
ring, and caps the end of the cylinder structure formed by GroEL (Lin and Rye 
2006b). This means that when fully formed, the massive chaperonin 
macromolecule is composed of 14 GroEL monomers and 7 GroES monomers, with 
a weight of 889 KDa (Shimamura et al 2003). Crystal structure analysis of the 
GroEL tetradecamer (Braig et al 1994) and the full GroEL/ES (ADP) macromolecule 
(Xu et al 1997) have greatly advanced the understanding of the protein folding 
mechanism. A general overview of their mechanism of action is shown in figure 
2.3. 
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Figure 2.3: Diagram demonstrating the usefulness of concomitant expression of 
GroEL/ES with 11β-HSD1. (A) Spontaneous folding of the nascent polypeptide chain 
occurs at an extremely low level for 11β-HSD1 with the remaining expressed protein 
deposited into inclusion bodies in the bacterial cells (B). The presence of chaperones 
assists folding of the nascent polypeptide chain, as shown in (C) (adapted from (Lin and 
Rye 2006a)).  
 
The presence and overexpression of both GroEL and GroES is required in order to 
enable proper folding of nascent 11β-HSD1 polypeptides in an ATP-dependent 
manner. They are expressed from one polycistronic expression vector pGro7 
(Takara, Japan, figure 2.4). The chaperone plasmid, pGro7, contains an origin of 
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replication derived from pACYC and a chloramphenicol resistance gene. The 
chaperonin genes are located downstream of the araB promoter with expression 
induced by L-arabinose.  
 
 
Fig. 2.4: Simplified vector map of pGro7 – a commercially available chaperone plasmid 
encoding GroEL and GroES – illustrating the location of Cmr
 
 (chloramphenicol 
resistance gene), pACYC origin of replication, and the arabinose operon. 
Temporal control of over-expression of the chaperone proteins and of 11β-HSD1 is 
paramount; it is necessary that the chaperones GroEL and GroES are already 
present in the cells and able to receive nascent 11β-HSD1 polypeptides from the 
ribosome. Accordingly, pGro7 is induced prior to the plasmid encoding 11β-HSD1. 
It is significant for compatibility that both expression vectors (pGro7, figure 2.4, 
and pET28-b, figure 2.1) utilize different promoters (and thus inducers) and 
different antibiotic resistance genes for selectivity. 
 
2.4.2 The Glucose Effect 
Glucose and sucrose are added to the culture media concomitantly with the L-
arabinose inducer. These additional sugars act indirectly as a lac promoter 
repressor (Grossman et al 1998) by enabling the bacteria to utilize glucose as a 
carbon source, which strongly and negatively influences the cyclic adenosine 
monophosphate (cAMP) levels in the cell. A reduction in the intracellular levels of 
cAMP will result in a more tightly controlled expression system; this is because 
cAMP stimulates the lac promoter. This characteristic is known as the ‘glucose 
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effect’ and is present in several E. coli operons (Robert Novy and Barbara Morris 
2001). 
 
2.4.3 Unraveling 11β-HSD1– GroEL Complexes 
In order to separate the 11β-HSD1 - GroEL complex, two main approaches were 
taken in an attempt to bypass this phenomenon: 
1. Varying expression conditions in an attempt to optimize yield and solubility 
of free enzyme 
2. Supplementing the culture media, lysis buffer and / or purification buffers 
with various ligands 
These methods are discussed more fully in the following sections in this chapter.  
 
2.4.4 Media Culture Additives to Enhance 11β-HSD1 Expression 
The addition of ligands to the culture media has been used successfully with 11β-
HSD1 by Oppermann et al., who published their results in 2008 detailing the 
supplementation of the culture media prior to protein induction with the clinically 
used 11β-HSD1 inhibitor carbenoxolone (Hozjan et al 2008a), figure 2.4.  
 
Figure 2.4: (A) 2-D carbenoxolone, (B) carbenoxolone in a 3-dimensional format. 
  
Prior to this the only known additive to culture media which improved 11β-HSD1 
yield was BVT.4584 (Biovitrum, Stockholm, Sweden), an arylsulfonamidothiazole 
inhibitor (Elleby et al 2004e) which increased the protein solubility and stability 
and  increased yield approximately 50-fold. Addition of a tightly binding 
compound such as carbenoxolone is thought to enhance stability and encourage 
the dissociation of 11β-HSD1 from the chaperone proteins. This is demonstrated in 
figure 2.5. 
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Figure 2.5: The polypeptide chain from the ribosome may be encouraged to fold by the 
presence of tight binding ligands in the surrounding environment. Pictured here is 
carbenoxolone, which binds to the active site of the enzyme with a Ki
 
 of 20 nM.  
Following the success of these examples, the same was attempted in this research. 
The supplements tried were either endogenous ligands or known binders of the 
enzyme, or compounds with published evidence of previously enhancing 
expression yield of difficult-to-express proteins, for example ethanol (Barroso et al 
2003b). 
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2.5 Results  
2.5.1 Expression Trials of Human, Mouse and Rat 11β-HSD1 
Determination of the optimal expression conditions through expression trials was 
carried out in an attempt to improve soluble protein yield. Small-scale screening 
and optimization of protein expression is a valuable method for determining 
subsequent high-yield experimental procedures as it reduces the cost and time of 
each expression trial and therefore allows for more conditions to be assessed 
simultaneously (Berrow et al 2006). It can also prove to be a useful indicator of the 
amount of soluble protein that may be produced on a larger scale. 
There were several main 11β-HSD1 expression conditions that could be varied for 
the expression trials. These are tabulated for clarity, in tables 2.3, 2.4, and 2.5, 
alongside the results.  
Trials were carried out systematically for all three species, initially by only varying 
one condition per trial. Controls were carried out alongside the expression trials 
and were identical in set-up to the experimental expression trial flasks in all 
conditions, but 11β-HSD1 expression was not induced. A ‘favourable’ condition 
was defined as one which caused the greatest increase in 11β-HSD1 protein 
expression, determined by running an aliquot from each trial sample and a control 
on an SDS-PAGE gel followed by analysis. Conditions for cell harvesting and lysis 
were standardised with all samples and the same volume of material was loaded 
each time onto the SDS-PAGE gels to correct for errors of variability. The materials 
and methods used are in chapter 7. 
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Table 2.3: Expression conditions varied for human, mouse and rat 11β-HSD1. The small 
scale expression trials were carried out systematically by adjusting one of the following 
conditions per expression trial alongside appropriate controls.  
 
Expression Condition Variation 
E. coli Cell Strain: BL21(DE3), BL21, C41, C43 
Culture Media: LB, 2xYT, Terrific Broth 
Concentration of IPTG for 
induction of 11β-HSD1: 
0.25mM, 0.5mM, 1mM, 2mM, 5mM final concentration 
Incubation Temperature: 
Cells were consistently grown to an optical density of A600  0.6 at 
37oC. At this point (prior to induction) the temperature was 
changed to: 10oC, 20oC, 25oC, 30oC, or 37o
Incubation Period: 
C. 
The period of incubation after induction was varied from 3 hours 




Figure 2.6: 12 % SDS-PAGE showing the effects of increasing IPTG on the expression of 
human 11β-HSD1. IPTG increases in final concentration from left to right. The level of 
11β-HSD1 appears to be stable with increasing IPTG and decreases past 7.5 mM.  
(A) is the band corresponding to GroEL (58 KDa), (B) is 11β-HSD1 (30 KDa). An error in 
the lane corresponding to 4 mM IPTG has occurred as is smeary and appears overloaded, 
so is not taken into account in this instance. The molecular weight marker (NEB) is 
shown in lane ‘M’. 
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Table 2.4: Expression conditions varied for the concomitant expression of GroEL and 
GroES. The chaperone proteins were induced one hour prior to 11β-HSD1 protein 
expression induction and were consistently expressed alongside 11β-HSD1 in the 
following trials. 
 
Expression Condition Variation 
Concentration of L-
arabinose for induction of 
GroEL and GroES 
Manufacturer recommendation: 0.05 %. 
Varied: 0.01 %, 0.05 %, 0.1 %, 0.2 %, 0.5 %, 1 %, and 5 % final v/v 
L-arabinose. 
Concentration of sucrose 
and glucose 
Manufacturer recommendation: 1 % of each. 
Varied: 0.25 %, 0.5 %, 0.75 % 1 %, 2 % final v/v glucose and 
sucrose, either; 
- added concomitantly with L-arabinose. 
- added to culture media at start of cell growth. 
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Figure 2.7 (top gel): Mouse 11β-HSD1 initial expression trials, showing:  
C = non-induced control,  
A = L-arabinose added so GroEL/ES expression only (the band at ~62 KDa is GroEL) 
I = IPTG added so only 11β-HSD1 expression (no GroEL/ES induction), 
E = L-arabinose and IPTG added, expression of all proteins observed,  
M=molecular weight marker, pre-stained broad range, New England Biolabs (NEB). 
 
Figure 2.8 (bottom gel): GroEL/ES expression trials with increasing L-arabinose 
concentrations (lanes 2, 4, 7 & 9: 0.01 %, 0.05 %, 0.1 %, 0.2 % final v/v L-arabinose, 
respectively) and corresponding controls (lanes 1, 3, 6 & 8). Lanes ‘M’ and 9 are pre-
stained broad range molecular weight markers (New England Biolabs).  
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Table 2.5: Media culture was supplemented with various compounds detailed below. 
Concentrations were determined by calculating a five- or ten-fold increase of the 






∙ 100 μM cortisol 
∙ 100 μM cortisone 
∙ 100 μM corticosterone (for murine 11β-HSD1) 
∙ 1 mM NADP/NADPH 
∙ 50 μM / 100 μM / 200 μM Carbenoxolone 
∙ ethanol 
(All were added concomitantly with L-arabinose) 
  
 
Figure 2.9: 10 % SDS-PAGE gel showing the effects of additives to the culture media 
during expression of mouse 11β-HSD1 (human 11β-HSD1 in figure 2.10). Un-induced 
samples are run beside induced samples. The letter ‘A’ refers to the 11β-HSD1 band at 30 
KDa. Corresponding un-induced samples are seen in lanes 2, 4, 6, 8, 10 & 12.  
 
Lane 1 of the SDS-PAGE gel in figure 2.9 has no additives but does have 
chaperones and very weak expression of mouse 11β-HSD1 (labeled ‘A’) is 
observed under these conditions. Lane 3 has no chaperones and no additives and 
only a low level of expression is observed. Lane 5 shows addition of 100 μM 
carbenoxolone (‘+CBX’) to the culture and chaperones are present; this shows the 
highest level of protein expression. Lane 7 shows a sample with no chaperones and 
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addition of 100 μM carbenoxolone, with a low level of 11β-HSD1 expression. Lane 
9 shows the expression with chaperones and the addition of 3 % ethanol (EtOH) 
prior to expression, with only weak expression seen. Lane 11 shows addition of 3 
% ethanol, no chaperones, and a small amount of 11β-HSD1 expression is 
observed. Therefore, the optimum conditions are presence of chaperone proteins 




Figure 2.10: 10 % SDS-PAGE gel showing the effects of additives on the expression of 
human 11β-HSD1.  Lanes 2, 4, 6, 8, 10 & 12 are corresponding un-induced lanes. The 
letter ‘A’ refers to the gel band corresponding to human 11β-HSD1 at 30 KDa.  
 
In lane 1 of the SDS-PAGE gel in figure 2.10 a faint band (labeled ‘A’) is visible 
which corresponds to 11β-HSD1; this sample had chaperone induction but no 
additives. This faint band is absent in lane 3, where there are no co-expressed 
chaperones and no additives. In lane 5 there is addition of 100 μM carbenoxolone 
and chaperones and the highest level of expression is observed with a stronger 
band at approximately 30 KDa (‘A’). The presence of carbenoxolone also appears 
to increase the level of GroEL observed on the SDS-PAGE. This may be due to the 
fact that the bacterial chaperones are constantly in use when there are higher 11β-
HSD1 expression levels as they facilitate the folding of the enzyme. In situations 
where there is a lower level of 11β-HSD1 expression, less GroEL/GroES is needed 
and redundant chaperone protein may be discarded by the bacterial cells.  
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Lane 7 shows no chaperones (a band often observed at ~ 60 KDa) but the addition 
of 100 μM carbenoxolone and has a faint band at ~ 30 KDa. Lane 9 shows 
chaperones and 3 % ethanol, with a faint band for 11β-HSD1, and lane 11 shows 3 
% ethanol with no chaperones, which surprisingly appears to have a higher level 
of expression than with chaperones. The presence of ethanol also has a positive 
effect on the level of GroEL present. Ethanol is commonly used to increase 
recombinant protein expression in bacteria through the induction of bacterial heat 
shock proteins from the bacterial genome, in this case ethanol simply increases the 
amount of GroEL/ES present (Barroso et al 2003a). As with the mouse variant, the 
optimum expression conditions are the presence of 100 μM (final concentration) 
carbenoxolone and chaperones. The final yield of protein is shown in table 2.6. 
 
Table 2.6: Average yield of protein in milligrams per 1 litre of media culture, with and 
without carbenoxolone (CBX) added to the culture. Mouse enzyme: approximately 80-
fold increase in protein yield observed. Human 11β-HSD1: 3.4 fold increase. Protein 





Average yield/ L with 
GroEL/ES 
Average yield/ L with 
GroEL/ES and CBX 
Mouse 250 μg 20 mg 
Human 5 mg 18 mg 
Rat Insoluble 500 μg (estimated) 
 
2.5.2 Optimal Expression Conditions for 11β-HSD1 
For the expression of human and mouse 11β-HSD1, it was found that the optimum 
yield of protein was obtained with the following conditions;  
1. Co-expression with GroEL and GroES in E. coli. BL21(DE3) cell strain 
2. High-cell-density fermentors were used 
3. The temperature was kept stable at 37oC until the induction of chaperonins 
(at A600 0.6) and then reduced to 20oC for the following 16h incubation 
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4. Chaperone induction with (final concentration) 1 % v/v glucose, 1 % v/v  
sucrose and 0.05 % v/v L-arabinose. After 1 hour, IPTG (final 1 mM 
concentration) was added to initiate the production of 11β-HSD1. 
5. The media culture was supplemented with 100 μM carbenoxolone, a 
known inhibitor of 11β-HSD1. 
 
2.6 Rat 11β-HSD1: Little Soluble Expression 
The rat (Rattus norvegicus) variant of 11β-HSD1 did not yield any significant 
amount of soluble protein. Expression trials were identical to those carried out for 
the human and mouse enzyme (section 2.5.1). 
In contrast to the human and mouse 11β-HSD1 variants, the rat enzyme remained 
insoluble, present in inclusion bodies. This is shown in figure 2.11; an SDS-PAGE 
gel of the bacterial cell pellet (insoluble fraction) in lane 3, and the soluble fraction 
in lane 2. It can be observed that all of the protein (labeled ‘A’) is present in the 
insoluble fraction.  
 
 
Figure 2.11: 12 % SDS-PAGE gel showing the soluble and insoluble fractions of the 
bacterial cell cultures. Lane 1 shows the un-induced control, this is the whole cell 
fraction (soluble and insoluble fractions) run. Lane 2 shows the soluble fraction of the 
bacterial culture overexpressing GroEL/ES and rat 11β-HSD1. Lane 3 shows the 
insoluble fraction of the same bacterial cell culture. The soluble and insoluble fractions 
are prepared by centrifugation post-lysis. The letter 'A' points to the band corresponding 
to rat 11β-HSD1 at 29 KDa. 
 
For expression trials with rat 11β-HSD1, 100 μM carbenoxolone was added to the 
expression cultures. This resulted in a small amount of rat 11β-HSD1 being 
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observed in the soluble fraction, which is shown on the SDS-PAGE gel in figure 
2.12. The soluble protein was purified with IMAC (section 2.8) and run on a 12 % 
SDS-PAGE gel.  
A low level of enzyme activity could be detected in these fractions; the specific 
activity was 3.64 μM min-1mg-1 enzyme (with corticosterone), approximately 3-fold 
lower than the average value for human enzyme under the same conditions (with 
cortisol) and considerably higher than the only currently published data which is 
for albino Wistar rat liver preparation, of 0.14 nM min-1mg-1
It can be seen in figure 2.12 that there is a significantly higher percentage of 
GroEL/ES present (labeled ‘B’) than rat 11β-HSD1 (labeled ‘A’). It is speculated that 
these two proteins are in complex; it was not possible to separate them with 
subsequent purification steps. Further attempts were made to separate the two 
proteins through the addition of ATP (and MgCl
 (Bush et al 1968). This 
value cannot be directly compared to specific activity obtained in this research, but 




carbenoxolone or corticosterone to the buffers, to stimulate the release of 11β-
HSD1 from the GroEL complex. Despite being demonstrated previously with D-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Zhang et al 2001), these 
additions failed to stimulate the release of rat 11β-HSD1. 
 
 
Figure 2.12:  A 10 % SDS-PAGE gel of rat 11β-HSD1 stained with Coomassie gel stain.  
U: uninduced control. O: original sample (the lysate prior to purification). FT: flow 
through from the IMAC column. Remaining lanes are elution fractions from the IMAC 
column. M: marker lanes. From left to right the concentration of imidazole increases to 
elute 11β-HSD1 from the column. A: rat 11β-HSD1 band (29 KDa), B: GroEL (60 KDa).  
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Attempts at denaturation of the protein present in inclusion bodies with a strongly 
denaturing solution (methods in chapter 7) were carried out, followed by IMAC 
purification. This was to denature rat 11β-HSD1 which would dissociate it from 
any putative GroEL/ES complexes and then purify the enzyme, followed by re-
solubilisation. 
Previously, expression of the rat enzyme has been possible in cultured CHO cells 
(Agarwal et al 1989d) where the enzyme was assayed in situ (avoiding cell lysis or 
extraction), in the yeast strain Pichia Pastoris (Nobel et al 2002c) from which it was 
purified, but most significantly E. coli (Elleby et al 2004f). Despite these efforts, the 
rat enzyme has as yet, little or no characterisation published and no crystal 
structure. 
 
2.6.1 Rat 11β-HSD1: An Isoleucine Deletion  
During this research, the rat enzyme remained insoluble or in complex with 
chaperone proteins. This was due to a deletion of one residue in the sequence, 
discovered at a later date. The faulty sequence was taken from Uniprot in 2006 and 
used to generate a synthetic cDNA encoding the rat enzyme. The incorrect 
sequence was originally deposited in 1989 (Agarwal et al 1989e) from a rat liver 
preparation, and was missing Ile 242 (in addition, Glu 235 is exchanged for Gln). 
The original sequence, which was taken from Uniprot, had the accession code 
AAA40886, and has now been amended. It is thought to have been originally 
deposited by Agarwal et al. in the 1990s from a sequence of a cDNA clone isolated 
from rat liver in 1989 (Agarwal et al 1989a). The deletion of an isoleucine at 
position 242 putatively affects the structural integrity of the enzyme, preventing 
the majority of it from folding correctly despite the presence of GroEL/ES, yielding 
an insoluble protein. A predicted three-dimensional structure of the rat enzyme is 
shown in figure 2.13, constructed using a similar, existing mouse X-ray structure 
(PDB: 1Y5R) and an online tertiary structure prediction tool, 3D-Jigsaw. The 
missing residue is highlighted to demonstrate the position and possible 
intermolecular interactions of Ile 242. This residue is located in helix 7 (for helix 
numbering see figure 1.6B) which is partially involved in binding the nicotinamide 
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moiety of the co-factor, although Ile 242 is not known to make any interactions out 
with the protein. 
 
Figure 2.13: Model structure of rat 11β-HSD1 prepared using 3D-Jigsaw and Pymol. 
Highlighted in red is Ile 242, positioned on helix 7. The backbone of Ile 242 forms a 
polar interaction with the backbone of alanine 237 (Ile 241 amine to Ala 237 carbonyl) as 
expected to enable the typical α-helical structure. In addition, interactions are seen with 
threonine 244 (Ile 242 carbonyl to Thr 244 amine) and valine 245 (Ile 242 carbonyl to Val 
245 amine). 
 
As can be seen from figure 2.13, Ile 242 forms several stabilising polar interactions. 
Isoleucine 242 is a hydrophobic residue and is seen to point inward in figure 2.13, 
and a disruption of this sequence may affect the overall amphiphilicity of the helix; 
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that is, one side of the helix is hydrophobic, the other is hydrophilic. This can be 




Figure 2.14: ‘Helical wheel’ drawn from the residues on helix 7. It can be seen that the 
lower face is charged and the upper face is hydrophobic.  The perimeter of the wheel 
corresponds to the backbone and the coloured boxes represent the amino acids.  The 
hydrophilic residues are circles, hydrophobic are diamonds. Negatively charged 
residues are triangles and positively charged amino acids are pentagons. Additionally, 
highly hydrophobic residues are green (with the intensity of colour decreasing 
proportionally with decreasing hydrophobicity) and red corresponds to hydrophilic 
residues. Charged residues are light blue. (A) is the wild type helix 7; (B) is the mutant 
helix 7. The sequence of the helix is shown below. Image created with wheel.pl v 1.3 
(Armstrong 2004). 
 
Figure 2.14 shows that the amphiphilicity of the helix is slightly disturbed by the 
loss of Ile 242, which could have a knock-on effect of disrupting the protein folding 
resulting in an insoluble rat protein. Previous mutagenesis studies on T4 lysozyme 
have demonstrated that 55 % of all mutations are tolerated by a general protein 
structure and do not affect folding or function. Overall, substitutions of surface 
residues are less likely to have an effect compared to solvent inaccessible residue 
substitutions or those in active site positions. A much smaller fraction, 16 % are 
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deleterious, that is, completely abolish protein integrity, which is postulated to 
have happened in this case.   
2.7 Expression of 11β-HSD1: Conclusion 
Previous research (Shafqat et al 2003; Walker et al 2001d) has demonstrated 
expression of an N-terminally truncated 11β-HSD1 in E. coli at low levels in the 
soluble cell fraction. More recently, expression of human 11β-HSD1 in E. coli has 
been shown to be improved by the addition of 11β-HSD1 inhibitors or cortisol 
(Elleby et al 2004g; Hozjan et al 2008b). In this research a higher level of soluble 
and active protein was expressed and consequently purified. 
This was achieved by using a series of expression trials which indicated the 
optimal conditions for expression. Several expression conditions are detailed in the 
literature, such as a lower incubation temperature (Elleby et al 2004h; Walker et al 
2001e) and co-expression of GroEL/ES (Lamark et al 2001; Lee et al 2002) although 
the particular combination of conditions used in this research is novel. 
For the human and mouse 11β-HSD1 it was determined that a co-expression with 
chaperone proteins and the addition of a tight binding inhibitor increased the final 
yield of the protein by approximately 80-fold. In addition, a bacterial fermentor 
was utilised to allow the cell cultures to reach a higher cell density under tightly 
controlled conditions. This increased the yield, as expected, and was consequently 
employed through out protein production. 
The addition of an 11β-HSD1 inhibitor to the culture media has both positive and 
negative implications. Significantly, carbenoxolone acts to stabilize the enzyme by 
binding to its active site (approximate Ki
Ultimately in the case of inhibitor supplements, the benefits outweigh the 
disadvantages, and thus several methods to displace the majority of the 
 20 nM). This increases the human enzyme 
yield over 3-fold, as seen in table 2.6. However, the subsequent and necessary 
removal of carbenoxolone entails a host of lengthy experimental trials and 
procedures in order to be able to test the activity of 100 % of the newly expressed 
and purified protein preparation. This is a challenge that has not been covered in 
literature, despite similar addition of inhibitor. 
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carbenoxolone were determined. These are detailed at the end of the purification 
section in this chapter.  
 
2.8 Purification of 11β-HSD1 
Difficulties purifying this membrane-integrated enzyme arise due to its in vivo 
dependency on the local phospholipid environment for the stabilization of its 
three-dimensional architecture. As an alternative in vitro measure, the presence of 
detergents during the lysis and purification process have promoted this stability 
and enabled a more fruitful procedure. 
There is also the intricacy of preserving the enzyme activity during the processes 
of lysis and purification that must be taken into consideration. This activity loss is 
not necessarily dependent on any one purification method, as it has also been 
observed in native enzyme purified from liver, for example (Agarwal et al 1990; 
Lakshmi and Monder 1988b). 
The presence of an N-terminal His-tag on the final 11β-HSD1 protein product was 
purposefully engineered to enable an effective first purification step of 
immobilized metal affinity chromatography (IMAC). This applied to both mouse 
and human enzyme and has been demonstrated previously in literature (Castro et 
al 2007b; Elleby et al 2004i; Hult et al 2006b; Nobel et al 2002d; Shafqat, Elleby, 
Svensson, Shafqat, Jornvall, Abrahmsen, and Oppermann 2003; Walker et al 2001f). 
Often, a second purification step was required for the human but not the mouse 
enzyme, in which case anion exchange was employed. This was followed by a final 
polishing step of gel filtration. Out of several purification methods that were tried 
and tested, it was these 3 chromatographic methods that were selected and 
optimised to produce the highest yield of pure enzyme.  
 
2.9 Aims of 11β-HSD1 Purification 
The aims of the purification step were to produce highly purified 11β-HSD1 that 
demonstrated both dehydrogenase and reductase activity. The enzyme activity 
was assayed using a simple fluorescence technique and compared with current 
literature evaluations. Purified enzyme was required in sufficient amounts to allow 
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preparation of the enzyme for crystallographic trials (i.e. milligram quantities) as 
well as in activity assays and inhibitor assays. 
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2.10 Purification Methods  
2.10.1 First Step Purification of 11β-HSD1: IMAC (Immobilized Metal Affinity 
Chromatography) 
In IMAC, the histidine affinity for chelated transition metals is exploited for 
purification purposes through immobilization of Ni2+
 
 on a solid sepharose matrix, 
over which flows the cell lysate (liquid phase). Ideally, the His-tagged protein will 
bind to the solid matrix through polar contacts whilst other proteins present in the 
lysate will instead pass over the solid matrix and through the column. This 
purification method was chosen for several reasons; 
1. Alternative first step methods using a dye-affinity purification (AffyGel 
Blue) using the co-factor binding site yielded inactive enzyme in the 
dehydrogenase direction, also seen in literature (Lakshmi and Monder 
1988a) 
2. IMAC is established as an effective and high-yielding purification 
procedure as the first step for either the full-length or truncated variants 
which produce an active enzyme (Castro et al 2007a; Elleby et al 2004j; Hult 
et al 2006a; Nobel et al 2002e; Shafqat, Elleby, Svensson, Shafqat, Jornvall, 
Abrahmsen, and Oppermann 2003; Walker et al 2001g). 
3. IMAC detergent tolerance – the presence of which is vital for the effectual 
purification of active 11β-HSD1.  
 
Both Ni2+ and Co2+ based resins were employed. The cobalt core has a higher 
selectivity for the hexa-histidine tag compared to a resin with a reactive Ni2+ core. 
This is due to spatial restrictions around the cobalt centre, meaning that only 
adjacent histidine residues may bind simultaneously. These spatial requirements 
are not present with a Ni2+
 
 core and so it may instead bind histidines present in the 
protein sequence. The protocol used is described in detail in Chapter 7 (Materials 
and Methods). 
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2.10.2 11β-HSD1 Elution Profile from IMAC 
Imidazole was used to elute the protein from the column as opposed to a pH 
elution as fewer bacterial contaminants were eluted alongside the protein with this 
method. The elution was a gradually increasing gradient of imidazole over the 
column, which involved an initial wash step with a low concentration of imidazole 
(30 mM). The elution of protein was detected by UV sensors at 280 nm, but also 340 
nm which gives an indication of NADPH present. The first elution peak 
corresponds to the chaperones GroEL/GroES and other bacterial contaminants 
(section 1 in figure 2.15(a)). The imidazole gradient is held at 30 – 50 mM until their 
elution is complete. The second UV peak, at a higher imidazole concentration (70 - 
100 mM) corresponds to 11β-HSD1 (section 2, figure 2.15(a)).  
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Figure 2.15: (a) A UV trace of the eluates from an IMAC column of human 11β-HSD1. 
The fraction tube numbers are listed along the bottom of the trace and were 1 ml each. 
Section ‘1’ of the elution trace is the chaperone proteins eluting from the column. This 
corresponds to the same section of the SDS-PAGE gel in (b). Section ‘2’ is human 11β-
HSD1 elution, with a section on the SDS-PAGE gel below accordingly. This particular 
protein preparation gave 9 mg of pure protein from a 500 ml culture of bacteria, and had 
a specific activity of 4.16 μM min-1 mg-1
(c) 12 % SDS-PAGE showing the mouse 11β-HSD1 fractions after IMAC (talon). Lane 1 
& 2 are the flow-through from the column. Lanes 3, 4, 5, 6 & 7 are the elution fractions 
after a wash step with 20 mM imidazole. M is the marker lane, a broad range molecular 
weight marker from NEB. Lane 8 is the crude lysate which was loaded onto the column. 
The letter ‘A’ corresponds to the gel band of mouse 11β-HSD1 (30 KDa). 
. (b) This 12 % SDS-PAGE gel is coupled with the 
UV trace above (a). Section 1 is predominantly chaperones co-expressed with the 
enzyme. Only two fractions have been shown on this gel. Section 2 correlates with the 
elution of the enzyme (enzyme band labeled ‘A’). 
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2.10.3 Second Step Purification of 11β-HSD1: Anion Exchange Chromatography 
The enzyme was either dialysed overnight or passed over a desalting column to 
rid the high salt concentration prior to loading onto an anion exchange column. 
The protein was eluted from the anion exchange column with a NaCl gradient and 
after elution the relevant fractions were analysed by SDS-PAGE (figure 2.16), 
assessed for dehydrogenase activity and pooled (details in chapter 7). 
Anion exchange was selected over cation exchange; the enzyme has a relatively 
high pI of 8.3. At lower pH (i.e a pH lower than 5.5) this enzyme is unstable and 




Figure 2.16: 12 % SDS-PAGE of mouse 11β-HSD1 after the second purification step of 
anion exchange. Lanes 1 and 2 are the same mouse sample loaded at different time 
points during a concentration step. 
 
2.10.4 Third Step Purification of 11β-HSD1: Gel Filtration Chromatography 
The purpose of the gel filtration step is to separate the different oligomeric states 
and aggregated portion of the protein sample. This is necessary for subsequent 
characterization; the sample must be pure and homogenous to enable 
crystallisation to occur. 
For this step, a Superdex 200 10/30 column was used. This apparatus has a column 
volume of 24 ml and a molecular weight range of 10 – 600 KDa. The initial run of 
human 11β-HSD1 showed that there were approximately two species of 11β-HSD1 
present in the sample. These were determined to be a dimeric (64 KDa) and a 
tetrameric (124 KDa) species and the UV elution peaks for each species appeared to 
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overlap quite significantly. Further experimentation and details of the methods are 
covered in chapters 3 and 7 respectively.  
 
2.11 11β-HSD1 Requires Detergent during Purification and Storage  
The absence of detergent during the cell lysis and purification processes results in 
a reduced final yield that is relatively inactive (Elleby et al 2004k). It is therefore a 
necessary additive for stabilising non-polar regions of the protein and enabling a 
higher yield. It is also possible to remove the detergent steadily during the last 
purification steps. 
Detergents are amphipathic molecules which consist of both a polar and a 
hydrophobic group. It is the hydrophobic group in the detergent molecule which 
comes into close contact with a surface exposed hydrophobic region of the protein 
which increases the stability of the macromolecule in aqueous solution. It is also 
this hydrophilic head group which classifies the type of detergent as non-ionic, 
zwitterionic or anionic. 
 Various detergents were screened for their ability to promote stability during 
purification and prevent aggregation of 11β-HSD1. These were Triton X-100, 
Thesit, and CHAPS (3-((3-cholamidopropyl) dimethylammonium)-1-
propanesulfonate). Thesit is a non-ionic detergent that has the typical structure of a 
hydrophilic polyethylene glycol tail attached to a hydrophobic hydrocarbon head. 
Triton X-100 is also a mild, non-denaturing non-ionic detergent with hydrophobic 
hydroalkane chains attached to a longer hydrophilic polyethylene glycol chain. In 
contrast, CHAPS is a zwitterionic detergent with a steroid-like structure. The three 
structures are depicted below in figure 2.17. 




Figure 2.17: A: Triton X-100 (pubchem ID 560774), x = 9.5, B: CHAPS (pubchem ID 
107670), C: Thesit (pubchem ID 24750), diagram prepared with Chemdraw 11.0. 
 
The concentrations of detergents used were below their critical micelle 
concentration (CMC): the concentration at which the detergent will spontaneously 
form micellular clusters in aqueous solution. Whereas lipids will spontaneously 
associate to form multi-lamellar (mono or bi-layers) structures in water, detergents 
will form micelles. These are organized, spherical structures composed of several 
detergent molecules with their aliphatic chains oriented toward the interior of the 
micelle and the polar heads facing the solvent. 
Thesit emerged as the optimum detergent for use in the purification steps, as it 
was found to be easier to remove during the final steps of purification.  
 
2.12 Removal of Carbenoxolone from 11β-HSD1 Preparations 
Several approaches were considered for the removal of carbenoxolone from the 
protein preparation. The many wash steps carried out during the purification 
procedure certainly aided in removing some of the inhibitor, evidenced through an 
apparent increase in enzyme specific activity, although a precise quantification of 
this is difficult. Figure 2.18 depicts the three principal methods approached for 
removal. 
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Figure 2.18: Flow chart showing the methods attempted for removal of carbenoxolone. At 
this point, several wash steps had been undertaken to remove as much as possible 
during purification. The three methods are dialysis, displacement and saturation.  
 
 
The principal caveat associated with a dialysis approach is time scale. Based on the 
Law of Mass Action;    
                k
E + C 
on 




The rate of a chemical reaction is proportional to the product of the concentration 
of the reactants; that is to say the ligand carbenoxolone, C, binds to the enzyme, E, 
with an association rate constant kON (with units M-1 time-1) to form EC: the 
enzyme–carbenoxolone complex. Only one carbenoxolone ligand can bind to the 
enzyme macromolecule, forming a complex that is stable for a time but eventually 
dissociates with a dissociation rate constant kOFF (units time-1
E + EC = E
). As there are no 
catalytic processes involved, the total concentrations of carbenoxolone and enzyme 
are constant: 
TOT     and       C + EC = C
This means that the total concentration of ligand C
TOT 
TOT is simply an addition of the 
free carbenoxolone (unbound) and bound ligand, and the same applies to the total 
enzyme concentration. However, this equation assumes there is no ligand 
depletion; the aim of the dialysis procedure is to provide a diffusion gradient to 
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encourage diffusion of free carbenoxolone across the dialysis membrane which the 
enzyme cannot cross. This reduces the levels of free carbenoxolone present in the 
dialysis bag. After an elapsed time, the dialysis buffer is exchanged for fresh 
buffer, thereby reducing the amount of carbenoxolone available to bind to the 
enzyme and a new cycle begins of dissociation and diffusion of the bound 
carbenoxolone molecules.  
Estimating the KON to be roughly 10 M-1s-1 - a relatively average value for protein 
and ligands - and bearing in mind the nanomolar Kd of carbenoxolone, we may 
estimate a KOFF in the region of 0.0001 s-1. In practice, the mechanistics of this 
method were much slower than this estimation. This is due to the hydrophobic 
interactions between carbenoxolone and 11β-HSD1 which result in a KOFF
However, dialysis remains the most efficient method for carbenoxolone removal. 
The other options, displacement and saturation were ineffective; with regards to 
displacement, there were difficulties with sourcing another inhibitor which would 
have a smaller K
 
potentially up to 10 times smaller. 
i than carbenoxolone and the subsequent consequences of this 
during assays. In future expression trials, the novel inhibitors assayed in this 
research could be used in place of carbenoxolone. This would facilitate further co-
crystallisation trials of the enzyme and novel inhibitor; it would circumvent the 
potentially destructive process of crystal soaking (into a solution of inhibitor) and 
by virtue of having a lower Ki than carbenoxolone it would also be easier to 
remove. In the absence of another suitable inhibitor, saturation of the binding site 
with another competing ligand would theoretically physically block free 
carbenoxolone from binding the enzyme. This was carried out with 1-methyl-
piperazine and cortisol, with no increase in activity in assays carried out afterward 
(1-methyl-piperazine: 0.044 μM sec-1mg-1
To encourage dissociation of the inhibitor during dialysis, constant stirring is 
applied to the solution and also the buffers were varied according to pH, salt 
 before and after). The specific activity is a 
good indication of free enzyme (that is: enzyme which is not bound to 
carbenoxolone).  
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concentration and presence of detergent or glycerol. The effect of varying buffers 
was insignificant as monitored by enzyme specific activity. 
A method for estimating the concentration of active sites ([E]) was used - an active 
site titration using carbenoxolone - which enabled further enzyme activity studies 
to be carried out (details are in chapter 3 and 7). 
 
2.13 Confirmation of protein identity 
Matrix Assisted Laser Desorption Ionisation–Time of Flight Mass Spectrometry 
(MALDI-TOF) was used to determine the exact molecular weight of the protein 
preparation (figure 2.19). In addition, a trypsin digest of the protein preparation 
was carried out to confirm the identity of the protein. Both methods confirmed that 
the purified protein was 11β-HSD1, with a molecular weight of 31924.54 g / mol. 
This molecular weight is slightly higher than the computationally predicted 
molecular weight (table 2.7). It is postulated that this is due to the presence of 
triton X-100 or carbenoxolone on corresponding sites in the enzyme. The full-
length spectra for human and mouse are shown here (figures 2.19 and 2.20 
respectively). A tryptic digest of rat 11β-HSD1 is shown in chapter 8 (appendix). 
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Figure 2.19: A spectrum from MALDI-TOF of human 11β-HSD1, showing a clean spectra 
with the major peak at 31924 Da which is a monomer species and a second smaller peak 




Table 2.7: Summary of molecular weights of NADPH, carbenoxolone, Triton X-100 and 
human and mouse 11β-HSD1 from MALDI-TOF (this particular enzyme preparation 
contained triton X-100) 
 
The molecular weights of the human and murine enzymes from the MALDI-TOF 
spectra reflect the presence of either co-factor, detergent or carbenoxolone in 
addition to a smaller molecular weight adjunct, such as an oxidative post 
translational modification. The exact reason for the discrepancy is unknown. 
 M.W: Corresponds to: 
MALDI-TOF Peak (human): 31924 Da 
 Human enzyme + triton 
X-100 or CBX 
Predicted 11β-HSD 1 M.W (human): 31248 Da - 
MALDI-TOF Peak (mouse): 31718 Da 
Mouse enzyme + triton 
X-100 or CBX 
Predicted 11β-HSD 1 M.W (mouse): 31255 Da - 
Carbenoxolone (CBX) M.W: 614.72 - 
NADPH M.W: 834.33 - 
Triton X-100 approximate M.W: 625 - 
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Figure 2.20: A spectrum from MALDI-TOF of mouse 11β-HSD1, showing a spectrum 
with the major, monomeric peak at 31718 Da. 
 
2.14 Conclusion 
An effective purification procedure was determined for human and mouse 11β-
HSD1, which yields a protein sample that is stable for up to a week at 4o
Due to the addition of carbenoxolone during expression, the final protein 
preparation is partially in complex with this tight binding inhibitor. To determine 
the quantity of carbenoxolone present, active site titration was carried out, which is 
covered in detail in chapter 3. Methods to dissociate the carbenoxolone from the 
enzyme were investigated and dialysis was determined as the most effective 
method. Future work would focus on complete removal of the carbenoxolone from 
the protein preparation. This could be carried out by attempting to add a tight-
binding novel inhibitor (chapter 5) to the expression cultures in place of CBX. 
Alternatively, the use of commercially available, hydrophobic beads used to 
remove detergent and other hydrophobic compounds may be used (e.g. BioBeads, 
BioRad, CA. USA) as have been previously employed with success in the removal 
of CHAPS (Arnold and Linke 2008; Hall and VandenBerg 1989). 
C and is 95 
% pure as determined by densitometric analysis of the SDS-PAGE gel.  
As a membrane-integrated glycoprotein, 11β-HSD1 is a challenging protein to 
express and purify. Recent evidence suggests that 11β-HSD1 does not require the 
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post-translational N-linked saccharides to carry out its physiological function 
(Blum et al 2000c). This is a double-edged sword; it means that it can be expressed 
in prokaryotic expression systems more easily; however it also results in the 
exposure of hydrophobic spots which would have previously been linked to 
saccharides. These hydrophobic spots may putatively interact with the membrane, 
and increase the yield of insoluble or aggregating enzyme. 
Rat 11β-HSD1 proved to be extremely challenging to express and repeated 
experiments concluded that the problem was due to an incorrect sequence rather 
than in expression conditions, as variation of several factors made very little 
difference to the yield of rat 11β-HSD1.  
In summary, the expression of high yields of an active and soluble human and 
mouse enzyme was achieved. Optimization of expression conditions culminated in 
the combination of co-expression with chaperone proteins and the addition of a 
supplementary ligand to the culture media, with low temperatures during 
induction and use of a fermentor. The cell products were subsequently lysed and 
the 11β-HSD1 was purified in two steps, in the presence of detergents, to apparent 
homogeneity and 95 % purity. 
 
- 95 - 
CHAPTER 3 
BIOPHYSICAL CHARACTERISATION OF 
11β–HYDROXYSTEROID DEHYDROGENASE TYPE I 
 
3.1 Introduction 
Many facets of 11β-HSD1 biochemistry are well-characterised, for example 
mutagenesis studies have pinpointed essential residues for function (White et al 
1997) glycosylation sites (Arampatzis et al 2005; Blum et al 2000),  kinetic studies of 
comparative species (Shafqat et al 2003) and of course several structural studies and 
X-ray crystal structures (Julian et al 2008, Patel et al 2007, Sorenson et al 2007, Zhang 
et al 2005). X-ray crystallography has provided definitive evidence of 11β-HSD1 as a 
tetramer in the crystal unit, as a dimer of dimers. There are several techniques which 
may be used to estimate the oligomerisation state of the enzyme in solution and also 
in which state it is active. Using gel filtration and Dynamic Light Scattering (DLS) in 
the present research, it has been possible to determine these characteristics. 
Finally this chapter will provide details of simple kinetic characterization for the 
mouse and human recombinant enzyme using fluorescence as an assay technique. 
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3.2 Gel Filtration Analysis 
Gel filtration is a high resolution chromatography technique for separating proteins 
by size. A Superdex 200 10/30 chromatography column was used which has a 
column volume of 24 ml and has a molecular weight range of 10 – 600 KDa. 
Superdex is composed of cross linked agarose and dextran and the particulate beads 
have an average size of 13 μm. It had been previously calibrated with high and low 
molecular weight gel filtration calibration kits (Amersham Biosciences), carried out 
in the same buffer and according to the suppliers instructions. This is shown in 
chapter 8 (Appendix). Each experimental run was carried out with 200 μl of a 
concentrated sample of human 11β-HSD1 (typically at 35 - 38 mg/ml) with a simple 
buffer for equilibration and elution (50 mM Tris pH 8.3, 20 mM NaCl, 0.01 % Thesit 
v/v). The initial run of human 11β-HSD1 showed that there were approximately two 
species present in the sample, shown in figure 3.1. These were determined to be a 
dimeric (64 KDa) and a tetrameric (124 KDa) species, although the UV elution peaks 
for each species appeared to overlap quite significantly.  
 
 
Figure 3.1: Chromatogram of gel filtration column elution (Superdex 200 10/30). Along the 
abscissa are the fraction tube labels in red, and the volume in millilitres in black. On the 
ordinate can be seen the UV absorbance units (mAU). Four runs were carried out which are 
overlaid in various colours.  
Void: 8 ml 
Major peak:  12.81 ml 
Shoulder peak:  11.62 ml 
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The apparent molecular weight of each protein species was determined from a 
calibration curve where the elution volumes of the standard proteins were plotted 
against the logarithm of their respective molecular weights (chapter 8). 
The non-globular three-dimensional shape of 11β-HSD1 purports that the classic 
method of determining the protein molecular weights from the calibration curve and 
diffusion co-efficient (KAV) will not generate accurate results. In practice, using this 
technique generates weights for the two peaks of 11β-HSD1 of 190 KDa for the major 
peak, and 340 KDa for the shoulder peak: much higher values than should be 
expected. This is because this method does not cater for discrepancies such as non-
globular proteins. 
 
3.2.1 The Effects of Protein Shape on Gel Filtration: 11β-HSD1 is Ellipsoid 
Further analysis taking into account the rather ellipsoid shape of the human 11β-
HSD1 dimer and tetramer involved basic calculations of the hydrodynamic radius of 
each oligomeric species. This is shown below, in figure 3.2.  
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Figure 3.2: Measurements of the length and width of the human 11β-HSD1 dimer (left) and 
tetramer (right) taken at the longest and widest parts respectively. Overall the dimer has an 
ellipsoid shape and has an axial radius of 1.4. For this analysis, two crystal structures of 
human 11β-HSD1 were chosen as models. These were 2IRW (Patel et al 2007) for the dimer, 
and 1XU7 (Hosfield et al 2005) as the tetramer. For the hydrodynamic radius, the 
measurements were taken as shown in the lower part of the diagram. The values shown in 
red are the diameters. 
 
The calibration allowed for a plot of √(-Log KAV) versus the Stokes radius to be carried 
out for each of the calibration proteins. Knowing the diffusion co-efficient and the 
calculated stokes radius of 11β-HSD1, it was possible to approximate the apparent 
oligomeric species of the 11β-HSD1 elution peak in question by extrapolating from 
the plot of the calibration proteins √( -Log KAV) vs Stokes radius. The results are 
tabulated below for clarity, in table 3.1. 
 
 

















Major peak 12.83 ml 0.301 48.8 Å ~ 50 Å DIMER 
Shoulder peak 11.69 ml 0.23 57.8 Å 57 Å TETRAMER 
 
 
Table 3.1: Calculated molecular weights of the two peaks from gel filtration. The molecular 
weight is estimated through analysis of the Stokes radii of a set of calibration proteins and 
the protein of interest and extrapolated. 
 
The major peak corresponds to a Stokes radius of 48.8 Å, which is approximately the 
length of the tetramer illustrated in figure 3.2 above. The shoulder peak 
corresponded to a Stokes radius of 57.8 Å, suggesting it is dimeric 11β-HSD1. These 
results are in accordance with current literature and all published crystal structures 
(Elleby et al 2004, Hosfield et al 2005, Maser et al 2002). 
An overlap observed between two peaks is indicative of either: rapid interchange 
between two heterologous species in solution, or a result of low resolution from the 
chromatography column used.  
At higher concentrations of 11β-HSD1, it may be that there is an interchange between 
dimer and tetramer occurring as a result of an increased probability of one 11β-HSD1 
dimer encountering another and forming a tetramer. By decreasing the concentration 
of the sample, this probability is also decreased and therefore promotes a better 
distinction of the dimer and tetramer peaks. Experiments carried out with a reduced 
concentration of 11β-HSD1 yielded a similar overlap between the peaks, suggesting 
no concentration-dependence of the overlap which in turn indicated that no rapid 
interchange between dimer and tetramer was occurring. As an alternative 
explanation, it is suggested that as a sample diffuses down a column, the molecules 
may also diffuse across the column; axial diffusion. It is this horizontal diffusion by 
11β-HSD1 that may create the overlap in the peaks, and may be fixed by using a 
higher-resolution column, i.e. one which has a longer column length but smaller 
diameter. This was tested using a Superdex 200 PC 3.2/30 column, which gives a 
higher resolution; it has the same length as the Superdex 200 10/30 (that is; 30 cm) but 
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Figure 3.3: A UV trace of elution from the gel filtration column Superdex 200 PC 3.2/30. Six 
runs were carried out which are overlaid in various colours. Each run consisted of the same 
volume but different concentration of human 11β-HSD1; 400 μM (blue dash), 200 μM (blue 
solid), 100 μM (pale blue), 50 μM (green), 25 μM (grey), 1 μM (brown). 
 
As can be seen from figure 3.3, the overlap between the two species’ peaks remains, 
although it is significantly reduced due to the higher resolving power of the 
Superdex 3.2/30 rather than a decrease in protein concentration. 
This suggests that there is no concentration-dependent interchange, but also that 
increasing the resolution power of the chromatography column has a beneficial effect 
on separation of the two heterologous species. Previous studies with non-reducing 
gels show several bands in each lane corresponding to various oligomeric states of 
the recombinant enzyme (Walker et al 2001), and human liver extracted-11β-HSD1 
indicated that there was a combination of oligomers present (Ozols 1995). Therefore, 
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this apparent heterogeneity is potentially not a result of bacterial expression of 
recombinant protein but is encountered with various preparations of 11β-HSD1.  
In addition to using gel filtration to determine the oligomeric states of human 11β-
HSD1, this technique was used to determine whether increasing the concentration of 
carbenoxolone or thesit detergent would improve the folded: unfolded form ratio or 
the oligomeric distribution of the enzyme, respectively. This was carried out for 
human 11β-HSD1, expressed with chaperonins but without the addition of 
carbenoxolone. To this end, a sample of 30 μM human 11β-HSD1 was applied to a 
Superdex 200 (10/300 GL) chromatography column with increasing concentrations of 
carbenoxolone (1-100 μM final concentration) as well as a blank containing ethanol, 
however this did not have an effect on the amount of folded enzyme, nor on the 
oligomeric forms. In addition, increasing the concentration of the detergent thesit 
from 0 – 0.5 % (ranging above and below the CMC) did not affect the oligomeric 
states of 11β-HSD1, as may be seen in figure 3.4. Detergents may be successfully 
employed to prevent aggregation and improve solubility of hydrophobic proteins. 
Consequently, a sample containing no detergent (dark blue trace in figure 3.4) might 
be expected to have a larger void volume as 11β-HSD1 may aggregate forming high 
molecular weight clusters. This is not observed, suggesting that the presence of 
carbenoxolone in the active site and residual thesit molecules from the purification 
process are sufficient to stabilize 11β-HSD1 in solution and prevent aggregation. 




Figure 3.4: A UV trace of elution from the gel filtration column Superdex 200 PC 3.2/30. 
Five runs were carried out which are overlaid in various colours. Each run consisted of the 
same volume but different concentration of the non-ionic detergent thesit (and 100 μM of 
human 11β-HSD 1); 0.05 % (red), 0.1 % (green), 0.5 % (magenta), 0.25 % (pale blue), a 0 % 
control (dark blue). 
 
3.3 Dynamic Light Scattering 
Dynamic Light Scattering (DLS) was used to identify the monodispersity of the 
mouse enzyme prior to crystallization and the oligomeric state in solution. 
Experiments were carried out with increasing concentration of enzyme to observe 
concentration effects on oligomerisation, and also with increasing concentration of a 
non-ionic detergent, triton X-100.  
Enzyme concentration ranged from 0.02 mg/ml to 1 mg/ml with little variation in the 
oligomerisation state of the enzyme, analogous to studies carried out with gel 
filtration using the non-ionic detergent thesit (section 3.1). Samples were analysed at 
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room temperature using a Wyatt DynaPro DLS instrument. A radius of ~14 nm was 
observed (table 3.2), which correlates to a tetramer assembly of mouse 11β-HSD1, at 
each concentration tested. The oligomerisation state was determined through 
comparison of measurements taken of the mouse crystal structure 1Y5R (Zhang et al 
2005a) (figure 3.5). Overall, a 50-fold increase in 11β-HSD1 concentration did not 
have any effect on the oligomerisation state of the protein or on the level of 
aggregation. 
 
Table 3.2: Effects on enzyme radius with varying concentrations of mouse 11β-HSD1, 
determined by DLS. Mean radius (nm) is calculated for each concentration with standard 
deviation (nm). The percentage mass aggregate is the percentage of the sample calculated 










0.02 mg/ml 13.02 3.78 22.1 
0.1 mg/ml 14.49 3.37 28.3 




7.98 5.31 1.2 
  
 
Figure 3.5: A surface representation of 1Y5R, mouse 11β-HSD1, shown as a dimer. 
Measurements are shown on the diagram, with a lengthwise diameter of ~81 Å and ~62 Å.  
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However, the addition of cortisone and co-factor resulted in formation of a dimer 
with a mean radius of ~ 8 nm. The switch from a tetramer to a dimer upon addition 
of activity-inducing components (substrate and co-factor) suggests that the mouse 
enzyme may be active in its dimeric form, but is able to create and break a tetrameric 
assembly when required. 
Additional experiments with increasing triton X-100 concentration were carried out 
in identical conditions, with the exception that purified, active mouse 11β-HSD1 (1.6 
μM) was incubated for approximately 2 hours at 4oC in assay buffer (50 mM Tris pH 
8.0, 50 mM NaCl) with varying concentrations of the non-ionic detergent Triton X-
100. The concentrations varied above and below the critical micelle concentration 
(CMC) of the detergent (which is 0.015 % / 0.26 mM). The degree of polydispersity 
was not calculated for samples containing detergent due to the scattering 
characteristics of triton X-100. In the absence of detergents, it was calculated using 
either the mono-modal or the bi-modal assumption within the instrumentation 
software and the four samples were all found to be polydisperse. 
Increasing the detergent concentration resulted in a decrease in the mean radius 
detected by DLS. The data are shown in table 3.3. 
 
Table 3.3: Overview of mouse 11β-HSD1 radius (nm) as determined by DLS, with 
increasing triton X-100 concentration. The mean radius (nm) of the highest percentage peak 
is shown, with standard deviation (in nm) and the calculated percentage of aggregates 
present in the sample. 
 
Triton X-100 
concentration, % v/v 




0.001 % 7.7 4.4 0.8 
0.005 % 7.3 4.5 0.6 
0.01 % 7.7 5.0 0.9 
0.05 % 4.5 5.1 0.1 
0.075 % 4.2 0.9 0.8 
0.1 % 4.2 0.9 1.6 
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The data showed a distinct switch from tetramer (below the CMC) to dimer (above 
the CMC). This is depicted in figure 3.6.  
 
 
Figure 3.6: Variation of mouse 11β-HSD1 radius with increasing triton X-100. The radius 
decreases with increasing detergent concentration. The green line depicts the CMC of 
triton X-100 (0.015 % v/v). A radius of ~ 4 nm corresponds to a dimer, and 8 nm indicates a 
tetramer assembly as indicated on the graph.  
 
Interestingly, in the absence of triton X-100, the mean radius is ~ 13 – 14 nm (table 
3.2), which is twice as large as it is in the presence of 0.001 – 0.01 % triton X-100 at ~ 7 
nm (table 3.3). This may well be a result of triton X-100 stabilising the protein in 
aqueous solution by binding to hydrophobic patches on the surface of the mouse 
protein, preventing small scale aggregation (which would have a radius ~14 nm, as 
observed in the absence of triton X-100). It has been noted previously that in the 
absence of detergent, 11β-HSD1 forms large multimers in solution (Elleby et al 2004).  
This is in contrast to results obtained with the detergent thesit in gel filtration 
experiments which did not have a significant effect on the oligomeric state of human 
11β-HSD1. This is accounted for by the presence of carbenoxolone in the human 
enzyme, which is not present in the mouse 11β-HSD1 preparation. Significantly, the 
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addition of co-factor and cortisone also shows a calculated radius of ~ 8 nm, akin to 
triton X-100 incubated samples.   
In 2005, Hosfield carried out static light scattering experiments with 11β-HSD1 and 
observed monodisperse masses of about 139 KDa (Hosfield et al 2005): a tetrameric 
assembly of 11β-HSD1. The results presented here show that in the absence of 
detergent the enzyme forms large, multimeric aggregates in agreement with 
previous literature. In addition, 11β-HSD1 appears dimeric above the CMC due to 
the stabilising effects of the detergent micelles, and tetrameric (or a higher assembly) 
below the CMC.  
 
3.4 Fluorescence Assay  
Background 
Fluorescence assays simplistically involve the molecular absorption of light energy at 
one wavelength and its re-emission at a longer wavelength. The light is absorbed by 
molecules in approximately 10-15 seconds, causing electrons to become excited to a 
higher electronic state. After approximately 10-8 seconds the electrons return to the 
ground state, emitting energy. Some of this excess energy may be lost through 
molecular collisions but that which is not can be detected as emission of light energy.  
All molecules absorb light, however only a relatively low number of species emit 
light, more often rigid conjugated polyaromatic hydrocarbons or heterocycles.  
It is only the light emitted from the electronically excited singlet state that is known 
as fluorescence. 
In terms of quantitation, enzymatic dehydrogenase reactions can exploit the light-
absorbing properties of NADP at 340 nm, which is not exhibited by NADPH. 
Similarly, the reduced form is capable of fluorescent emission at 458 nm when 
excited at 340 nm, whereas the oxidised form is not. In this manner, the rate of the 
enzymatic reaction can be followed as the increase in fluorescence (i.e. the rate of 
formation of NADPH) emitted over time. The intensifying fluorescence corresponds 
to an increase in the concentration of NADPH present in the reaction cuvette (or 96-
well plate), equivalent to the increase in cortisone concentration, as the reaction has a 
co-factor to product stoichiometry of 1:1 (figure 3.7A).  
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Figure 3.7: (A) Summary of the enzyme reaction resulting in the formation of the 
fluorescent product NADPH, with excitation and emission wavelengths. (B) 
Representation of the dehydrogenase reaction raw fluorescence data from two human 11β-
HSD1 fractions post-purification (in magenta and blue, control is yellow). The x-axis 
shows the time scale of the reaction, the y-axis shows the counts per second (CPS) of 
fluorescence. This is subsequently converted into a quantity of NADPH using calibration 
charts. 
 
The sensitivity of fluorescence is dependent on the fluorophore and the instrument 
employed. The response of the fluorophore is dependent on its molar absorption and 
the quantum yield. The fluorescence quantum yield (Q) is defined as the ratio of the 
number of fluorescence photons emitted (F) to the number of photons absorbed (A), 
i.e. the probability that a compound will fluoresce: 
 
A
FQ =          Eqn 3.4 
 
The sensitivity of a fluorometer is expressed as the ratio of the signal of a standard 
sample to the noise level (SNR). 
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Fluorescence assays were used for the determination of all kinetic data in the 
dehydrogenase direction. For data pertaining to the reductase direction, SPA was 
employed (chapter 4). Emission data were obtained with a Molecular Devices 
SpectraMax M5 Multimode plate reader instrument, with a 340 ± 9 nm bandpass 
exciter and a 458 ± 15 nm band-pass emitter. Fluorescence has been used previously 
for determining kinetic data for 11β-HSD1 (Hosfield et al 2005, Hult et al 2006).  
Optimisation of fluorescence conditions was determined through a gradual increase 
in the concentration of 11β-HSD1, with fixed NADP (final 500 μM) and cortisol (final 
100 μM) concentrations. It was found that 30-40 μg of enzyme (1 – 1.3 nM) per 
dehydrogenase reaction would allow for no more than 20 % of substrate conversion, 
and so measurements were carried out in the linear range of product formation 
versus reaction time and enzyme concentration. This is consistent (Hult et al 2006, 
Shafqat et al 2003) or is lower than literature values (these are: 5 nM (Castro et al 
2007e); 50 nM (Hosfield et al 2005); and 100 nM (Kim et al 2006)).  
 
3.5 Kinetics 
Several recent studies have demonstrated the importance of incubating the enzyme 
with co-factor NADP(H) prior to addition of the steroid or substrate in assays. This is 
based on evidence of an ordered sequential mechanism, whereby NADP(H) binds 
first to the enzyme (Castro et al 2007, Monder et al 1991, Sahni-Arya et al 2007). This 
suggests that binding of the co-factor first allows for a conformation more adept at 
binding steroids. Certainly, the interactions observed between co-factor and 
substrate and / or ligands serve to enhance binding (chapter 1). This has also been 
observed with 11β-HSD2 (Niu and Yang 2002).  
In addition, several additives to the assay reaction may increase the activity of 11β-
HSD1, as demonstrated by Castro et al., with the addition of various lipids to the 
reaction. In particular, phosphatidyl serine had a positive effect on both rabbit and 
human variants of 11β-HSD1 (Castro et al 2007). In a similar manner, in this research 
the addition of triton X-100 not only facilitated purification, but altered the 
oligomerisation state (figure 3.6) and also increased the activity of the mouse 
enzyme, as discussed below. 
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3.5.1 Effects of Experimental Conditions on Enzyme Activity 
The presence of a detergent was found to increase the rate of reaction, as 




Figure 3.8: Plot showing the rate (Vo
 
) versus the percentage (v/v) of triton X-100 added. As 
can be clearly seen from the plot, there is an upward trend with additional triton X-100. 
Standard deviation shown calculated using the ‘n-1’ method where n=3.  
The presence of 0.07 % v/v detergent in the assay buffer increased the rate of reaction 
(Vo
It is postulated that this increase in rate is a direct result from the stability incurred 
by the presence of hydrophobic additives in the buffer. However, there are more 
rational and structural-based hypotheses; firstly, in vivo, the C-terminal helices of the 
dimeric enzyme form a non-polar ‘plateau’ which is in contact with the non-polar 
region of the membrane. Hydrophobic steroids can then more easily enter the active 
site of the enzyme, as this arrangement in vivo effectively ‘funnels’ the ligand in. 
Transferring this to an in vitro setting, it is plausible that the presence of a 
) 1.47-fold. This significant increase has been mirrored in previous studies with 
the addition of various phospholipids to the assay buffer (Castro et al 2007).   
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hydrophobic compound, such as Triton X-100 (above its CMC) or phosphatidyl-
serine, may exert a similar effect by similar means. Secondly, research with DLS 
(from section 3.2) demonstrated that an increased triton X-100 concentration will 
yield 11β-HSD1 macromolecules with a lower radius i.e. dimers rather than 
tetramers, as compared to samples with a lower concentration of triton X-100. As the 
enzyme is thought to be active as a dimer, the increase in triton X-100 may therefore 
increase the amount of dimeric, active enzyme. A correlation between the enzyme 
activity and radius is depicted in figure 3.9. 
 
 
Figure 3.9: Correlation between the mouse 11β-HSD1 radius with increasing triton X-100 
and rate of reaction (in μM min-1 μg-1
 
). DLS experiments were carried out in 50 mM Tris pH 
8.0, 50 mM NaCl. Kinetic assays were carried out in 50 mM Tris pH 7.7, 50 mM NaCl,   
With increasing triton X-100 concentration, an increase in enzyme activity is 
observed which reflects the stabilising effects of the detergent, and a switch from the 
tetramer to the dimer form of the enzyme. The detergent mimics the role of 
phospholipids in vivo by forming micelles which act as artificial membrane 
structures. This shift in oligomerisation state and increase in activity occurs around 
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the CMC point of the detergent, which is not an exact boundary but rather a broad 
transition. The absence of detergent results in enzyme aggregation and a loss of 
activity. This enhancement of enzyme activity by detergent has also been observed in 
other membrane-associated enzymes (Kronenburga and de Bont 2001). 
Further experiments observing the effects of increasing ethanol or DMSO 
(dimethylsulfoxide) on activity were carried out (data not shown). A roughly 
proportional relationship was determined between increasing DMSO and human 
11β-HSD1 activity, at low concentrations of DMSO ([specific activity]/ (%DMSO) = 
2). A similar trend was seen with ethanol, although the increase in activity was less 
([specific activity]/ (% EtOH) = 1.2). Potentially these solvents are having an effect on 
the substrate rather than the enzyme, facilitating solubilisation of the hydrophobic 
cortisol, enabling a higher concentration to reach the enzyme. 
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3.5.2 Enzyme Kinetics 
The apparent Km (Kmapp
 
) for 11β-HSD1 may be determined from a standard 









=       Eqn 3.0 
 
 
Figure 3.10: A: Michaelis-Menton plot of 11β-HSD 1, dehydrogenase reaction. The Kmapp 
was determining by measuring the rates of conversion of cortisol to cortisone, at a fixed 
concentration of 1 μM enzyme and NADP. This gives a Kmapp of 21.9 μM. B: A Michaelis-
Menton plot of the reductase reaction, with cortisone. The Kiapp
 
 is 0.5 μM. 
The mouse enzyme has a lower affinity for cortisol than the human enzyme (the 
mouse Kmapp value is 48 μM ± 8.9, data not shown) as expected; cortisol is not the 
endogenous substrate; crucial differences between the active sites (Y 177 exchanged 
for Q 177, chapter 1) which edge the mouse enzyme toward a higher affinity for 
corticosterone, which has a hydroxyl group at position 17. The values obtained are in 
general agreement with previous studies (Castro et al 2007, Hult et al 1998, Nobel et 
al 2002, Shafqat et al 2003). Published kinetic data for 11β-HSD1 can be ambiguous; 
there can be a roughly a 100-fold variation in Km values due to the wide variety of 
expression systems and vectors used.  The kinetic data are summarised in table 3.4. 
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Table 3.4: Summary of averaged kinetic data. Data were determined using a 
fluorescence assay which monitors the NADPH concentration. All assays were 
carried out under identical conditions as detailed in materials and methods. The 








Mouse 11βHSD1 Rat 11βHSD1 
Kmapp cortisol 21.9 ± 5.4 μM 20.6 ± 3.2 μM 48 ± 8.9 μM / 
Kmapp cortisone 0.55 ± 0.1 μM 1 ±  0.8 μM / / 
Specific Activity 
(μM min-1mg-1) 
2.82  1.98  2.08  
0.4 /  
(0.9 in lysates) 
[E]t  6.2 % 5.8 % / / 
 
The Kmapp for cortisone (reductase) was lower than the Kmapp for cortisol 
(dehydrogenase reaction) in accordance with previous studies (Shafqat et al 2003) in 
addition, the Vmax
In the majority of 11β-HSD1 kinetic studies, homogenated material is used which 
generally show lower apparent Km values for cortisone (low micromolar range) 
whereas higher Km values are reported for recombinant homogenates or purified 
samples. This is due to intracellular co-factor availability and the predominance of 
the reductase reaction in vivo, with enzymes exhibiting little dehydrogenase activity. 
Difficulties arise as values derived from recombinant, purified material may not be 
consistent with circulating glucocorticoid levels (which are in the nanomolar 
concentration range). This may be putatively explained with two rationalisations; 
firstly that the intact intracellular environment primes the enzyme for the reduction 
of cortisone, by the presence of excess NADPH and possibly substrate, and secondly 
a hypothesis put forward by Shafqat (Shafqat et al 2003) is that the purified 
recombinant enzyme is partially inactivated during cell lysis and purification. To 
 for cortisol is higher. The kinetic data obtained in this research 
complements previous studies with tissue-derived or full-length enzyme, 
demonstrating that recombinant, N-terminally truncated human 11β-HSD1 is viable 
for use in activity and inhibitor assays, and also structural studies.  
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determine the degree of inactive enzyme, active site titration is carried out using a 
tight binding or irreversible inhibitor.  
This technique is extremely useful in this research, due to the necessary addition of 
carbenoxolone to the culture media to ensure free, folded enzyme. This leads to 
many active sites of the enzyme being occupied with carbenoxolone, the 
quantification of which is important for subsequent activity assays.  
 
3.6 Active Site Titration 
Active site titration (AST) is a technique based on the partial inactivation of an 
enzyme preparation with a known quantity of inhibitor, followed by the 
measurement of residual catalytic activity. The applicability of AST for 11β-HSD1 
has been demonstrated previously (Elleby et al 2004, Shafqat et al 2003). The 
procedure is repeated with increasing amounts of inhibitor (over a range of 1 – 10 
μM) until total inactivation is observed, the data is subsequently fitted by non-linear 
regression to equation 3.1. The amount of inhibitor required for complete 













i Eqn 3.1 
 
Where: vi is the observed velocity in the presence of inhibitor, vo is the uninhibited 
velocity, [E] is the active enzyme concentration, Kiapp is the apparent inhibition 
constant, I is the concentration of inhibitor. The concentration of active sites was 
measured for each new protein preparation, with background controls, and a plot of 
Vi / Vo versus Log[inhibitor] prepared (figure 3.11). 
 
- 115 - 
 
Figure 3.11: Active site titration of human 11β-HSD1, fractional velocities vs. Log 
[inhibitor]. Fractional velocities (Vi / Vo) of purified material were determined in the 
presence of increasing concentrations of carbenoxolone. Data was fitted to the equation 3.1, 
as defined originally by (Morrison 1969). Graph prepared using Kaleidagraph v4.0 
(Synergy Software).  In the adjoining table, ‘m1’ corresponds to [E]. 
 
Previously,  ~ 40 – 50 % (Shafqat et al 2003) and ~20 % (Elleby et al 2004a) of total 
enzyme preparations were determined to be active using this method with the ligand 
BVT 24829. In both cases, the protocol for expression and purification are nearly 
identical (and similar to this research) hence such differences in active site 
percentages are unexpected but exemplify the possible variation in the quality of 
protein produced. Nevertheless, this does support the notion of a destabilization of 
the enzyme during lysis or purification procedures (Monder et al 1991, Nobel et al 
2002) and thus a lower value than those published is expected in this research, due to 
the presence of carbenoxolone. From figure 3.11, [E] is calculated to be 107.07 nM 
(when taking Kiapp to be 20 nM, Webster et al.) indicating that 6.2 % of the enzyme 
active sites are available and functional in the purified material, a value similar in all 
other AST assays carried out in this research. This method also allowed monitoring 
of the levels of carbenoxolone after further dialysis or buffer exchange steps.  
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AST proved to be a useful tool for removing ambiguity which may surround the 
nature of the purified enzyme; i.e. that a preparation retaining 25 % of the initial 
activity may infact be all in the form with 25 % native activity (due to a decrease in 
Vmax or increase in Km) or alternatively 75 % inactive enzyme. Thus, a clear distinction 
can be made between these two states. It is thought that inactive enzyme may be a 
reason for higher Km values obtained from purified samples, as compared to tissue-
derived homogenates (Shafqat et al 2003). 
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CHAPTER 4: 
DESIGN AND SELECTION OF COMPOUNDS FOR 
INHIBITION OF 11β-HSD1 ACTIVITY 
4.1 Introduction 
 
‘The most fruitful basis for the discovery of a new drug is to start with an old drug’. 
Sir James Black, the 1988 Nobel Prize winner in Physiology & Medicine.  
 
There is currently a great deal of research and development in pursuing potent and 
11β-HSD1-selective small molecule inhibitors by the pharmaceutical industry and 
academia alike.  
In silico methods are now widely used in the early stages of drug design and 
development (Ekins et al. 2007). A computational approach can include data mining, 
databases and compound libraries, molecular similarity searches, pharmacophore 
building and searching, homology modeling, and quantitative structure activity 
relationships (QSAR). Conveniently, these techniques provide a list of novel 
molecules which are not only predicted to have an affinity for the particular target, 
but which have suitable ‘drug-like’ physicochemical properties and may also have 
predicted reasonable absorption, distribution, metabolism, excretion and toxicity 
(ADMET) parameters (Ekins et al. 2007;Lipinski et al. 2001).   
Virtual screening is a high throughput method of screening a large compound 
library for suitable candidate compounds (Ekins et al. 2007). These compounds are 
subsequently scored and ranked according to one or a consensus of multiple scoring 
functions. It is a knowledge driven approach, ergo requires input: structural 
information in the form of either the target site or existing ligands for the target 
(Ekins et al. 2007). 
The principal approaches employed in more recent years to identify novel lead 
compounds for the inhibition of 11β-HSD1 inevitably employ the high-throughput 
virtual screening of a small molecule library followed by the identification of hits, 
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laboratory analysis and subsequent refinement of the candidate compounds to try 
and increase potency. The vast majority of small molecule 11β-HSD1 inhibitors 
currently being developed target the active site of the enzyme, as this site will impart 
the greatest possible selectivity with maximum inhibitory action. This ‘linear’ process 
of identification of novel ligands has been extensively employed by Amgen Inc. and 
Abbott, using in-house compound libraries with a good deal of success (Julian et al. 
2008;Rohde et al. 2007;Sorensen et al. 2007).  




Figure 4.1: Overall linear process of identifying novel ligands. 
 
This approach involves the assignation of molecular descriptors to existing ligands 
followed by virtual screening for similar compounds. These molecular descriptors 
may be defined as; ‘the end result of an experimental or mathematical procedure 
transforming chemical information into a useful number’  (Roberto Todeschini and 
Viviana Consonni 2002). Descriptors vary from method to method, and may be 
pharmacophoric features of the existing compound (Cheeseright et al. 2006;Schuster 
et al. 2006) or structural (Ballester, Richards 2007). This method of drug discovery 
relies heavily on the current scientific paradigm that similar compounds will have 
similar biological activities.  
Accordingly, this approach was employed in this part of the project to develop 
potent and selective inhibitors of 11β-HSD1 activity. A discussion of the method 
applied in this project is discussed here alongside the results; the evaluation of the 
compounds selected is discussed in chapter 5.   
 - 119 - 
4.2 Aims 
The aims were to better understand the interactions necessary for an inhibitor to bind 
to the active site of 11β-HSD1 and ultimately to use this information to fuel the in 
silico drug discovery and selection of novel compounds for the inhibition of 11β-
HSD1. This involved an analysis of existing inhibitors, their interactions with the 
enzyme and co-crystal structures where available. A specialised novel algorithm 
known as ‘Ultra Fast Shape Recognition with Atom Types’ (UFSRAT, section 4.4) 
was used to identify and calculate several specific descriptors on these existing 11β-
HSD1 inhibitors, referred to as ‘query molecules’. Similar descriptor characteristics 
were then screened for through millions of molecules (i.e. ‘candidate molecules’) in 
the chemical library ‘EDULISS’ (EDinburgh University LIgand Selection System, 
section 4.3). The programs UFSRAT and EDULISS were developed at the University 
of Edinburgh (Taylor et al. 2008) and were employed to identify potential 
compounds with similar functional and structural properties to the query molecules. 
This initially produced a large amount of data, which was subsequently filtered and 
sorted to result in a short-list of available, soluble, small molecules which could 
potentially inhibit 11β-HSD1. A more detailed perspective of the procedure carried 
out in this research is shown in figure 4.2. 
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EDULISS is EDinburgh University LIgand Selection System; a small-molecule 
database of which the development and upkeep is currently overseen by Dr. Kun-Yi 
Hsin at the University of Edinburgh. This in-house, large database contains the 3-
dimensional structure co-ordinates for each molecule in addition to thousands of 
molecular, physicochemical, and geometric (to name a few) descriptors for each of 
the 5.5 million compounds, 4 M of which are unique. These features are user-defined, 
a process facilitated by a user-friendly web interface. It sources these compounds 
from 29 commercial databases, ensuring that each chemical is currently available for 
purchase. The 29 different commercial databases and the number of compounds that 
each contributes are shown in figure 4.3. 
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Figure 4.3: Histogram showing the 29 commercial databases and the number of compounds 
each contributes to EDULISS. Adapted with permission from Dr. Hsin. 
 
The EDULISS database was originally developed by Dr. A Hinton (Hinton 2005) and 
has since been expanded to include more suppliers, more physicochemical 
information about each compound and is continuously updated. For example, each 
compound has over 1500 descriptors defining it, allowing users to search for very 
specific subsets of compounds. The 2-D atomic co-ordinates for compounds in 
EDULISS are collected from supplier catalogues. Generating a single, low-energy, 3-
D co-ordinate map for each molecule from this 2-D data is then carried out using the 
program CONCORDTM (Hendrickson et al. 1993). It is this 3-D representation of each 
molecule that is stored and displayed in EDULISS.  
In the present research, EDULISS was used as a source of compounds for the virtual 
screening (VS). Descriptors were defined by applying the UFSRAT algorithm to all 
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4.4 UFSRAT  
Potential inhibitors were selected through the use of a novel virtual screening 
algorithm; Ultra Fast Shape Recognition with Atom Types (UFSRAT). The UFSRAT 
algorithm assesses the similarity between two compounds; in this case a query 
compound and the candidate compounds i.e. those contained in EDULISS. The 
query molecules used for the searches of novel 11β-HSD1 inhibitors are pictured 
below in figure 4.3. These are current inhibitors (A, carbenoxolone), pre-clinical 
inhibitors (B and D: adamantine series, and 2-anilinothiazolone) and the endogenous 




Figure 4.3: The 4 query molecules used as a template by UFSRAT and Eduliss.  
A. Carbenoxolone, B. Adamantane, C. Cortisol, D. 2-anilinothiazolone. 
 
These four structurally-varied compounds were selected as query molecules to 
encompass a broader molecular range as guidelines for potential inhibitors. For 
example, carbenoxolone (A) and cortisol (C) have a typically steroidal 4-ring 
structure, whereas adamantane (B) and 2-anilinothiazolone (D) represent non-
steroidal inhibitors with varying substituents. In addition, co-crystal structures of 
human 11β-HSD1 and compounds B and D were available along with kinetic data, 
allowing for comparison of any subsequent candidates from virtual screening. 
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The importance of similarity in the overall shape of the novel 11β-HSD1 inhibitors is 
fundamental; it is evidently a prerequisite for being able to physically enter the active 
site pocket, and also for the ligand to approach catalytic residues within 3 - 5 Å to 
enable polar and hydrophobic contacts and to avoid empty space within the pocket 
(Ballester, Richards 2007;Kortagere et al. 2009). The atom type and atom location is 
also an important consideration; the pharmacophore features of an existing ligand 
govern its binding ability and its relative affinity to the target, thus compounds with 
similar pharmacophoric parameters should bind with similar interactions. The 




Figure 4.4: The four query compounds (from A-D; carbenoxolone, adamantane, cortisol and 
2-anilinothiazolone). Hydrogen bond acceptors (HBA) are shown with red spheres, 
hydrogen bond donors (HBD) are shown with blue spheres, hydrophobic components are 
shown in yellow. 
 
Figure 4.4 shows that each of the four query compounds contains at least two 
hydrogen bond acceptors (HBA) and one hydrogen bond donor (HBD) group. 
Application of the UFSRAT conditions in a virtual screening process leads to the 
subset of molecules being similar not only in overall shape but also in atom type and 
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molecular location of these atom types. The original method, coined UFSR (Ultra-
Fast Shape Recognition) was developed by Ballester and Richards (Ballester, 
Richards 2007) and did not take into account the atom types. Thus the original UFSR 
algorithm is successful only in identifying similarly shaped molecules, irrespective of 
atom type (i.e. hydrogen acceptors, hydrogen donors and hydrophobic entities).  
Recently, UFSR has been extended greatly to include discrimination between atom 
types. This research has been carried out by members of the Computational Biology 
Group at the University of Edinburgh, principally by Dr. Steven Shave (unpublished 
data). Simplistically, this method involves the assignation of descriptors to a query 
molecule (those shown in figure 4.3) and all candidate molecules (i.e. all molecules in 
EDULISS). This is followed by a comparison of the query and candidate molecule 
using the descriptor sets and applying a scoring function. The compounds are then 
ranked according to similarity to the query compound, with the highest scoring 
compounds as the most similar. In this research, the top scoring 500 compounds 
were selected for inspection. 
Assigning descriptors to ligands using UFSRAT initially involves the calculations of 
12 molecular shape descriptors. These are the calculations of the atomic distances of 
all atoms in the molecule to four main points: the molecular centroid (called point 1, 
or P1), the closest atom to the centroid (called P2), the furthest atom from the 
centroid (called P3) and the furthest atom from point 3 (called P4). This is shown in 
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Figure 4.5: Illustration demonstrating the method of converting the molecular volume of 
carbenoxolone into distances between all atoms in the molecule to P1, P2, P3 and P4. 
 
This provides 4 sets of distances which are regarded as statistical distributions. The 
first three moments of these distributions are taken: the mean, the variance and the 
skew. This gives a total number of 12 descriptors for the molecule (i.e. 4 subsets with 
3 values each). These 12 descriptors are unique to each molecule and define its 
overall size, compactness and symmetry. 
In addition to the 12 descriptors detailed above, UFSRAT also takes into account 
three atom types; whether they are hydrogen bond donors (HBD), hydrogen bond 
acceptors (HBA) or hydrophobic. The three possible atom types each generate a 
distribution, which contributes 12 descriptors (per distribution), giving an additional 
36 descriptors to the existing 12. Figure 4.6 shows the four UFSRAT descriptions 
simplistically. 
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Figure 4.6: The algorithm UFSRAT describes four atom types; all atoms (as described in 
detail in figure 4.2), hydrogen bond acceptors, hydrogen bond donors, and hydrophobic 
atoms, as shown for the clinical 11β-HSD1 inhibitor carbenoxolone. Adapted with 
permission from Dr. Steven Shave. 
 
In total, UFSRAT uses 48 descriptors to describe a molecule both topologically and 
biochemically. These descriptors were assigned to each query molecule. A search 
through the EDULISS database for each query compound was carried out to identify 
similar compounds to each one. The candidate compounds from the EDULISS 
database are scored based on their individual similarity to the query molecule. A 
normalised scoring function is used; a molecule with a score of 1 would be identical 
to the query molecule, a score closer to zero suggests less similarity. Some examples 
of these compounds and their scores are shown in figure 4.7. 
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Figure 4.7: The query molecule 2-anilinothiazolone from the co-crystal structure 2RBE is 
shown here as the query molecule. The top 5 scoring candidates are shown (compounds 
which scored highly with regards to similarity to the query compound). 
 
As can be seen from figure 4.7, the top five scoring compounds are similar in size, 
shape and the types of atoms present. Four out of the five top scoring hits contain a 
sulfur atom; three of these are incorporated into a 5-membered ring with, or in close 
proximity to a nitrogen, akin to the query molecule. In all cases a central hydrogen 
acceptor group is found either in the form of a carbonyl or a nitrogen.  
 
4.5 Filtering Potential Inhibitor Compounds: Selecting ‘Drug-likeness’ 
The top 500 hits selected with UFSRAT were taken (500 per query molecule, giving a 
total of 2000 compounds) and filtering was carried out. This followed several criteria 
based on established quantitative structure-activity relationship (QSAR) guidelines. 
These criteria were the commonly accepted Lipinski’s rule of 5 (Ro5) (Lipinski et al. 
2001).  
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The Lipinski criteria are listed (the ‘Rule of Five’ nomenclature refers to the 
persistent appearance of the number 5 in the rules, rather than five rules); 
 
1. A molecular weight of < 500 Daltons 
2. Less than 10 hydrogen bond acceptor (HBA) groups 
3. Less than 5 hydrogen bond donor (HBD) groups 
4. An MLogP < 5 
 
Adherence to these rules results in a ‘drug-like’ compound which has better 
predictions for solubility, bio-availability, toxicology and metabolism. Simply 
defined; the compound will have ‘functional groups, and/ or have physical 
parameters consistent with the majority of known drugs’ (Walters, Murcko 2002). 
This provides a base for the pharmacokinetic and pharmacological predictions to be 
made. However difficulties may arise when defining physical drug-like 
characteristics and several studies have attempted to identify these (Muegge 
2003;Sheridan 2002). The ‘Lipinski Ro5’ is one of several accepted sets of criteria used 
to filter compounds for drug-likeness. Similar concepts have been developed by 
Oprea (Hann, Oprea 2004) and Astex (Congreve et al. 2003). 
The LogP is the water/ octanol partition coefficient, a measure of the hydrophobicity 
of a compound (Moriguchi et al. 1992;Delaney 2005). A higher LogP value (greater 
than 4 or 5) gives an indication of compounds which will have poor aqueous 
solubility. This implies that the compound will have a sub-optimal ADME profile as 
well as incurring difficulties at initial screening stages. A fine balance must be made 
between preserving potential bioavailability of the drug but also an adequate degree 
of lipophilicity to facilitate binding. It should be noted that several existing potent 
11β-HSD1 inhibitors are exceptionally hydrophobic and thus do not meet the 
solubility criteria; indeed the ‘LogP’ is also the most difficult parameter to control 
combinatorially. In addition to this, many of the current pre-clinical inhibitors have a 
molecular weight greater than 500, the limit set by the Lipinski guidelines.  
Application of these rules eliminated approximately 1600 candidate compounds, the 
majority of which were purged on the basis of an inappropriately high LogP value. 
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This is because other Lipinski drug-like parameters (i.e. number of HBD, number of 
HBA) were used as UFSRAT descriptors and so decreased the possible range of HBD 
and HBA in the candidate molecules. The range of LogP values and molecular 
weights in the top 500 highest scoring compounds are shown as an example in figure 
4.8.  
 
Figure 4.8: A: Range of LogP values obtained using either thiazolone (red) or adamantane 
(blue) as query molecules. B: Range of molecular weights of candidate compounds 
discovered using carbenoxolone (green) or cortisol (yellow) as query compounds. 
Compounds discovered using carbenoxolone have a higher mean MW than those 
compounds discovered with cortisol. This follows from the same trend in the query 
compounds. 
 
Interestingly, it has been postulated that the average lipophilicity and molecular 
weight of compounds for clinical use currently being synthesized is slowly 
increasing (Gleeson et al. 2009) thought to be due to an over-emphasis on the in vitro 
potency of the compound rather than the safety / toxicity. 
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Following physicochemical filtering, further sorting to the subsequent final shortlist 
of compounds was carried out through a manual selection through the remaining 
compounds.  This was to eliminate compounds which: 
∙ May undergo further chemical alteration once in vivo or once in a reducing 
environment (e.g. Michael acceptors) 
∙ May have already been patented 
∙ May have already been evaluated in published literature with negative results  
∙ Have a steroidal core structure 
This enabled the short-list to be reduced to a total of 52 compounds, categorised into 
6 structural classes. These compounds are shown in tables 4.2 – 4.7 below, in section 
4.8.  
 
4.6 Additional Compounds: Manual Selection  
In addition to the 52 candidate compounds short-listed from UFSRAT, an additional 
8 compounds were selected ‘manually’ from supplier catalogues on the basis of their 
similarity to several unavailable UFSRAT candidate compounds. These included 
compounds which had small variations in their side groups as compared to 
UFSRAT selected candidates. These 8 manually selected compounds fitted all 
physicochemical criteria for drug-like compounds. 
 
4.7 Results: Short-listed Compounds 
The short list of compounds was initially comprised of 52 compounds, out of which 
27 were available for immediate dispatch from the suppliers; the remaining 25 were 
unavailable. A table with all 52 compounds may be found in the appendix; only the 
27 analysed are shown here (tables 4.2 – 4.7). Out of these 52 candidate compounds, 
the majority were ‘hits’ from the query molecule carbenoxolone. This can be seen in 
figure 4.9. 
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Figure 4.9: A summary of which query molecules provided the most feasible hits. 
Carbenoxolone generated the most number of feasible, drug-like compounds (51%), 
followed by 2-anilinothiazolone (37%), then adamantane (12%). The query molecule 
cortisol did not generate any feasible hits. 
 
The query molecule adamantane generated hits which were bulky on one side, the 
majority of which central amino group resembling the parent molecule. The 
adamantane molecule has some interesting pharmacophore features, as shown 
previously, in figure 4.4. Cortisol generated compounds with a low score 
(predominantly scores lower than 0.6). Furthermore, no final hits were generated 
from this query molecule, as seen in figure 4.9 as the majority of consequent 
compounds were steroidal which would have been rejected by the filters applied.  
In the following section (section 4.8) the short-listed compounds selected as 
candidates for inhibition of 11β-HSD1 using UFSRAT are tabulated. These are the 
compounds with reference numbers ranging from 1 – 52, in tables 4.2 – 4.7. 
Compounds with identification numbers ranging from 53 – 60 are those which were 
selected ‘manually’, that is, directly through supplier’s catalogues based on their 
similarity to compounds from UFSRAT which were not in stock.  
Of the 35 compounds analysed, 27 were from the application of UFSRAT and 8 were 
selected ‘manually’. 
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4.8 Classification of compounds 
The 35 compounds available were loosely clustered into 6 different groups according 
to the central structural features of the ligands. These were: 
1. Ureas 
2. Tetrazines and triazoles 
3. Thioethers 
4. Benzamides and amides 
5. Cycloheptanones, cyclohexanones and keto-groups 
 
This clustering is shown in tables 4.2, 4.3, 4.4, 4.5, 4.6, and 4.7 below. 
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1. Ureas 
Current patents by Incyte cover many of the urea containing 11β-HSD1 inhibitor 
compounds, such as tetra-substituted ureas (patent number W02007130898). There 
were three main urea skeletons and variations thereof that were looked for; shown 




Figure 4.10: The three urea scaffolds searched for through the compounds generated with 
VS. Compound ‘a’ has two isopropyl substitutions off the right hand nitrogen of the urea 
(this part of the molecule, referred to as the right hand side, is thought to point toward the 
entrance of the binding pocket. The left hand side will be buried in the hydrophobic 
pocket in close proximity to NADP).  Compound ‘b’ has the urea nitrogen forming one 
member of a 6 (or more)-membered cycle, putatively with another cyclic group substitution 
(shown in grey). Molecule ‘c’ is symmetric; each nitrogen has an aromatic ring substitution.  
 
The scaffold of compound ‘c’ (figure 4.10c) appeared just once in the whole selection 
of compounds from UFSRAT, this is now known as compound 45 (table 4.2). 
 
 - 134 - 
Table 4.2 (also continued on next page): Clustering of urea–type compounds (N-(C=O)-NH) 
from VS. The table describes the molecular weight, solubility in water (MLogP), Supplier 
and the query molecule it was generated from. The right-hand most column denotes 
whether the compound was selected manually (‘R’) or through the use of UFSRAT (where 
the query molecule used in the similarity search is quoted). 
 
2D Structure # M.W (Da) 
MLogP Supplier Query Molecule 
 
27 204.1 1.82 ChemBridge 2-
anilinothiazolone 
 
28 246.1 3 ChemBridge 2-
anilinothiazolone 
 
29 232.3 2.1 ChemBridge 2-
anilinothiazolone 
 





31 234.3 0.875 ChemBridge 2-anilinothiazolone 
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2D Structure # 
M.W 
(Da) MLogP Supplier Query Molecule 
 














53 222.3 1.5 Specs R 
 
55 303.4 5.2 TimTec R 
 
59 304.4 1.6 Specs R 
 
60 302.4 1.6 Specs R 
Table 4.2 continued from previous page. 
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2. Tetrazines and Triazoles 
Many of these compounds also contain a thioether. Several of the tetrazine 
compounds generated from UFSRAT were found to be under patent (NovoNordisk, 
Denmark) or analogous to compounds discovered previously at the University of 
Edinburgh using a different approach to drug discovery. Several were predicted to 
be in the nanomolar range of IC50
 
 values based on SAR with previous compounds. A 
number of the thiol-triazole compounds are also under patent by Novo Nordisk. 
Table 4.3: Clustering of compounds with a tetrazine or triazole ring (with or without a 
thioether group) from UFSRAT. This table describes the molecular weight, solubility in 
water (MLogP), Supplier and the query molecule it was generated from. The right-hand 
most column denotes whether the compound was selected manually (‘R’) or through the 
use of UFSRAT (where the query molecule used in the similarity search is quoted). 
 
2D Structure # M.W (Da) MLogP Supplier Query 
Molecule 
 
7 386.4 2.21 InterBioScreen CBX 
 
10 371.4 1.56 InterBioScreen CBX 
 
12 425.5 2.65 InterBioScreen CBX 
 
13 395.4 3.17 InterBioScreen CBX 
 
16 395.4 3.18 InterBioScreen CBX 
 
23 423.4 3.39 InterBioScreen CBX 
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3. Thioethers 
The basic skeleton in this class consists of an acetophenone with a thioether group, 
shown in figure 4.11. 
 
Figure 4.11: Acetophenone scaffold with a thioether. 
 
 The acetophenone group (figure 4.11) was predicted to be a good scaffold for novel 
inhibitors due to the central carbonyl acting as a hydrogen acceptor and the 
lipophilic group which would be buried inside the binding pocket. Various 
substitutions from this scaffold would affect the binding, making it an interesting 
scaffold for SAR analysis. 
 
Table 4.4: Loose clustering of compounds containing a thioether (R-S-R’) group (but no 
tetrazole or triazole) from VS. The table describes the molecular weight, solubility in water 
(MLogP), Supplier and the query molecule it was generated from. The right-hand most 
column denotes whether the compound was selected manually (‘R’) or through the use of 
UFSRAT (where the query molecule used in the similarity search is quoted). 
 
2D Structure # M.W (Da) MLogP Supplier Query 
Molecule 
 
5 420.5 2.15 Specs CBX 
 
21 330.4 1.07 ChemBridge CBX 
 
22 358.4 1.55 InterBioScreen CBX 
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2D Structure # M.W (Da) MLogP Supplier Query Molecule 
 
54 356.4 5.4 TimTec R 
 
56 259.3 3 TimTec R 
 
57 269.3 3.7 TimTec R 
Table 4.4 continued from previous page. 
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4.  Benzamides and amides 
A class of benzamide inhibitors has been previously screened in lysates for 11β-
HSD1 inhibition, with a relatively low percentage inhibition (personal 
communication, Scott Webster). A SAR analysis from this study showed that there 
was an increase in 11β-HSD1 inhibition if an amide nitrogen formed part of a cyclic 
group, or if the group it is attached to is large and bulky, for example, an 
adamantane. For this reason, several benzamide derivative compounds were 
excluded if they did not comply with these guidelines. 
Two of the compounds categorized in this class, 40 and 42 (table 8.8) were imidazole 
derivatives, analogous to drugs to treat diabetes currently on the market. Although 
the diabetes drugs do not target 11β-HSD1, Roche currently own a patent over 
imidazole containing compounds to inhibit 11β-HSD1 and so these compounds were 
excluded from the final short-list. 
 
Table 4.5 (continued on next page): Loose cluster of amide- or benzamide containing 
compounds from VS. Description of molecular weight, solubility in water (MLogP), 
supplier and the query molecule are shown. The right-hand most column denotes whether 
the compound was selected manually (‘R’) or through the use of UFSRAT (where the query 
molecule used in the similarity search is quoted). 
 
2D Structure # M.W (Da) MLogP Supplier Query Molecule 
 
46 345.3 3.01 InterBioScreen Adamantane 
 
47 277.3 2.38 TimTec Adamantane 
 
49 262.3 1.16 Sigma Aldrich Adamantane 
 
58 327.4 3.5 TimTec R 
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6. Cycloheptanones, cyclohexanones and keto-groups 
The reactivity of these compounds was a challenge as many are Michael acceptors. 
Decalins (2 fused cyclohexane rings, non-aromatic) were avoided due to existing 
patents. 
 
Table 4.6: Clustering of cycloheptanone / cyclohexanone / central ketone containing 
compounds from VS. The table describes the molecular weight, solubility in water 
(MLogP), Supplier and the query molecule it was generated from. The right-hand most 
column denotes whether the compound was selected manually (‘R’) or through the use of 
UFSRAT (where the query molecule used in the similarity search is quoted). 
 
2D Structure # M.W 
(g/mol) 
MLogP Supplier Query 
Molecule 
 
2 394.5 2.84 Sigma Aldrich CBX 
 
3 354.4 2.59 ChemBridge CBX 
 
18 413.8 1.75 Specs CBX 
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4.9 Pharmacology of candidate ligands 
ADMET 
Several important properties to consider are the absorption, distribution, 
metabolism, excretion, and toxicity (known as ADMET) of the candidate drug. Early 
screening of ADMET parameters can reduce the possibility of drug attrition later on 
during preclinical, or even clinical trials (Tsaioun et al. 2009). There are currently no 
straight forward predictive computational tests for ADMET, although studies exist 
where the potential impact of common substituents has been determined and 
tabulated (Gleeson et al. 2009).  
 
Potential to cross the Blood-Brain Barrier 
With the recent interest in 11β-HSD1 as a therapeutic target for improving cognitive 
decline (Sandeep et al. 2004) it is important that a potential drug candidate must be 
able to cross the blood-brain barrier (BBB). The BBB effectively separates the blood 
and brain through tight junctions between endothelial cells. Predictive combinatorial 
calculations for whether a compound will cross the BBB involve setting a limit to the 
solvent accessible polar surface area of the compound (e.g. < 90 Å2), which also 
conveniently lays restrictions on other physicochemical properties of the compound.  
Experimental determination of whether or not the compound is a potential P-
glycoprotein - an efflux pump - substrate is also an important factor in determining 
the CNS-penetrative prospects of the drug candidate. There are predictive 
computational systems for this (e.g. the program Almond v 3.2). In addition, the 
presence of the multi-drug-resistance protein (MRP) which actively removes 
exogenous molecules from within neural endothelial cells is another opposition in 
CNS targeting drugs. A recent development in the CNS-drug field is the novel co-
culture of two types of cells: human brain capillary endothelial cells and human glial 
cells; currently the most accurate predictive test for passive and active transport of 
molecules into the CNS (Megard et al. 2002). 
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4.10 Conclusions 
The virtual screening program UFSRAT provided a list of potential inhibitors of 11β-
HSD1 which were selected on the basis of chemical and geometrical similarity to a 
set of four query molecules. This was achieved through the application of 48 
descriptors which defined molecular and structural constraints in candidate 
molecules. The resulting candidate compounds looked feasible and contained a wide 
range of viable functional groups and substituents. 
There is no general solution for virtual screening; the output is as good as the input 
data. Therefore, every prospective application requires tuning to user-defined 
parameters. All available information possible should be used to generate and 
validate the models, such as an X-ray crystal structure to define the binding site, or, 
as in this case existing potent ligands which provide a framework for candidate 
compounds. Clearly, virtual screening works best as a case by case process (Oprea, 
Matter 2004).  
Also, subsequent filters should be as stringent as possible according to the particular 
future function of the candidate ligand. In this research, this was reflected in a slight 
leniency with regards to the MLogP value of the compounds, due to the hydrophobic 
environment of the binding pocket. The use of filters can significantly reduce the 
number of candidates for screening as it eliminates compounds with undesired 
chemotypes and thus undesired physicochemical properties. The second round of 
filtering in this research eliminated many compounds reducing the number by 
approximately 90%.  
Also, UFSRAT is fast: the process of target preparation, pre-docking filters, docking, 
post-docking analysis and ranking of compounds takes a matter of hours per query 
molecule.  
Future challenges for this field include the incorporation of adjustable parameters 
pertaining to pharmacodynamic (PD) and pharmacokinetic (PK) determinants, 
which may prevent the attrition rate of weak drugs in the early drug development 
stages (Tsaioun et al. 2009). Additional challenges lie with regards to the flexibility of 
the ligand and the protein target – e.g. conformational changes that may occur 
during binding, but also in dielectric constants and partial charges of ligands. 
 - 143 - 
CHAPTER 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
ANALYSIS OF 
11β – HYDROXYSTEROID DEHYDROGENASE TYPE I 
INHIBITION BY NOVEL LIGANDS 
  
5.1. Introduction 
The enzyme 11β-hydroxysteroid dehydrogenase 1 regulates the tissue availability of 
cortisol through the interconversion of cortisone and cortisol. Dependent on the 
surrounding milieu, it will act as either a reductase or a dehydrogenase. An excess of 
11β-HSD1 can lead to insulin resistance and metabolic syndrome as shown by transgenic 
models, thus it is a viable drug target for inhibition in the treatment of type 2 diabetes 
and related diseases (chapter 1). Novel inhibitors were selected through virtual 
screening to inhibit 11β-HSD1 (chapter 4), the potency of these 35 novel inhibitors 
belonging to 6 distinct structural classes are studied here.  
The flow chart in figure 5.1 shows the sequence of events in testing the inhibitors. Initial 
screens were carried out which tested the efficiency of the compounds to inhibit 11β-
HSD1 in the dehydrogenase and reductase directions. Each compound was tested at a 
concentration of 100 µM, and the percentage of inhibition determined. This was carried 
out in triplicate with appropriate controls. Following on from this, the most promising 
compounds were taken for further analysis to allow for calculation of a Ki
 
. These 
compounds were those which caused a greater than 40% inhibition of the human 
enzyme in the initial screen. These more comprehensive assays involved inhibition of 
11β-HSD1 in mammalian cells in addition to assays with recombinant protein, which 
allowed a comparison to be made between the potency of the compound in vivo and in 
vitro. Furthermore, a comparison between human and mouse inhibitor binding was 
achieved. 
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Figure 5.1: A flow chart showing the sequence of events in testing the novel inhibitors of 11β-
HSD1. Initial screens are followed by full screening of compounds which inhibit greater than 
25% of the recombinant enzyme activity or more than 40% activity in 11β-HSD1-transfected 
HEK-293 cells. Finally, the successful compounds are assayed for 11β-HSD1 selectivity with an 
11β-HSD2 binding assay.  
 
 
5.2 11β-HSD1 Inhibition Assays: Fluorescence and SPA 
Inhibition assays were carried out using two methods: Scintillation Proximity Assay 
(SPA) and a fluorescence assay. The fluorescence assay has been discussed in chapter 3 
and a brief description of SPA will be given here. Both are sensitive, high through-put 
assays which are able to monitor the reaction in both directions (reductase and 
dehydrogenase). The fluorescence assay was used to monitor the inhibition profiles of 




  CORTISONE + NADPH 
Figure 5.2: The reductase reaction of 11β-HSD1 monitored using a fluorescence assay. 
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SPA was used to monitor the reverse, reductase reaction, shown in figure 5.3. 
 
 
CORTISONE + NADPH  CORTISOL + NADP
 
+ 
Figure 5.3: The dehydrogenase reaction of 11β-HSD1 which was monitored using SPA. 
 
5.3 Scintillation Proximity Assay 
A Scintillation Proximity Assay (SPA) is a well established high throughput screening 
assay for ligand-11β-HSD1 binding (Mundt et al 2005; Solly et al 2005). SPA is founded 
on the principle of microscopic beads containing scintillant which are stimulated to emit 
light when radio-labelled cortisol binds to the surface of the bead via interaction with a 
previously coupled anti-cortisol antibody (figure 5.5). A mouse monoclonal antibody is 
coupled to protein A-coated beads with a greater than 100-fold affinity for cortisol than 
cortisone. The assays are carried out in buffers using radioisotopes which emit low 
energy radiation ([3H] or [125I]). For the purposes of this research, the assay is a method of 
measuring the conversion of: 
 
[1,2(n)-3H]Cortisone (3H-C21H28O5)  →  [1,2(n)-3H]Cortisol (3H-C21H30O5) Eqn 5.1 
 
 
Figure 5.4: Chemical structures of [1,2(n)-3H]Cortisone and [1,2(n)-3H]Cortisol, showing the 
position of the tritium atoms. The forward reaction is the reductase reaction. 
 
Equation 5.1 and figure 5.4 show the reductase reaction monitored with SPA. Once the 
radioactive substrate binds the bead-coupled anti-cortisol antibody, it is in close enough 
proximity for the emitted radiation to activate - through energy transfer - the scintillant 
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contained within the bead which then produces a light signal. The amount of light 
produced is proportional to the amount of labelled molecules bound to the beads. This is 
detected by a scintillation counter and converted into the concentration of cortisol 




Figure 5.5: Diagram depicting the mechanism of SPA. On the left is a SPA bead (green sphere) 
coupled to an anti-cortisol antibody. Radio-labelled cortisol (blue sphere) is free in solution 
and will bind to this antibody (picture on right). At this point the proximity of the 
radioactivity excites the scintillant inside the SPA bead. This is detected and measured on a 
scintillation counter. 
 
A high concentration of a potent inhibitor will result in less radioactive cortisol being 
produced and therefore a lower signal from SPA beads, as compared to controls with no 
inhibitor. The beads are typically composed of polyvinyltoluene (PVT) containing 
diphenylanthracine (DPA) and have an average diameter of 5 microns. SPA is a 
homogeneous binding assay (Janzen 2002) which is able to measure weak interactions 
without disturbing the equilibrium with a separation step, such as HPLC - as was 
previously employed to assay 11β-HSD1 activity and assess novel inhibitors (Maser et al 
2003; Oppermann et al 2000). 
Assays were carried out in a 96-well plate format, with each well carried out in duplicate 
or triplicate with appropriate controls. A detailed protocol for this and other assays is 
found in chapter 7 – Materials and Methods. 
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SPA was carried out with both recombinant mouse and human 11β-HSD1 and human 
embryonic kidney cells (HEK 293) (Graham et al 1977) overexpressing human, rat and 
mouse 11β-HSD1. SPA was used to follow the effects of inhibitors on the reductase 
reaction only; there are no anti-cortisone antibodies available that are as effective as the 
anti-cortisol antibodies used. The plates are set up with high and low controls of [3H]-




















LCcompoundinhibition     Eqn 5.2 
 
Where ‘compound’ refers to the light emitted from the reaction with a particular 
inhibitor, LC is the low control and HC is the high control. The optimum conditions for 
SPA are well documented (Henriksson et al 2005, Zheng et al 2005, Mundt et al 2005). 
These assays were carried out at the QMRI at the Royal Infirmary, Edinburgh, with the 
help of Dr. Scott Webster, Ms. Kirsty McConnell, Dr. Karen Sooy and Ms. Margaret 
Binnie. 
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5.4 Ki Determination 
Assays were carried out as described in chapter 7. The Ki values for carbenoxolone and 
the other inhibitors were calculated using nonlinear regression with a three parameter 
logistic model. The experimental data were fitted to equation 5.4 using Kaleidagraph 
software, assuming the following:  
 
Figure 5.6: A Cleland notation (Cleland 1963) reaction of competitive inhibition, where E is 
enzyme (11β-HSD1), S is substrate (cortisol for dehydrogenase assays, cortisone for reductase 
assays) and I is inhibitor. 
 
Figure 5.6 is representative of a competitive inhibition model of inhibition, where the 








kKm −=         Eqn 5.3 
In equation 5.4, [E]o and [I]o are the active enzyme and inhibitor concentration, 
respectively. Kiapp is the apparent inhibition binding constant, Vi and Vo
 
 are the rates of 
cortisone reduction in the absence or presence of inhibitor, respectively (Morrison 1969). 

























1   Eqn 5.4 
Two additional equations are required in this research, to take into account to effects of 
substrate and inhibitor both competing for the active site i.e. competitive inhibition.  
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i ×+=         Eqn 5.5 
 
5.4.1 IC50
The Cheng-Prussoff equation (Cheng and Prussoff 1973) is shown as equation 5.6, and 
enables a calculation of a K
 Determination  
i from the IC50 as determined in cell-based assays for 
competitive inhibitors. As IC50 values may vary for the same ligand depending on 
experimental conditions, a more accurate and comparable quantity is required which 
does not depend upon the experimental set-up, i.e. a Ki. The IC50
 
 is concentration of 
inhibitor which causes a 50 % inhibition of enzyme activity. It is experiment-dependent 
and is determined by three factors; 
∙ The Ki
∙ Concentration of cortisone (substrate): higher concentrations of cortisone will 
require higher concentrations of inhibitor to displace. Increasing the cortisone 
concentration will increase the IC
 of the compound, 
50 (without altering Ki
∙ The K
) 
m  of cortisone; it will require a higher concentration of inhibitor to displace a 
tightly bound substrate. A substrate with a lower Km  compared to cortisone (i.e. a 
tighter binding ligand) would increase the IC50
 
. 
The Ki cannot be determined directly from the inhibition assay data as the enzyme 
concentration in the cultured cells is unknown. Therefore, a dose-response curve for each 











=          Eqn 5.6 
 
Conversion of IC50 values to Ki values is a much discussed problem in the literature 
(Brandt et al 1987; Cheng 2001; Cortes et al 2001; Lazareno and Birdsall 1993) and the 
most widely accepted conversion for competitive inhibitors is used here. The Km for 
cortisol was taken as 21.9 µM.  
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5.5 The Short-Listed Compounds for Inhibition Analysis  
The 35 inhibitors analysed are shown in figure 5.7 below. 
 
Figure 5.7: Each inhibitor analysed is depicted and numbered corresponding to chapter 4. 
Those numbered 53 to 60 are compounds selected manually, based on the top hits from virtual 
screening (VS). Compounds from VS are labelled 1 – 52.  
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5.6 Results of 11β-HSD1 Inhibitor Assays  
Assays were carried out with recombinant protein and also with cultured HEK-293 cells 
transiently transfected with 11β-HSD1. The following sections are organised according 
to the assay material used i.e. recombinant enzyme or cultured cells. The assay technique 
used i.e. fluorescence assay or SPA, is also stated, and this was dependent on the 
reaction direction that was being monitored. For reductase reactions, SPA was 





Figure 5.8: Summary of the analyses carried out on potential 11β-HSD1 inhibitors. Analyses 
carried out on the reductase reaction were: SPA with recombinant protein, and HEK-293 cells 
overexpressing 11β-HSD1 (the three species investigated are shown in sub-boxes). The 
fluorescence assay was carried out on the dehydrogenase reaction, with recombinant protein - 
the species examined shown in the sub-boxes. 
 
5.6.1 Initial Screens of 11β-HSD1 Inhibitors with Recombinant Protein 
Initial screens of the 35 compounds were carried out with mouse and human purified 
recombinant 11β-HSD1 to observe the efficiency of each compound at inhibiting the 
dehydrogenase reaction. As it was the dehydrogenase activity of 11β-HSD1 being 
observed, a fluorescence assay was used. Each compound was at a final concentration of 
100 μM in 1% DMSO and the screen was carried out in triplicate, in a 96-well plate. 
Details of the protocol are found in chapter 7 (Materials and Methods). The results are 
shown in the histograms below (figure 5.9). The percentage inhibition was determined 
by using equation 5.2, where the high control was a sample well with no inhibitor 
present (labelled ‘control’ in figure 5.9) and the low control was a sample well with 100 
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Figure 5.9: Histograms showing the degree of inhibition (%) of each compound tested at 100 
μM with recombinant protein. A: Recombinant human 11β-HSD1, B: Recombinant mouse 11β-
HSD1. Superimposed onto the charts are chemical structures of three ligands showing a 
significant inhibition of activity.  
 
Overall, there were 6 compounds which caused a greater than 25 % inhibition in 
recombinant human 11β-HSD1 assays (10, 16, 22, 37, 45 and 56). With the consideration 
 - 153 - 
of residual carbenoxolone from the protein expression protocol still present in the 
enzyme, this is a very high hit rate for a small set of selected compounds (14.3 %) with 
the expected hit rate estimated at 2 - 5%. The mouse enzyme assay also showed 5 
compounds which inhibited greater than 25 % of 11β-HSD1 activity, with some overlap 
of the compounds seen to inhibit the human enzyme. In particular, compound 22 
showed greater than 73 % inhibition in human and 100 % inhibition in mouse 11β-HSD1 
assays. However, this compound, with a central thioether group and two aromatic 
structures either side showed a lower percentage inhibition in cell-based assays, as seen 
in figure 5.9. Promising compounds (those which showed a greater than 25 % inhibition 
with recombinant 11β-HSD1) in fluorescence assays were analysed further (section 
5.6.4). 
 
5.6.2 Initial Screens of 11β-HSD1 Inhibitors with Cell-Based Assays 
Cell-based assays are an invaluable pre-determinant of in vivo drug properties; namely 
compound penetration of the cell membrane. Initial screens were also carried out in 
HEK-293 cells which had been transiently transfected with the mouse, human or rat 
enzyme. These were carried out as described in chapter 7. The results are shown in 
figure 5.11. As mentioned, compound 22 (shown in figure 5.10) exhibited a lower 




Figure 5.10: Chemical structure of compound 22 (left) in 3-D (right).  
 
Despite its lipophilicity - a prime determinant of the rate of absorption - compound 22 is 
likely ionized at physiological pH which may be the cause of poor membrane 
permeability. The partitioning of a drug between water and octanol at a constant 
temperature; the partition co-efficient (logP) is a useful predictor of membrane transport, 
and generally the higher the logP then the more easily the compound will be transported 
across the membrane (Hansch and Clayton 1973). However, this simplistic view is 
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applicable only to those drugs which do not ionise. The degree of ionisation is also an 
important determinant for membrane permeability, and so an adjustment for the degree 
of ionisation of the drug can be made which gives a more accurate description of the 
drug behaviour. This is known as logD; the dissociation co-efficient (Evans 2004). The 
logP for compound 22 is 4.03, however by virtue of having polarisable groups (6 
hydrogen bond acceptor groups and 1 hydrogen donor) it is potentially this that is 
preventing efficient membrane crossing. 
For reductase assays in transfected HEK-293 cells, each compound was tested in 
duplicate. The wells containing no inhibitor (labelled ‘control’ in figure 5.11) were used 
as the high controls and wells containing 100 µM carbenoxolone (‘CBX’) were the low 
controls. 
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Figure 5.11: Bar charts showing the percentage inhibition effectuated by each compound at 100 
μM in transfected HEK-293 cells in the reductase reaction. (A) Cells expressing with human 
11β-HSD1 (B) Cells expressing with mouse 11β-HSD1 (C) Cells expressing rat 11β-HSD1.  
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As can be seen from figure 5.11, there are 5 compounds which cause greater than 30 % 
inhibition in all three species. These are compounds 7, 21, 37, 46 and 56, and were taken 
for further testing. Surprisingly, fewer compounds caused significant inhibition of the 
mouse enzyme in comparison to the rat and human assays, which is thought to be due to 
experimental difficulties with cell confluence.  
Compounds exhibiting greater than 40 % enzyme inhibition in human 11β-HSD1 cell-
based SPA underwent further analysis to quantify inhibition and determine IC50 and Ki
Of particular interest are the compounds which showed inhibition and are structurally 
similar yet differ enough to allow an initial structure-activity analysis. For example: 
compounds 7 and 10, or compounds 28 and 29. Compounds 7 and 10 differ solely by the 
substituents off one of the benzene rings. These compounds are shown in figure 5.12. 
 




Figure 5.12: Chemical structure of compounds 7 and 10, with the varying substituents 
highlighted with a yellow circle. Image prepared with ChemDraw. 
 
As can be seen in figure 5.12, compound 7 has a methoxy- substituent, 10 has a 
benzamide. This increases the hydrogen bond donors by a factor of 2 (from 2 to 4) and 
concurrently reduces the potency. This may suggest a preference for a lower number of 
HBD at this deeply buried end of the molecule (docking positions, figure 5.25) which 
would potentially interact with the co-factor. The non-aromatic substituents of the 
carboxamide compounds 28 and 29 differ as a piperidine and a 7-membered nitrogen-
containing ring, also decreasing potency, shown in figure 5.13. 
 - 157 - 
 
 
Figure 5.13: Chemical structure of compounds 28 and 29, the varying substituents are 
highlighted with a yellow circle. Images prepared with ChemDraw. 
 
The presence of a 7-membered ring and an ethyl substituent from the benzene ring 
decreases the potency in transfected HEK-293 cells. Whether this is due to spatial 
restrictions or other factors is inconclusive. 
 
5.6.3 A Comparison: Inhibitor Binding in Transfected Cells and Recombinant 
Protein 
Overall the cell-based assays are a more accurate reflection of inhibitor binding, as they 
have not been in contact with the tight binding inhibitor carbenoxolone at any point 
prior to the assays, in contrast to the recombinant material. This may explain the 
occurrence of higher inhibition for the same compound in assays using recombinant 
protein compared to cell-based assays, for example, in mouse 11β-HSD1: compounds 7, 
21 and 46 exhibit a higher percentage inhibition in cells than with recombinant material. 
With human 11β-HSD1, these are compounds 2, 7, 10, 37, and 56. In addition to effects 
related to carbenoxolone, the compounds may have a higher affinity for an enzyme-
NADPH complex (an enzyme ready to reduce cortisone) as opposed to an enzyme-
NADP+ complex (as an enzyme ready to oxidise cortisol), i.e. one reaction direction over 
another (Sahni-Arya et al 2007) or alternatively there may be non-specific binding events 
occurring accounted for by the differing complexities of each system. 
 
5.6.4 Dose-Response Curves: Further Analysis of Inhibitor Binding 
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Dose-response plots have the form of a Langmuir isotherm and are frequently used to 
follow the effects of an inhibitor on the initial velocity of an enzymatic reaction at fixed 
substrate concentration. These were employed to analyse experimental data of 
compounds demonstrating sufficient inhibition in the initial screens and to determine an 
IC50
The following results section is divided into: assays carried out using SPA (section 5.6.5) 
which monitored the reductase reaction (figure 5.2), or fluorescence assays (section 5.6.6) 
which monitored the dehydrogenase reaction (figure 5.3). 
. Overall, the initial screens with human 11β-HSD1 produced 5 compounds which 
inhibited greater than 25 % of recombinant protein activity monitored by a fluorescence 
assay, and 10 compounds which showed greater than 40 % inhibition enzyme activity as 
determined by SPA. A lower criterion of percentage inhibition is set for recombinant 
protein in view of the presence of carbenoxolone. There is overlap between the 
compounds identified by the two screening methods. They are discussed and compared 
later in this text. 
 
5.6.5 Further Analysis: Inhibition Assays with SPA  
The ten compounds exhibiting greater than 40 % inhibition are shown in table 5.1. 
 
Table 5.1 (following page): Compounds which showed greater than 40 % inhibition in 
reductase assays with human 11β-HSD1 and similar inhibition in recombinant human 11β-
HSD1 assays. The fluorescence assays are less sensitive to inhibition due to the partial 
presence of carbenoxolone in the enzyme binding site, reflected in lower inhibition by the 
same compounds in this assay. It is also due to differences in the assays and reaction 
directions. 













3 62.3 % 1 - 2 % 
 
 
5 > 90 % 0 
 
 
7 > 90 % 3.6 % 
 
 
10 50.3 % 28.4 % 
 
 
21 93.6 % 1 - 2 % 
 
 
28 40 % 1 - 2 % 
 
 
29 >90 % 1 - 2 % 
 
37 82.6 % 26.6 % 
 
46 76.8 % 1 - 2 % 
 
 
56 > 90 % 41.9 % 
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Further analysis carried out on these ten compounds employed SPA. Wells were set up 
in triplicate with 8 inhibitor concentration points per compound, spanning 3.5 orders of 
magnitude. Further details are found in Chapter 7 – Materials and Methods.  
A high control (no inhibitor, 100% activity) and low control (no enzyme, 0% activity) 
were present on each 96-well plate, which gave values for the top and bottom 
asymptotes, respectively, in the log dose-response plot. The Log dose-response plot was 
the sigmoidal plot of enzyme activity (in counts per minute) versus log[I] (nM). Without 
the 0% and 100% controls, the data obtained is useless therefore appropriate controls 
were always used. From these plots, an IC50 is obtained and application of the Cheng-
Prussoff equation (equation 5.6) gives values for the Ki. As the Ki cannot be directly 
calculated from SPA, a dose-response curve is plotted to calculate the IC50, with 
subsequent calculation of the Ki





 values in table 5.2. In addition to transfected cells, recombinant human 
protein was used with SPA, with the results shown in figure 5.15, to complement the 
data from cells overexpressing 11β-HSD1 of the same species. 
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Figure 5.14: continued overleaf. 
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Figure 5.14: continued overleaf. 
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Figure 5.14: Plots of cpm versus Log(inhibitor concentration) or Log[I] (nM) for human 11β-
HSD1 transfected cells. The ordinate has units of cpm (counts per minute) which is the signal 
detected from the scintillation counter.  For each compound, a dose-response plot, the chemical 
structure and the IC50
 
 is shown. These are; (A) compound 37, (B) compound 31, (C) compound 
7, (D) compound 56, (E) compound 46, (F) compound 10, (G) compound 28, (H) compound 29, 
(I) compound 3, (J) compound 5. Standard deviation shown calculated using the ‘n-1’ method 
where n=2. Graphs prepared using Kaleidagraph version 4 software from Synergy Software. 
As may be observed in figure 5.14, the top plateau corresponds to the value of 
radioactive substrate binding in the absence of competing drug (total binding). The 
bottom plateau is more difficult to obtain experimentally due to solubility restrictions of 
the compounds analysed – high concentrations of inhibitors were not always possible in 
addition to a minimum 1 % DMSO final volume restriction. This is why a ‘no-enzyme’ 
control is used as the low control. 
It may be seen that for all ten compounds tested in cell SPA, the majority have low 
micromolar IC50 values and Ki values, with the exception of compound 28 (IC50 102.7 
µM) and compound 56 (IC50 67.1 nM). These were converted to Ki values (table 5.2) and 
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compared to the Ki
In several cases the data were difficult to fit to a sigmoidal dose-response curve due to 
high error (e.g. compound 10 in cell based assays) and many showed no inhibition with 
the recombinant protein; these included compounds 3, 21, 28, 29, 37 and 46. As an 
example of this, compound 5 has been shown in figure 5.9D. The data fit to a dose-
response curve however the error on the IC
 values determined for the same compounds with recombinant 
protein with SPA (table 5.2).  
50 is almost the same as the IC50
 
 itself (table 
5.2). This is due to the presence of remaining carbenoxolone in the protein preparation, 
which acts to disguise any low-level inhibition exhibited by the new compounds. Those 
that were not affected were plotted, and are shown in figure 5.15A, B and C.  
Table 5.2: A summary of results from cell SPA of the ten compounds seen in table 5.1. 
Equation 5.6 is applied to the IC50 values above, taking [cortisol] = 100 nM and Km
 
= 340 nM 











3 11.34 ± 2.6 µM 8.7 µM N/A 
5 13.9 ± 3.01 µM 10.7 µM 109.5 nM ± 95.6 
7 5.82 ± 0.33 µM 4.5 µM 68.9 µM ± 25 
10 9.61 ± 13.5 µM 7.4 µM 174.9 µM ± 29.9 
21 7.92 ± 2.96 µM 6.1 µM N/A 
28 102.7 ± 11.7 µM 79.3 µM N/A 
29 9.77 ± 2.23 µM 7.5 µM N/A 
37 14.6 ± 7.05 µM 11.3 µM N/A 
46 6.22 ± 0.93 µM 4.8 µM N/A 
56 67.1 ± 3.35 nM 51.8 nM 853.4 nM ± 53.5 
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Figure 5.15: Recombinant human 11β-HSD1 dose-response curves for four compounds from 
the top ten of the initial human screen analysed with SPA. Six of the compounds showed data 
with high error which did not fit to a sigmoidal dose-response. (A) compound 10, (B) 
compound 7, (C) compound 56, (D) compound 5 – an example of a ‘bad’ fit. 
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5.6.6 Further Analysis: Fluorescence Inhibition Assays with Recombinant 11β-HSD1 
In addition to SPA analysis of inhibitor potency on the reductase direction, fluorescence 
assays were carried out observing inhibitor effects on the dehydrogenase reaction with 
recombinant protein. The compounds analysed were those exhibiting greater than 25 % 
inhibition in initial screens with recombinant enzyme. These are shown in table 5.3. In 
addition, ligands exhibiting more than 40 % inhibition of enzyme activity in cell-based 
assays were analysed with fluorescence. These were compounds 3, 5, 7, 21, 28, 29 and 46 
(shown in table 5.1). 
 
Table 5.3: The six compounds which showed greater than 25 % inhibition in dehydrogenase 
assays with recombinant human 11β-HSD1, and the corresponding inhibition in cell-based 
human 11β-HSD1 assays. Variations observed between the two right-most columns (between 





Fluorescence % inhibition 
(dehydrogenase reaction) 




10 50.3 % 28.4 % 
 




22 73.4 % 19.4 % 
 
37 82.6 % 26.6 % 
 
 
45 27.9 % - 
 
 
56 > 90 % 41.9 % 
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Three of the compounds shown in table 5.3 overlap with the group of compounds found 
to effectively inhibit activity in cell-based assays with 11β-HSD1. These are compounds 
10, 37 and 56. Methods are detailed in chapter 7. The data were analysed as described in 
section 5.4, the results are shown in figure 5.16. 
Despite a promising level of inhibition in the initial screen, compound 45 - which did not 
inhibit 11β-HSD1 in cell-based assays at all - was found to show little inhibition in 
further fluorescence screens and is not shown here. Similar performances were observed 
for compounds 5, 7, 28, 29 and 46; gaving Ki
 
 values of 10.7 µM, 4.5 µM, 79.3 µM, 7.5 µM 
and 4.8 µM respectively, in the cell-based assay. Compound 22 displayed a noisy 
spectrum, and data were not analysable. Results are summarised in table 5.4, plots in 
figure 5.16. 
Table 5.4: A summary of results from fluorescence assays with recombinant protein, assaying 
inhibition of 11β-HSD1 in the dehydrogenase direction. The six potent compounds are shown 
here with the calculated Kiapp
 
















3 141.53 ± 66.1 µM 2.36 µM 8.7 µM 
10 46.8 ± 12.7 µM 0.78 µM 7.4 µM 
16 27.35 ± 2.5 µM 0.45 µM - 
21 247.7 ± 72.5 µM 4.14 µM 6.1 µM 
37 234.2 ± 27.6 µM 3.91 µM 11.3 µM 
56 26.1 ± 6.5 µM 0.43 µM 51.8 nM 
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Of the twelve compounds which were assessed for 11β-HSD1 inhibition with this assay; 
6 were impotent and 6 were potent. Out of the 6 potent inhibitors, 5 were also effective at 
inhibiting 11β-HSD1 activity in HEK-293 cells. 
A potential challenge faced during fluorescence assays is the possible interfering effects 
of the compounds on the assay. The majority of the compounds analysed contain at least 
one aromatic component, which means that they may interfere with the fluorescence 
assay by excitation and emission at the same wavelengths. Alternatively the compound 
may exert an inner filter effect on light emitted by NADPH, absorbing the light before it 
can be detected by the fluorometer. In addition, quenching of fluorescence at 340 nm by 
the compounds is a possibility (Albinsson et al 1994). To detect possible effects of each 
compound, background controls were consistently carried out. For example, compound 
22 showed high background fluorescence in the presence of NADP. In the absence of co-
factor and enzyme, a much reduced signal is detected. A full visible light emission 
spectrum for the compound (excited at 340 nm) carried out in assay buffer only showed 
emission at 680 nm, outside the detection range of the assay. Thus, there is potentially an 
interaction between NADP and compound 22 which results in a high level of emitted 
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Figure 5.16: Recombinant human dose response plots for the top ten compounds assayed with 
fluorescence, monitoring inhibition of the dehydrogenase reaction.  The most potent 
compound, 56, is shown in A. This compound also potently inhibited 11β-HSD1 in cell-based 
assays (Ki
 
 51.8 nM). B: compound 37; C: compound 10; D: compound 16; E: compound 3; F: 
compound 21. 
Differences in the Ki values calculated between the two screening methods are due to the 
presence of carbenoxolone in the recombinant protein, and potentially the affinity of the 
compound for a particular conformation of the enzyme. In this respect, the recombinant 
enzyme can only be used to calculate approximate values in inhibition assays and will 
almost always give an apparently higher Ki
The most potent compound in both assays is compound 56. This compound has a simple 
thioether scaffold, with a piperidine ring on one side and benzene with a methoxy 
substituent opposite. Compound 16 inhibits recombinant 11β-HSD1 with a very low 
micromolar K
 value than the true value.  
i
The five compounds: 3, 10, 21, 37 and 56 are the most potent inhibitors of human 11β-
HSD1 from the pool of 35 ligands assayed. All have K
, however, it does not appear to inhibit 11β-HSD1 in cell-based assays, 
indicating membrane permeability difficulties. For this reason, the compound was not 
included in the top 5 compounds for inhibiting 11β-HSD1 in this research. 
i values in the low micromolar 
range, with compound 56 having a nanomolar Ki
The most potent compounds were subsequently docked into the enzyme active site 
using LIDAEUS to predict ligand-enzyme interactions (section 5.8). Simultaneously, 
crystallisation trials were carried out in an effort to co-crystallise a ligand-enzyme 
complex (chapter 6). 
. These are shown in figure 5.29. 
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5.6.7 Structure – Activity Relationships in the Inhibition of Human 11β-HSD1 
It is apparent from this research that a broad structural range of compounds can inhibit 
11β-HSD1 activity. An initial structure–activity analysis of the compounds tested in this 
research reveals some of the structural features which facilitate inhibitor binding and 
potency. As a general rule of thumb, 11β-HSD1 inhibitors have a central HBA group 
(typically containing oxygen) flanked on either side by lipophilic groups which interact 
hydrophobically in the enzyme active site (Webster and Pallin 2007). To a great extent, 
this molecular arrangement is observed with the hit compounds in this research. A SAR 
analysis of compounds 2 and 3 suggest that although a central HBA is essential, what it 
is attached to is also a point of importance – the presence of a central phenol as opposed 
to an aliphatic carbon chain ketone disrupts potency completely (figure 5.7). In addition, 
certain HBD groups at one or both ends of the molecule can enhance potency, as 
exemplified well by compounds 21 and 22 (figure 5.17, the dark blue region shows the 




Figure 5.17: Structure of compounds 21 (Ki
 
 6.1 μM) and 22 (no inhibition). Dark blue regions 
show the similar structural features, pale blue show the dissimilar regions. 
The only structural difference between these two compounds is the presence of 2 HBA 
groups in compound 22, which are replaced with 2 HBD groups in compound 21. 
Compound 22 does not inhibit 11β-HSD1; however compound 21 has a Ki of 6.1 μM 
(data from transfected HEK-293 cells). Complete removal of all HBA and HBD 
substituents at either end of the molecule ablates potency, as observed with compounds 
21 and 57 (figure 5.18, the yellow regions depict similarity, pink depict differences). 
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Figure 5.18: Structure of compounds 21 (Ki
 
 6.1 μM) and 57 (10% inhibition of activity in initial 
screens). Yellow regions are the similar structural features; pink regions are where the 
compounds differ.  
Replacement of substituents capable of forming hydrogen bond interactions (i.e. groups 
highlighted in pink in figure 5.18) with aromatic ring structures does not improve 
potency (e.g. compound 54, figure 5.7). Of additional interest is the effect of added 
methyl substituents on compounds; these substituents simply add volume to a ligand 
but do not form interactions within the active site therefore it is surprising that they 
create such a significant increase in potency. This is shown with compounds 27 and 29 
(figure 5.19). Compound 27 shows a small amount of inhibition in initial screens; 
compound 29 has a Ki
 
 of 7.5 μM. 
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Figure 5.19: Structure of compounds 27 (little inhibition) and 29 (Ki
 
 7.5 μM). The presence of 
two methyl groups significantly affects the potency. 
Interestingly, removal of the non-aromatic ring from compound 29 disrupts inhibitory 
activity even with the addition of varying substituents from the aromatic ring (as seen in 
compounds 31 (pictured, figure 5.19), 32, 33, 34, 35 and 37 (pictured figure 5.19) none of 
which displayed inhibition of 11β-HSD1). 
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5.7 Species Differences between Mouse and Human 11β-HSD1 Inhibitor Binding  
An excellent example in previously published research of the distinct effects of one 
compound on 11β-HSD1 from many species is from Arampatzis et al. A selected 
compound: T0504 (Figure 5.20, Enamine Ltd) which was previously described by Merck 
(patent WO 03/065983) displayed approximately 100-fold selectivity for the inhibition of 
human 11β-HSD1 (Ki 15 nM) compared with human 11β-HSD type 2 (Ki 2 µM).  
 
Figure 5.20: Chemical structure of T0504 (Enamine) which was found to be 67 times more 
potent in human 11β-HSD1 enzyme than mouse enzyme (expressed in HEK-293 cells). 
  
In addition, T0504 effectively inhibited all species enzymes analysed; however there 
appeared to be significant differences between potency: a 67-fold difference between 
human and mouse (Arampatzis et al 2005). This provided the first evidence that subtle 
differences in the molecular structures of both active site and 
Initial screens with mouse recombinant and in vivo 11β-HSD1 (in HEK-293 cells) showed 
that there were eight compounds which displayed greater than 25 % inhibition. These 
were compounds 7, 10, 21, 22, 37, 46, 56 and 60. Four of these compounds are in the top 
five from human screens (10, 21, 37, and 56). Further analysis was carried out with the 
top 8 hits from the mouse screens, which were assayed using the fluorescence technique 
with recombinant mouse enzyme. As carbenoxolone is added to the mouse expression 
cultures, the values determined from these assays are again approximate figures.  
inhibitor may have a big 
impact on ligand affinity and potency, respectively. 
Compounds 21, 22 and 60 were the only compounds which displayed sufficient 
inhibition of mouse 11β-HSD1 to allow dose-response plots and the subsequent 
calculation of a Kiapp. These are shown in figure 5.21. Interestingly, none of these 
compounds showed great affinity for the human enzyme. Furthermore, compound 56 - 
the most potent human 11β-HSD1 inhibitor - showed mild inhibition of mouse 11β-
 - 175 - 
HSD1, with a predicted Kiapp of approximately 500 µM which is a 10,000 fold decrease in 
potency, compared to ~50 nM in cells with human 11β-HSD1. 
 
 
Figure 5.21: Dose-response plots of mouse 11β-HSD1 inhibition assays. A: compound 21, B: 
compound 22, C: compound 60.  
 - 176 - 
5.7.1 Structure – Activity Relationships in the Inhibition of Mouse 11β-HSD1 
As can be seen from figure 5.22, compounds 21 and 22 inhibit mouse 11β-HSD1 with a 
low micromolar range Ki
 
. The compounds differ by the dihydroxyphenyl (21) / 
dimethoxyphenyl ring (22) and the substituent positions on this ring, as shown in figure 
5.14 and highlighted in yellow.  
 
Figure 5.22: Chemical structures of compounds 10, 21 and 22. The latter two inhibit mouse 11β-
HSD1. Differences in structures are highlighted with a yellow or blue circle. 
 
With regards to compounds 21 and 22, an exchange of two hydroxyl substituents for two 
methoxy substituents (yellow circles, figure 5.22) results in a 2-fold drop in mouse 
enzyme potency due to the loss of two hydrogen donor groups. Docking studies (figure 
5.25) show that these substituents would most likely be at the mouth of the active site 
potentially forming hydrogen bonds with Gln 177 (which is Tyr 177 in humans), Leu 171 
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or the backbone of Ala 172. The benzimidazole moiety would be buried deep within the 
pocket. Compound 10 differs from compound 21 (shown with blue circles, figure 5.22) 
and is a V-shape (due to the tetrazole ring substitutions) rather than linear. This results 
in a complete loss of inhibition of mouse 11β-HSD1. As can be seen in figure 5.25 and 
5.26 (docking figures), the V-shape of compound 10 means that it sits differently in the 
active site as compared to compound 21, with important HBD groups buried deeper 
within the pocket, as opposed to being nearer the mouth of the pocket as seen in 
compound 21. This has a knock-on effect with regards to potency. As seen with human 
11β-HSD1, the presence of HBD groups near the entrance of the active site improves 
potency. 
 
5.8 Docking of New 11β-HSD1 Inhibitors 
As the search for novel 11β-HSD1 inhibitors ensues, there is ever-more published 
research into the potential docking of these compounds in the absence of a co-crystal 
structure (Lee et al 2008; Miguet et al 2006; Schuster et al 2006; Vicker et al 2007; Yang et 
al 2009; Yang et al 2008). 
The program LIDAEUS (LIgand Discovery at Edinburgh University) was used for 
docking studies of the inhibitors investigated in this research. The X-ray crystal 
structures 2BEL (Hale et al 2008) and 2RBE (Yuan et al 2007) of human 11β-HSD1 were 
used for docking studies. These two particular structures were used as they were the 
best available data at the time of research, with resolutions at 2.11 Å and 1.9 Å 
respectively. Furthermore, each structure was in complex with carbenoxolone and a 2-




LIDAEUS (Taylor et al 2008; Wu et al 2003) is an in-house virtual screening program 
which screens 3-D structures by docking the inhibitor atoms onto pre-determined site 
points in the active cavity. The pre-determined site points (or grid-points) define the 
preferred protein interaction e.g. HBA, HBD or hydrophobic. As the inhibitors are 
docked and matched to the site points, each pose is given a score which is based on 
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several factors including the van der Waals and hydrogen donor and acceptor bonding 
energies. Various orientations of the ligand are attempted to achieve a chemical and 
shape complementarity between the ligand and the binding site. The site points 
generated using LIDAEUS for the crystal structure 2BEL (Wang et al 2008) are shown in 
figure 5.23. 
 
Figure 5.23: Illustration prepared with Pymol showing: (A) the active site in 2BEL with ligand 
(carbenoxolone) in yellow stick format. The enzyme has been given a surface, coloured 
according to atom type. (B) the active site with grid points generated by LIDAEUS, Blue 
spheres are HBD, red spheres are HBA and grey spheres are hydrophobic. (C) the grid points 
alone (colours as described).  
 
The end product is a list of ligand poses for each inhibitor, ranked according to their 
score. This score function represents how well the ligands fit into the binding site. It is a 
sum of the energy factors mentioned, but it is not representative of the free energy as it is 
not complete (e.g. it does not take into account the movement of water molecules) and is 
used as a guide. The scores in this study ranged from -36 to -11 kcal mol-1, with a good fit 
having a negative score. The energy scores of each of the docking positions are shown in 
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table 5.5, as determined by LIDAEUS. The energies calculated by LIDAEUS are all in the 
acceptable range. 
 





-11.89 -18.86 -18.87 -16.17 -11.92 -16.72 -19.75 
 
Table 5.5: The scores generated by LIDAEUS to demonstrate the ‘goodness’ of a docking pose. 
All the docking positions shown here are in the top 4 positions identified by LIDAEUS. 
 
5.8.2 Docking Hits into 11β-HSD1 
Eight compounds (3, 5, 7, 10, 21, 37, 46 and 56) were docked into the ligand binding 
pocket. Five of these were predicted to form interactions with the catalytically active 
residues Tyr 183 and /or Ser 170 in the docking poses shown here (figure 5.24). The poses 
shown in figure 5.24 were always one of the top four positions identified by LIDAEUS. 
The relative energy scores of the 8 compounds docked are shown in table 5.5. The three 
dimensional structures are shown in figure 5.24 of each compound docked, beside an 
overview of the compound in the binding site. 
Compounds 10 and 21 enter deeply into the binding site (figure 5.24, 4b and 5b 
respectively) due to different spatial characteristics of the two compounds; the V-shape 
of 10, and the small volume of 21. In contrast, the planarity of compound 3 means that it 
protrudes from the binding site entrance. The remaining five compounds fill a fairly 
similar space in the binding site, as seen in figure 5.24. 
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Figure 5.24: (a) Depiction of each compound docked, 2-D and 3-D representation, (b) overview 
of the compound in the active site. 11β-HSD1 is shown in green, in cartoon form, as this 
facilitates viewing. The co-factor may be seen behind the compound, in magenta/red. This 
applies to (A) compound 3, (B) compound 5, (C) compound 7, (D) compound 10, (E) compound 
21, (F) compound 37, (G) compound 46, and (H) compound 56. Compounds 37 and 56 are 
shown in the binding site with 11β-HSD1 depicted with a surface. This allows a better spatial 
perspective of binding however was only possible for these compounds. 
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5.8.3 Compounds with Catalytic Triad Interaction 
There were five compounds which showed interactions with one or more of the catalytic 
triad of residues in the active site (Ser 170, Tyr 183 and Lys 187). The polar interactions 
shown between each compound and residues in the binding pocket are shown in figure 




Figure 5.25: Close up view of inhibitor binding in the active site of 11β-HSD1, as determined 
by LIDAEUS. Shown are the highest scoring positions of each compound. (A) compound 5, (B) 
compound 7, (C) compound 21, (D) compound 46 and (E) compound 56. The co-factor is shown 
on the left-hand side in each case, with inhibitor on the right. Interacting residues are shown 
in stick format and labelled accordingly. 
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Docking of compound 7 into 2BEL (figure 5.25B) highlights six polar interactions which 
may occur, far more than any other compound examined. This is due to a higher number 
of HBAs (9) and HBDs (2) on compound 7 as compared to the other inhibitors. The 
diphenyl ring points toward the solvent, but also acts as a HBA to the methionine (Met 
233) amino nitrogen backbone. Several high scoring docking poses positioned the 
molecule very deep within the binding pocket so it appeared to be exiting the enzyme 
through the co-factor entrance, at the opposite end of the substrate entrance.  
Docking of compound 46 into 2RBE (figure 5.25D) showed entry of the electronegative 
fluoro-pyrazole moiety first into the binding pocket and four polar interactions between 
the compound and 11β-HSD1. The fluoro- moiety of compound 46 is in close proximity 
to the nicotinamide ring of NADPH (approximately 2.5 Å) putatively allowing the 
fluorine p-orbital electrons to delocalize into the П-bonding network of the nicotinamide 
pyridine ring of NADPH (Loh et al 2003). Indeed, removal of this tri-fluoro group 
ablates potency, as seen when compared to compound 47 (figure 5.26). 
 
 
Figures 5.26: Structure of compounds 46 and 47 showing the differences (shown in yellow) and 
effects. 
 
Several previously developed inhibitors have included a halogen moiety at or around 
this position; it has been observed that a halogen positioned here may mimic a halogen 
at the 9-α position of a steroid skeleton (see chapter 1 for steroid numbering) reported in 
1968 to inhibit the dehydrogenase reaction but to enhance the reductase reaction 
direction; as demonstrated with the use of 9α-fluorocortisone and 9α-fluorocortisol 
(Bush et al 1968). Analysis of compound 46 has been carried out previously in many 
instances with several diverse primary screens carried out and the results reported 
(PubChem BioActivity Services), for example; compound 46 has been tested for 
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inhibition of T. Cruzi replication, inhibition of human galactokinase (GALK), antagonism 
of the G-protein coupled receptor 7 (GPR7) and inhibition of the Plasmodium 
Falciparum M18 aspartyl aminopeptidase (PFM18AAP). Of 109 initial screens in which it 
exhibited activity (excluding the current research) 87 had a particular protein target, 
none of which were 11β-HSD1. 
Docking of compound 5 with LIDAEUS (figure 5.25A) into 2BEL displays few polar 
interactions; the catalytic residue serine 170 is the only residue creating polar contacts 
with the inhibitor. Compound 21 displays two polar interactions, one with the catalytic 
residue Tyr 183, and another with the backbone nitrogen of Leu 171 (figure 5.25C).  
Docking of compound 56 into 2RBE (figure 5.25E) shows the nitrogen of the pyridine 
moiety interacting with the catalytically active tyrosine 183 hydroxyl group. In addition 
the central carbonyl of compound 56 acts as a hydrogen acceptor with serine 170. The 
proximity of the nicotinamide ring allows for П-stacking between inhibitor and the 
pyridine ring. This is a classic 11β-HSD1 inhibitor binding scenario, and is commonly 
seen with other inhibitors (chapter 1), that is; Tyr 183, Ser 170, the co-factor nicotinamide 
ring and several hydrophobic interactions.  
 
5.8.4 Compounds with no Catalytic Triad Interaction 
The three remaining compounds; 3, 10 and 37 do not interact with any of the catalytic 
residues, indeed 37 does not appear to make any polar contacts with the enzyme and 
relies predominantly on hydrophobic interactions for binding. Compounds 3 and 10 
form hydrogen bonds with residues out-with the catalytic triad which surround the 
active site; Thr 124, Ala 172 (backbone), Leu 215 (backbone), as shown in figure 5.27. 
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Figure 5.27 The four docked compounds which did not display polar interactions with the 
catalytic triad in the binding pocket; a close up view of binding in the active site of 11β-HSD1 
and (A) compound 3, (B) compound 10, (C) compound 37. The inhibitor compound is shown on 
the right hand side in all cases, and co-factor NADPH on the right (as labelled). Residues 
playing a role in binding are depicted in stick form and are labelled accordingly. Diagram 
prepared with Pymol. 
 
Compound 10 (figure 5.27B) showed slightly different binding, partially due to its 
awkward V-shape, allowing the compound to bury deeply into the pocket in close 
proximity to NADP(H). Despite this, there does not appear to be any co-factor 
interactions. There are four polar interactions which dominate binding; the backbone 
nitrogen of Thr 124 with the hydroxy oxygen from the benzene ring of compound 10; 
Asn 123 and the hydroxy hydrogen of compound 10; the backbone of Ala 172 and the 
amide oxygen on the other end of the molecule; Leu 215 and the amide nitrogen at the 
same end of the molecule (shown in figure 5.27B). 
The docking model for compound 37 (figure 5.27C) showed that binding is dominated 
by hydrophobic interactions. The compound sits deeply buried within the pocket with 
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the naphthalene ring group planar to tyrosine 183, but at a distance of 6 Å prevents π-
stacking. However, perpendicular π-stacking is possible between Tyr 177 and the 
naphthalene rings (~ 2 – 3 Å distance). 
Compound 3 differs from the other inhibitors in that it is planar (figure 5.27A). The 11β-
HSD1 binding pocket tilts downward slightly from the mouth toward the co-factor. A 
planar molecule will thus not complement this shape completely (a V-shaped molecule 
may have a better ‘fit’, refer to figure 1.32). Due to its planarity, compound 3 does not 
arch toward the co-factor so they cannot interact: they are a distance of 5 Å apart at their 
closest point. This inhibitor is held in place predominantly by hydrophobic features, in 
addition to one polar interaction with threonine 264, which shares its hydrogen with the 
methoxyphenyl oxygen at the mouth of the binding site. The compounds sits fairly high 
up in the binding tunnel and is flanked by three threonine residues at each corner, as 
shown in figure 5.28A. The residues Thr 222 and Thr 224 are just out of range for 
forming polar interactions with the methoxy oxygens on compound 3 (a distance greater 
than 3 Å). An interaction with threonine residues in the active site has been seen 
previously with other 11β-HSD1 inhibitors (chapter 1). 
 
5.9 Discussion 
Of the 35 compounds tested, 12 were based on carbenoxolone, 11 are based on 2-
anilinothiazolone, 4 were based on adamantane (chapter 4) as UFSRAT query molecules 
and a further 8 were selected from supplier’s catalogues to complement the 27 existing 
compounds. Those which displayed inhibition of 11β-HSD1 ranged in molecular weight 
(from approximately 200 – 400 Da), LogP and structural class. 
Several compounds were found to inhibit in cell-based assays but not with recombinant 
protein, and vice versa. For example, compound 16 inhibited recombinant protein, but 
not 11β-HSD1 in HEK-293 cells. This is summarised in figure 5.28. 
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Figure 5.28: Chart showing the overlap of compounds which inhibited both in cells and in 
recombinant protein assays. Out of 35 compounds, 5 inhibited both in cell and recombinant 
human 11β-HSD1 inhibition assays (overlap between green and blue circles). One of these five 
also inhibited mouse 11β-HSD1 (two other compounds inhibited mouse 11β-HSD1 but not 
human). One compound inhibited recombinant 11β-HSD1 (in vitro) but not HEK293 expressed 
11β-HSD1 (in vivo) shown in the green circle. Five compounds inhibited in cell based assays 
but not recombinant 11β-HSD1 (blue circle). 
 
Five compounds inhibited 11β-HSD1 in HEK-293 cells but not recombinant protein; 
these compounds (5, 7, 28, 29, and 46) had low micromolar range Ki values in cell-SPA. 
The lack of inhibition of recombinant enzyme is due to the presence of carbenoxolone in 
the recombinant protein preventing the ligands binding, and possibly a preference for 
the NADPH-bound form of the enzyme over the NADP+ bound form. In a study carried 
out by Sahni-Arya et al, (Sahni-Arya et al 2007) the binding of a competitive pyridyl 
amide inhibitor showed that the presence of NADPH (as opposed to NADP+) increased 
the affinity of the compound 5-fold (from a Ki 279 nM to 53.2 nM). In similar 
experiments, a sulfonamide compound was determined to preferentially bind to an 
NADP+
The five compounds which exhibited inhibition of 11β-HSD1 in both cellular and 
recombinant enzyme assays were selected as the top five inhibitors. These are shown in 
figure 5.29 and summarised in table 5.6. In this table, the UFSRAT query molecule is 
denoted; this is the compound with which a similarity search was carried out according 
to its various physicochemical parameters. As can be seen from table 5.6, the majority of 
compounds used carbenoxolone as a query molecule. 
 bound form of 11β-HSD1, evidenced through a small negative effect on the 
affinity of the compound in the presence of NADPH.  
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Table 5.6: Summary of the top five compounds inhibiting 11β-HSD1, and the query molecules 
used to mine for similar compounds (chapter 4). The Ki
 
 values are taken from the cell SPA 
experiments where possible. 
Compound ID Query Molecule Calculated K
3 
i 
Carbenoxolone 8.7 µM 
10 Carbenoxolone 7.4 µM 
21 Carbenoxolone 6.1 µM 
37 2-anilinothiazolone 11.3 µM 




The five compounds which exhibited bidirectional inhibition of 11β-HSD1 were docked 
into the active site and showed a variety of interactions with the enzyme, with two of the 
compounds docked interacting with Ser 170 and Tyr 183 (compounds 21 and 56).   
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Figure 5.29: Summary of the structure and chemical parameters of the top five compounds 
found to inhibit both recombinant 11β-HSD1 and in cells transfected with human 11β-HSD1. 
 
5.10 Conclusions and Future Work 
Overall, five of the 35 compounds analysed showed low micromolar bidirectional 
inhibition of human 11β-HSD1; an estimated 14% hit rate.  
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Further work would determine the mode of inhibition by construction of a Dixon plot. 
This is a reciprocal graphical representation of the inhibitor data obtained by varying the 
inhibitor concentration over a fixed substrate concentration. This is carried out with, for 
example, four fixed substrate concentrations which would give four sets of data to be 
plotted on the 1/V vs [I] graph. The four resulting lines will intersect in a manner 
characteristic of the type of inhibition assayed. For example, for competitive inhibitors 
the lines will intersect beyond the ordinate, at a point -Ki. For non-competitive inhibitors 
the lines will intersect on the abscissa, below zero, defining the -Ki
The selectivity of these inhibitors must also be assessed for cross-inhibition of 11β-HSD2. 
Inhibition of this isoform in the kidney would result in activation of the 
mineralocorticoid receptor (through inhibition of inactivation of the active steroid) and 
cause hypertension and hypokalemia (Frey et al 2004). In addition, due to a higher 
sequence identity (36%), 17β-HSD2 cross-inhibition screening may be useful, although 
recent research shows that it is the spatial structure similarities rather than the amino 
acid sequence identity which determines whether a ligand will bind (Koch et al 2004). 
. Alternatively, a 
Lineweaver-Burk plot can be used to determine inhibition type but due to its double 
reciprocal nature it cannot be used to derive reliable kinetic data. 
 Further preclinical assays will include PXR selectivity, and additional tests to investigate 
the metabolic stability and safety of the ligands. These include P450 assays, a clearance 
assay in liver microsomes, a membrane permeability assay in intestinal cells, and 





CRYSTALLISATION AND STRUCTURE OF  
11β – HYDROXYSTEROID DEHYDROGENASE TYPE I 
  
6.1 Introduction 
There are a total of 17 crystal structures deposited in the online protein data bank (PDB) to-
date (table 6.1). To a great extent, the crystal structures of human 11β-HSD1 - which 
constitute 14 out of the 17 deposited structures - are a very recent emergence, powered by 
the surge of interest by the pharmaceutical industry at around the same time in 11β-HSD1 as 
a novel drug target. This flurry of interest drove forward important developments in 11β-
HSD1 expression and purification which was previously the principal obstruction in 11β-
HSD1 crystallographic research: attaining sufficient quantities of recombinant human 
enzyme.  
At the start of this present research, there were two mouse structures, three human 
structures (one of which still remains to be published) and one guinea-pig structure in the 
PDB, all produced through academic efforts. From the start of 2007 until November 2008, a 
further 11 crystal structures were deposited in the PDB of the coveted human enzyme. All of 
these structures came from pharmaceutical industry laboratories, with Amgen Inc. being the 
major player with 8 of these published structures, all in complex with novel inhibitors (table 
6.1). Figure 6.1 shows one of the X-ray crystallography derived structures from Amgen; a 
tetramer of 11β-HSD1 deposited in 2008 (3BYZ) in complex with a thiazolone compound. 
With similar goals, attempts at human and mouse 11β-HSD1 crystallisation were carried out 
in this research in an endeavour to produce single, diffracting co-crystals of 11β-HSD1 with 
a novel inhibitor (from chapter 5).  
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# 
PDB Code & co-crystallised 
ligand 
Title of deposited crystal 
structure 
Title & Date of publication 
(PubMed ID) 





The Crystal Structure of 
Murine 11B-HSD1 complexed 
with corticosterone 
(PubMed ID: 15865440)  
May 2005 
(Zhang et al., 2005) Resolution [Ǻ]: 3                 
R-value: 21 %                    
R-free: 24.7 %                
Space Group: P4122 
Vapour Diffusion 
1.8M Li2SO4,  




The Crystal structure of 
Murine 11B-HSD1: an 
important therapeutic target for 
diabetes  
(PubMed ID: 15865440) 
May 2005 
(Zhang et al., 2005) Resolution [Ǻ]: 2.3               
R-value: 21.9 %                    
R-free: 25 %               
Space Group: P4122 
Vapour Diffusion 
1.8M Li2SO4,  




Crystal Structure of the 
Interface Closed Conformation 
of 11B-HSD1 isozyme 1  
(PubMed ID: 15513927)  
November 2004 
(Hosfield et al., 
2005) 
Resolution [Ǻ]: 1.5               
R-value: 15.8 %                     
R-free: 18.1 %                     
Space Group: P1211 
Vapour Diffusion 
PEG,  






Structure Of Human 11B-
HSD1 In Complex With NADP 
And Carbenoxolone 
(PubMed ID: ) 
December 2004 
(Hale, 2008) Resolution [Ǻ]: 2.11                 
R-value: 19 %                      
R-free: 24.6 %                    
Space Group: P21212 
0.1 M MgCl2 




Crystal Structure of the 
Interface Open Conformation 
of Tetrameric 11b-HSD1  
(PubMed ID: 15513927)  
November 2004 
(Hosfield et al., 
2005) 
Resolution [Ǻ]: 1.8                
R-value: 19.8 %                              
R-free: 21.7 %                     
Space Group: P1211 
Vapour Diffusion 
PEG,  
MES pH 7.0,  
298K 
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# PDB Code & co-crystallised 
ligand 
Title of deposited crystal 
structure 
Title & Date of publication 
(PubMed ID) 
Authors Parameters Crystal Conditions 
6 1XSE 
 
The Crystal Structure of 
Guinea Pig 11β-HSD Type 1 
Provides a Model for Enzyme-
Lipid Bilayer Interactions 
 
(PubMed ID: 15542590)  
November 2004 
(Ogg et al., 2005) Resolution [A]: 2.5                      
R-value: 19. 6% (obs)                       
R-free: 26.7 %                
Space Group: I 4 2 2 
Vapour Diffusion   
38-40 % PEG 550 
MME,  







The discovery of 2-
anilinothiazolones as 11B-
HSD1 inhibitors 
(PubMed ID: 17919905) 
AMGEN 
January 2008 
(Yuan et al., 2007) Resolution [A]: 1.9                        
R-value: 21.9 % 
(work)                     R-
free: 26.4 %                        
Space group: P212121 
 




Human 11B-HSD1 with NADP 
and Adamantane Sulfone 
Inhibitor 
Adamantane sulfone and sulfonamide 11-
beta-HSD1 Inhibitors (PubMed ID: 
17070044) 
ABBOTT, April 2007 
(Sorensen et al., 
2007) 
Resolution [A]: 2.3                
R-value: 21.2 % (obs) 
R-free: 27.5 %                          
Space group: I 2 3 





Dehydrogenase (HSD1) with 
NADP and Adamantane Ether 
Inhibitor 
Discovery of adamantane ethers as 
inhibitors of 11beta-HSD-1: Synthesis and 
biological evaluation (PubMed ID: 
17110106) ABBOTT, January 2007 
(Patel et al., 2007) Resolution [Å ]: 3.1                      
R-value: 23.9 % (obs) 
R-free: 27.8 %                          
Space group: H 3 2 
No details Supplied. 
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# 
PDB Code & co-crystallised 
ligand 
Title of deposited crystal 
structure 
Title & Date of publication 
(PubMed ID) 






ones as Potent and Selective 
11-Hydroxysteroid 
Dehydrogenase Type 1 
Inhibitors 
2-amino-1,3-thiazol-4(5H)-ones as potent 
and selective 11beta-hydroxysteroid 
dehydrogenase type 1 inhibitors: enzyme-
ligand co-crystal structure and 
demonstration of pharmacodynamic effects 
in C57Bl/6 mice                         (PubMed 
ID: 18419108) 
AMGEN, February 2008 
(Johansson et al., 
2008) 
Resolution [Å ]: 2.69 
R-value: 22.2 % (obs) 




25% PEG 3350, 
0.1M Na Citrate 
pH 5.6, 






Crystal structure of human 11-
beta-hydroxysteroid 
dehydrogenase(HSD1) in 
complex with NADP and 
thiazolone inhibitor 
Structural characterization and 
pharmacodynamic effects of an orally 
active 11beta-hydroxysteroid 
dehydrogenase type 1 inhibitor (PubMed 
ID: 18069989) 
AMGEN, June 2008 
(Hale et al., 2008) Resolution [Å]: 2.25 
R-Value: 20.4 % 
(obs) 
R-Free: 26.3 % 
Space Group: 
P 21 (P1 21 1) 
Vapour Diffusion, 
sitting drop, 
16-18% PEG 3350, 
0.1M MES pH 6.2 
298K 
12 





Crystal Structure of 11beta-
HSD1 Double Mutant (L262R, 




Pyridine amides as potent and selective 
inhibitors of 11beta-hydroxysteroid 




(Wang et al., 2008) Resolution [Å]: 2.35 
R-Value: 18.8% (obs) 
R-Free: 23% 
Space Group: 
P 21 21 21  
Vapour Diffusion, 
hanging drop 
22% (w/v) PEG 
3350, 200 mM 
potassium formate 
pH 7.3,   1.5mM 
Zwittergent 3-12, 
277K 
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# PDB Code & co-crystallised 
ligand 
Title of deposited crystal 
structure 
Title & Date of publication 
(PubMed ID) 




Crystal Structure of Human 
11-beta-Hydroxysteroid 
Dehydrogenase (HSD1) in 
Complex with 
Arylsulfonylpiperazine Inhibitor 
Discovery and initial SAR of 
arylsulfonylpiperazine inhibitors of 11beta-
hydroxysteroid dehydrogenase type 1 
(PubMed ID: 18511278)  
AMGEN 
June 2008 
(Sun et al., 2008) Resolution [Å] : 2.35 
R-Value: 22.1% (obs) 
R-Free: 24.7% 
Space Group:  
P 31 2 1  
Vapour Diffusion, 
sitting drop  
16% PEG 3350,  





(truncated at 284. Also –missing 
232H and 233M) 
Crystal Structure of Human 
11-beta-Hydroxysteroid 
Dehydrogenase (HSD1) in 
Complex with Benzamide 
Inhibitor 
Discovery of novel, potent benzamide 
inhibitors of 11beta-hydroxysteroid 
dehydrogenase type 1 (11beta-HSD1) 
exhibiting oral activity in an enzyme 




(Julian et al., 2008a) Resolution [Å]: 2.6 
R-Value: 23 % (obs) 
R-Free: 28.3%     
Space Group:  
P 21 (P 1 21 1)  
Vapour Diffusion, 
sitting drop 19% 
PEG 3350,  





Further studies with the 2-
amino-1,3-thiazol-4(5H)-one 
class of 11-HSD1 inhibitors: 
Reducing pregnane X receptor 
(PXR) activity and exploring 









Space Group:   
P 212121   
 
Vapour Diffusion, 
hanging drop  
25% PEG 3350,  
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# PDB Code & co-crystallised 
ligand 
Title of deposited crystal 
structure 
Title & Date of publication 
(PubMed ID) 




Crystal Structure of Human 
11-beta-Hydroxysteroid 
Dehydrogenase (HSD1) in 
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# PDB Code & co-crystallised 
ligand 
Title of deposited crystal 
structure 
Title & Date of publication 
(PubMed ID) 
Authors Parameters Crystal Conditions 
20 Present Research 
Crystal Structure of murine 
11β-HSD1 in complex with 
Carbenoxolone Inhibitor 
July 2009 
Iain McNae Resolution [Å]: 2.30 
R-Value:  20.1% 
(obs.) 
R-Free: 25.8% 
Space Group:  




22 % PEG 8000,  
10 % propanol,  
0.1 M Hepes pH 7.5 
277.15 K 
 
Table 6.1: A summary of available crystal structures of 11β-HSD1 in the protein data bank (PDB), as of 10th November 2009. 
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Figure 6.1: The crystal structure 3BYZ of 11β-HSD1 from the PDB (Johansson et al 2008c). 
Each monomer is coloured differently in this representation which was prepared with 
Pymol. The co-factor NADPH is shown in pink, the thiazolone inhibitor is shown in pale 
blue. 
 
The majority of the 11β-HSD1 constructs used for crystallization are N-terminal 
truncated forms (Δ1 - 23) which occasionally lack parts of the C-terminus (as shown 
in table 6.2, column 3). The majority of recently deposited structures also have a Cys 
272 to Ser mutation (table 6.2, column 2). These truncations and mutations serve to 
facilitate the production and yield of soluble protein but also aid in crystallography 
by reducing the net hydrophobicity of the protein.  
In this research, two forms of human 11β-HSD1 were used in crystallography trials, 
in addition to the mouse enzyme. These were both expressed and purified under 
identical conditions and were found to have similar activities. These were; a ‘wild 
type’ 11β-HSD1 which had an N-terminal truncation (residues 1 – 23) as described in 
chapters 1, 2 and 7; and a C272S mutant which also had an N-terminal truncation (1 – 
23). 
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The majority of structures deposited into the PDB in the last 12 – 18 months have had 
the C272S mutation, and it is thought to facilitate crystallization of the enzyme.  
 
PDB code: Mutations: Truncations: Chemical co-complexes: 
3FRJ C272S 21 - 292 Piperidine Benzamide inhibitor 
3CZR C272S 24 - 292 Arylsulfonylpiperazine inhibitor  
3D3E C272S 24 - 292 Benzamide inhibitor  
3D4N C272S 24 - 292 Sulfonamide inhibitor  
3EY4 C272S 25 - 292 Thiazolone inhibitor 
3CZR C272S 24 - 292 Sulfonyl Piperizine inhibitor 
3CH6 L262R,  F278E 24 - 292 Pyridine Amide inhibitor 
3BZU C272S 24 - 292 Thiazolone inhibitor 
3BYZ C272S 25 – 292 Thiazolone inhibitor 
2IRW NONE 25 - 288 Adamantane inhibitor 
2ILT NONE 23 - 284 Adamantane inhibitor 
2RBE C272S 24 - 292 Thiazolone inhibitor 
2BEL NONE 26 - 284 Carbenoxolone 
1XU9 C272S 21 - 292 No chemical complex 
1XU7 C272S 21 - 292 No chemical complex 
3FCO - - As yet unreleased 
 
Table 6.2: Sequence details of all current structures of human 11β-HSD1 in the PDB. The 
full-length sequence is 292 amino acids in length. 
 
 
Human 11β-HSD1 contains four cysteines, three of which are conserved across 
species. The residue cysteine 272 is located in the C-terminal and is unique to 
primates. Mutation of this cysteine to a serine residue produced a mutant with 
similar activity and kinetics (Walker et al 2001) as observed in this research. Despite 
initial experiments with non-reducing gels indicating the inability of the C272S 
mutant to dimerise (Walker et al 2001, Maser et al 2002), more clear-cut experiments 
using static light scattering with the C272S mutant demonstrated its retained ability 
to form dimers and tetramers in solution, similar to the wild-type control (Hosfield et 
al 2005). This has since been supported by crystal structures of the C272S mutant. 
Truncation of the C-terminus from residue 264 onwards abolished the tendency to 
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tetramerise (supporting the role of the C-terminal helices in tetramer formation) but 
did not prevent dimerisation (Hosfield et al 2005). It has since been postulated that 
Cys 272 is not directly involved in dimer formation but can form disulphide bridges 
between two dimer partners under favourable conditions. 
 
6.2 Detergents and Additives in 11β-HSD1 Crystallography 
Detergents play a number of roles in the present research. It solubilises 11β-HSD1 
prior to purification and confers stability during purification procedures. It is 
removed for kinetic and inhibitor assays, and replaced in the crystal buffers to 
facilitate protein crystallisation.  
To enable successful crystallization of the guinea-pig enzyme, Ogg et al. determined 
through screening various combinations that the presence of 0.05 % triton X-100 and 
0.5 M of the denaturant guanidinium hydrochloride (GuHCl) were necessary 
additives in the drops. It was suggested that these sub-denaturing conditions 
allowed the protein to maintain the monodispersity required for crystallization. It 
was noted that the enzyme also retained full activity after a 16 hour incubation in 
these conditions (Ogg et al 2005). Triton X-100 is a non-ionic surfactant which has a 
high molecular weight and a low critical micelle concentration (CMC) which means 
that it is often difficult to remove if used during a protein purification protocol.  
It is also reported that certain detergents (including triton X-100) and a variety of 
phospholipids (dilauryl phosphatidylserine, dioleeoyl phosphatidylcholine, dilauryl 
phosphotidylcholine, sphingomyelin and dioleoyl L-α-phosphotidylethanolamine) 
may have a positive effect on the activity of 11β-HSD1 (Castro et al 2007) as 
supported in chapter 3. Previous unpublished crystal structures have been obtained 
with the addition of triton X-100, for which electron density can be seen close to the 
hydrophobic substrate pocket opening. 
Similar published data is available with the detergent CHAPS (3-[(3-
Cholamidopropyl) dimethylammonio]-1-propanesulfonate)(Hosfield et al 2005) 
depicted in figure 6.2B.  
In these structures (PDB accession 1XU9 and 1XU7) the CHAPS molecule is observed 
in the steroid binding pocket, with the A-ring of the steroidal core of CHAPS at the 
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catalytic end of the pocket toward to NADP+ nicotinamide, and the zwitterionic tail 
of the detergent extending toward the solvent. The molecule CHAPS was found to 
bind in an opposite manner to substrate, which projects the A-ring carbonyl toward 




Figure 6.2: (A) Monomer from the crystal structure 1XU7 showing the molecule CHAPS 
entering the active site. The co-factor NADPH is behind CHAPS (pink). (B) Steroidal 
structure of CHAPS. 
 
Several hydrophilic contacts with the cofactor NADPH and also Tyr 183 from the 
catalytic triad of residues can be seen with the detergent, with the majority of the 
interactions being hydrophobic.  
Thesit is another non-ionic detergent which is used in this research in the enzyme 
purification procedure as it has a lower CMC as compared to triton X-100 and 
CHAPS and was found to be easier to remove through dialysis and chromatography 
procedures. In contrast, detergent may also hinder the process of protein 
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crystallisation due to interference with the crystal lattice formation – preventing the 
close approach of the particles for intermolecular polar contacts to occur (Fethiere 
2007). Buffer additives (i.e. PEG, dextran, glycerol, sugars), pH, temperature and 
ionic strength may have significant effects on the CMC or cloud point of detergents, 
inducing an unexpected phase separation in the crystallography drop. For example; 
a high salt concentration can decrease the CMC of a detergent (the CMC of SDS is 
decreased 16 fold when NaCl concentration is increased from 0 to 500 mM) (Arnold 
and Linke 2008). This phenomenon is taken into account when preparing for protein 
crystallography, as above the CMC the drop solution will separate into a detergent 
rich and a detergent poor phase, with crystals often being found close to the phase 
separation. Figure 6.3 shows a detergent phase diagram for a general detergent 
where crystals may form above the CMC at lower precipitant concentrations, or 
below the CMC at higher precipitant concentrations. At high detergent and salt 
concentrations, the protein will aggregate or precipitate out of the drop, at low 




Figure 6.3: A Detergent phase diagram for protein crystallography. The yellow line 
indicating CMC decreases with increasing precipitant concentration. Protein crystals are 
often found at the phase boundaries.  
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6.3 Crystallography of Murine 11β-HSD1: Initial Trials 
Active murine 11β-Hydroxysteroid Dehydrogenase 1 was prepared for 
crystallography at 16 mg/ml in a crystal buffer (20 mM Tris pH 7.8, 20 mM NaCl, 1 
mM EDTA, 1 % glycerol). The hanging drop method was used to crystallise the 
enzyme (details in chapter 7 – Materials and Methods). The initial strategy to 
determine crystallisation conditions for mouse 11β-HSD1 was a simple ammonium 
sulphate screen to determine the phase change in the protein drops. This was due to 
published protocols for obtaining crystalline 11β-HSD1 often being ambiguous and 
irreproducible in the laboratory.  
A solubility curve of 11β-HSD1 with increasing ammonium sulphate concentration is 
shown in figure 6.4. The plates were set up with varying (NH4)2SO4 concentrations 
(taken as a percentage of a 3.5 M solution per well) and varying pH of Hepes buffer. 
It was observed that there was a slight phase change at between 42 – 48 % (NH4)2SO4. 
These conditions from the initial screen were set up again, varying additives and the 
temperature of crystallisation (290 K and 277 K) to improve crystal form and size. 
These additives were different detergents and the tightest binding ligand from the 
set of compounds chosen as 11β-HSD1 inhibitors (compound 21). As can be seen in 
figure 6.4, the detergents triton X-100 and CHAPS had a mild effect on the enzyme 
solubility by shifting the solubility curve to the left. This is expected; the presence of 
detergent increases the total amount of precipitants present in the drop. Compound 
21 had the opposite effect, increasing the solubility of the mouse enzyme, while thesit 
had no significant effects. 
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Figure 6.4: Solubility of mouse 11β-HSD1 with increasing (NH4)2SO4 concentration, as a v/v 
percentage of a 3.5 M solution. Solubility has been normalised, with clear drops assigned a 
value of 1 and fully precipitated drops assigned a value of 0. Values of 0.4 – 0.6 are phase 
changes, and were wells in which micro-crystals were observed. 
 
As a detergent screen was not available, three detergents were selected as additives 
on the basis of their previous use, either in protein preparations or published crystal 
structures. These were CHAPS, Triton X-100 and Thesit. Each reservoir contained the 
following components in addition to the detergents; (NH4)2SO4 ranging from 42 – 48 
% and 0.2 M Hepes pH range 6.8 – 8.0. Drops containing thesit formed micro-crystals 
over a period of 48 – 72 hours at 290.15 K (17oC) which are shown in figure 6.5C. 
Micro-crystals can often be difficult to distinguish from precipitate however they 
have a shiny appearance and may polarise light. Optimisation of microcrystal 
conditions can lead to larger crystals, preferred for X-ray crystallography. The micro-
crystals were generally clustered, however there were single rods present (figure 
6.5B). As X-ray crystallographic data is collected at low temperatures (generally 100 
K) protein crystals must be treated with a cryoprotectant prior to freezing to prevent 
cracking. Low temperatures are necessary to minimise degradation of the crystal by 
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free radicals generated by the X-ray beam. There are many different types of 
cryoprotectant that can be used (the JAXA cryoprotectant database lists all those 
used in structures deposited in the PDB); the most common are glycerol, ethylene 
glycol, sucrose or glucose. Attempts were made at cryoprotecting the crystals of 
mouse 11β-HSD1, with a solution of the mother liquor and increasing amounts of 
glycerol (v/v) ranging from 5 – 40 %. This method damaged the already fragile 
crystals and so they were simply frozen in liquid N2 without cryoprotectant. The 
crystals were screened at the Grenoble Synchrotron, and showed diffraction at a 
resolution of 11 Å which is too low a resolution to obtain any good quality data. A 
high resolution (a lower number signifies higher resolution) will give more 
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Figure 6.5: A –C are photographs of drops taken with a Nikon DXM1200 camera attached to 
a Nikon SMZ100 microscope. (A) A drop with 0.4 mM Triton X-100, the drop is oily in 
appearance, as many of the drops with triton X-100. (B) Drop with 0.01 mM thesit, showing 
the micro-crystals obtained, grown over a period of 48 – 72 hours. These were mostly 
clustered; there were also some single thin rods, which were taken for screening at the 
Grenoble Synchrotron. (C) A close-up of the same drop in B, the green arrow shows a 
single rod which was approximately 0.075 mm in length. (D) The diffraction pattern from 
the crystals shown in B and C at the Grenoble Synchrotron, October 2008. The dark rings 
around the centre are ice rings, a result of no cryoprotectant used. A close-up of the centre 
of the diffraction pattern shows the reflections at 11 Å (circled in green).  
 
The micro-crystals were subsequently used to seed into wells with identical 
conditions but for the addition of inhibitors from virtual screening. In particular, 
compound 21 (from Chembridge) shown in figure 6.6B, produced crystals that were 
single, thin rods after several days incubation at 20oC. The crystals are shown in 
figure 6.6A. Seeding is a technique used in protein crystallography which promotes 
nucleation and single crystal growth by ensuring the presence of already established 
nuclei  - the seeds (Stura and Wilson 1990). The seeds are micro-crystals which are 
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crushed gently producing a large number of microscopic crystals. This solution is 
then diluted and added to a fresh, supersaturated crystallisation drop. There are 
three seeding methods; streak seeding – where the crystals seeds are streaked across 
the fresh crystallisation drop; microseeding – where the seeds are crushed and 




Figure 6.6: A: Photograph taken with a Nikon DXM1200 camera attached to a Nikon 
SMZ100 microscope; a drop containing mouse enzyme, thesit and compound 21, grown 
over a period of 72 hours at 290.15 K. The needles are approximately smaller than 0.1 mm 
in length. B: Structure of compound 21. 
 
However, these delicate crystals did not grow beyond a size of 0.1 mm, and were 
unable to be screened. In addition, the published conditions for mouse 11β-HSD1 
were set-up (Zhang et al., 2005). These were 1.8 M Li2SO4, Hepes pH 7.5, and 
conditions which ranged around this, although did not yield any form of crystal. 
 
6.4 Crystallography of Murine 11β-HSD1: Further Trials 
Subsequent work to this research, carried out by Dr. Iain McNae, gave rise to rod 
shaped mouse 11β-HSD1 crystals, as shown in figure 6.7. To obtain these fast 
growing crystals (48 hours), an unintentionally different purification protocol was 
employed to the one developed in this research. This protocol differed as the 
chaperonin proteins were not co-expressed with the mouse or human 11β-HSD1 
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enzyme; in addition, Rosetta cells were employed in the place of BL21(DE3) E. coli 
cells (chapter 2 for expression and purification details). Following an IMAC 
purification procedure, the protein was used for crystallography in a buffer 
containing 50 mM Tris pH 8.0, 250 mM NaCl, 750 mM imidazole, and the 
crystallisation conditions were: 22 % PEG 8000, 10 % propanol, 0.1 M Hepes pH 7.5 
carried out at 277.15 Kelvin (figure 6.7).  
 
 
Figure 6.7:  (A) and (B) Photograph taken with a Nikon DXM1200 camera attached to a 
Nikon SMZ100 microscope; a drop containing 10 mg/ml mouse 11β-HSD1,  22 % PEG 8000, 
10 % propanol, 0.1 M Hepes pH 7.5, grown over 48 hours at 277.15 K. (B) is a close-up of the 
rod-shaped mouse 11β-HSD1 crystals. The crystals are approximately 0.1 mm in length. 
 
These crystals were found to diffract up to a resolution of 2.7 Å. Upon refinement of 
the mouse 11β-HSD1 crystal data, an electron density fitting carbenoxolone is seen to 
occupy the active site of the enzyme. This is expected; this inhibitor is added to the 
culture media prior to expression to stabilise the nascent protein, and binds tightly 
with a Ki of 20 nM. More surprisingly is the presence of NADP(H); it is derived from 
bacterial cells, post-expression - it was not added to buffers at any stage of the 
expression, purification or preparation for crystallography. Similar to carbenoxolone, 
which was also not replenished at any preparative stage, it has remained bound to 
the enzyme through out.  
Several of these crystals were soaked into a solution containing one of the novel 
inhibitors from this research. The inhibitors used in the soaking experiments are 
shown in table 6.3. These particular compounds were chosen as they exhibited 
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inhibition in both mouse and human enzyme assays, or a strong inhibition in either 
one of the species. 
 
Table 6.3: Table listing the ten compounds discovered using virtual screening which were 
soaked into the crystals shown in figure 6.6. Assay results are shown in the middle 
column; in vivo refers to the human 11β-HSD1 expressed in HEK-293 cells.  Approximately 
a ten-fold higher concentration than the experimental Ki was used in soaking experiments.  
ID: Inhibition Assay Results: Structure: 
3 
Excellent inhibition of human 11β-
HSD1 in HEK-293 cells (42% at 100 
μM) 
  
5 Inhibition in human 11β-HSD1 in HEK-293 cells (Ki 10 μM) and rat 11β-HSD1  
7 
Good inhibition of recombinant human 
and in vivo 11β-HSD1 (Ki 4.5 μM). 
Mouse and rat 11β-HSD1 also show 
excellent inhibition.  
10 
Good inhibition in recombinant (Ki 25 
μM) and in vivo human 11β-HSD1 (Ki ~ 
4 μM). Also with rat 11β-HSD1. 
 
21 
Human 11β-HSD1 in vivo (IC50=7.6 μM). 
Significant inhibition in mouse (95 %) 




Good inhibition in human 11β-HSD1 in 
vivo (26 % at 1 mM) and rat (30 % at 1 
mM).  
29 
Human in vivo (IC50=10 μM) and rat 
11β-HSD1 (43 % at 100 μM) showed 
inhibition.  
37 
Recombinant (Ki ~ 200 μM) and in vivo 
human 11β-HSD1 (Ki 10 μM) 
30 % mouse 11β-HSD1 at 10 μM 
Rat 11β-HSD1 100 % at 10 μM. 
 
46 
Inhibition in recombinant (Ki ~ 100 μM) 
and in vivo (Ki 4.5 μM) human 11β-
HSD1. Also in mouse (54%) and  rat 
11β-HSD1 (100% at 100 μM).  
56 
Inhibition in recombinant (Ki 23 μM) 
and in vivo (82% at 100 μM) human 11β-
HSD1. Also in mouse (72%) and rat 
(100%) 11β-HSD1 at 100 μM. 
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In particular, one compound was found to decrease the occupancy of carbenoxolone 
in the active site: compound 28. This ligand was added to a final concentration of 500 
μM to mother liquor, into which the crystal was soaked. The occupancy of 
carbenoxolone decreased from ~ 90 % to ~ 75 % in crystals soaked with compound 
28. Unfortunately there is no visible electron density for compound 28, and further 
refinements of the crystal / soaking conditions are required. This protein crystal 
diffracted to 2.71 Å at the Diamond Light Source Synchrotron (Oxfordshire, U.K) and 
may be seen in figure 6.8 as 4 11β-HSD1 monomers in the crystal unit forming a 
tetramer. Carbenoxolone may be seen interacting with Tyr 183, Ser 170 and Asp 259 
in the active site, in addition to hydrogen bonding interactions with the co-factor 
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Figure 6.8: (A) 3-D representation of murine 11β-HSD1 tetramer in complex with 
carbenoxolone to a resolution of 2.71 Å, each subunit is a different colour. (B) One 
monomer, with N- and C-termini labelled, (C) aerial view of active site, showing CBX and 
NADPH and the interactions with the active site. Polar interactions are shown in yellow 
dashed lines. Image prepared with Pymol. 
 
Similar to the human–carbenoxolone co-crystal structure (2BEL, figure 1.19), there 
are polar interactions between the enzyme and Tyr 183 and Ser 170; two members of 
the catalytic triad. In mouse 11β-HSD1, there is an additional interaction with Asp 
259, which is not observed in 2BEL, the human structure. In both cases, Leu 217 is 
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positioned parallel to the plane of carbenoxolone’s steroidal rings at a distance of 3.5 
Å, potentially allowing for interaction although this is not observed in the mouse 
structure. The aspartic acid at position 259 in the mouse structure is perpendicular to 
the steroidal ring plane and is able to form hydrogen bonds with the carbenoxolone 
tail, as depicted in figure 6.8. In the human structure, this residue lies ~ 6 Å away 
from the ligand preventing interaction. 
The crystal data was refined by Dr. McNae using the program Phenix (Adams et al 
2002) to obtain an R-value of 20.97 % and an R-free of 25.78 %. The R-value is a 
reflection of how well the X-ray crystallographic data and the proposed 
crystallographic model agree. As a general rule, this value ranges from 0 to 0.35 in 
refined structures - a smaller value of R suggesting a closer agreement between the 
calculated and the observed data and so is an important indicator in model quality 
(Rhodes 1992). The crystal belongs to a C 2 2 21 space group (C centred 
orthorhombic).  
The mouse variant of 11β-HSD1 is easier to crystallise compared to the human form; 
this is the third mouse crystal structure obtained by the Walkinshaw research group, 
two structures in complex with carbenoxolone (including this research) and one with 
another tight binding inhibitor (not from this series).  
 
6.5 Crystallography of Human 11β-HSD1 
Human 11β-HSD1 protein was prepared for crystallography with an initial 
purification of IMAC, followed by a gel filtration step to yield a homogeneous, pure 
sample as shown with SDS-PAGE. Protein samples should be as pure and as 
homogeneous as possible for commencing crystallisation screens; the 11β-HSD1 
sample was checked for sufficient activity with a fluorescence assay and 
densitometric analysis employed to determine the relative purity. Human 11β-HSD1 
was concentrated to 24 mg/ml in a buffer of 500 μM NADPH, 0.01 % Thesit, 1 mM 
EDTA, 50 mM Tris pH 7.7, 50 mM NaCl and 2 % glycerol.  
A recently deposited crystal structure from Amgen Inc. (Johansson et al 2008b) under 
the PDB code 3BYZ has published crystallisation conditions for the co-crystallisation 
of human 11β-HSD1 in complex with a novel inhibitor currently in development; 
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(5S)-2-(cyclooctylamino)-5-methyl-5-propyl- 1,3-thiazol-4(5H)-one – a ligand from 
the thiazolone class of inhibitors produced by Amgen / Biovitrum. These crystals, 
which were obtained with vapour diffusion and diffracted to a resolution of 2.69 Å, 
were derived in the following conditions; 25 % polyethylene glycol (PEG) 3350, 0.1 M 
Sodium Citrate pH 5.6, 0.2 M ammonium acetate, at a temperature of 298 K (24.85 
oC). These conditions and others are shown in table 6.1. Using these conditions as 
guidance, crystal plates were set up in this research with varying PEG 3350 (15 % - 35 
%), varying ammonium acetate (0.2 M, 0.4 M, 0.6 M) and varying pH of 0.2 M 
sodium citrate. The hanging drop method is detailed in chapter 7 - Materials and 
Methods. Two of these conditions provided micro-crystals; conditions are shown in 
table 6.4 below. As can be seen, the published conditions and those determined in 
this research are extremely similar with the exception of a higher concentration of 
precipitant required in this research. This is potentially due to a lower concentration 
of salt in the protein buffer, which is not disclosed by Amgen (Johansson et al 2008a) 
in this instance. 
 
3BYZ Condition 1: Condition 2: 
 
25 % PEG 3350 
0.1 M Na Citrate pH 5.6 
0.2 M ammonium acetate 
298 K 
 
21 % PEG 3350 
0.2 M Na Citrate pH 5.2 
0.6 M ammonium acetate 
290.15 K 
 
23 % PEG 3350 
0.2 M Na Citrate pH 5.2 
0.6 M ammonium acetate 
290.15 K 
 
Table 6.4: Table showing the conditions used for 3BYZ and the two conditions which 
produced micro-crystals in this research. All conditions formed crystals under hanging 
drop conditions.  
 
A photograph of the micro-crystals obtained in one of these conditions is shown in 
figure 6.9. Regrettably, these crystals were too small and too fragile to allow for 
fishing, mounting and screening of the crystals. 
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Figure 6.9: Photograph taken with a Nikon DXM1200 camera attached to a Nikon SMZ100 
microscope; A: a drop containing 24 mg/ml human 11β-HSD1,  21 % PEG 3350, 0.2 M 
sodium citrate pH 5.2, 0.6 M Ammonium Acetate, grown over 48 hours at 290.15 K.  
 
Similar conditions were set up with the addition of one or more varying inhibitors, 
discovered using the UFSRAT algorithm and EDULISS (chapter 4). These were 
inhibitors found to have a high affinity for the human enzyme. 
In addition to reproducing the published conditions for 3BYZ, alternative initial 
screens for crystallisation were performed; these consisted of screening a range of pH 
from 5 – 7 (using sodium cacodylate, MES and piperazine), a range of PEG 3350 (10 – 
50 % v/v) and / or varied (NH4)2SO4 (10 – 45 % v/v). An ammonium sulphate 
solubility screen is shown in figure 6.10. As expected, PEG shifts the solubility to the 
left, as it is a precipitant. Thesit has a mild effect, also decreasing the solubility, in 
contrast to very little effect on the mouse enzyme (c.f. figure 6.3). 
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Figure 6.10: Solubility of human 11β-HSD1 with increasing (NH4)2SO4 concentration, as a 
v/v percentage of a 3.5 M solution. Solubility has been normalised, with clear drops 
assigned a value of 1 and fully precipitated drops assigned a value of 0. Values of 0.4 – 0.6 
are phase changes, and were wells in which micro-crystals were observed. 
 
Interestingly, the ‘wild-type’ enzyme precipitated immediately in the presence of 
sodium cacodylate pH 5.0 whereas the mutant variant did not (not shown). Several 
wells under the relatively wide ranging conditions of sodium cacodylate (pH 5 -6) 
and (NH4)2SO4 (10 – 25 % v/v of 3.5 M solution) produced micro-crystals. These 
resembled a small crystalline cluster in the centre of the drops, and were tested for 
protein content with the addition of IZIT (Hampton Research). IZIT is a blue protein 
dye which may distinguish between salt and protein crystals. The micro-crystals 
rapidly absorbed the dye; however despite further optimisation did not grow 
beyond ~ 0.1 mm and were fixed to the siliconised cover slip. This optimisation 
involved additives such as ligands (chapter 4) and DTT, and variation in the ratio of 
protein to reservoir solution, from 1:1, to 1:2 and 1:3. 
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Several commercial screens were also tested for protein crystallisation conditions. 
These were sparse matrix screens (Hampton Research) with widely varying pH, salt 
and precipitants, and a membrane-protein screen which contains varying additives 
suitable for the crystallisation of relatively hydrophobic proteins.  
 
6.6 Conclusions 
Crystallisation of 11β-HSD1 is a difficult and intricate process. It was possible to 
obtain crystals of mouse and human 11β-HSD1 (Δ1 - 23) which appeared as needle 
clusters or micro-crystals, often unsuitable for X-ray studies, and were used in 
seeding experiments. Seeding into fresh wells produced single, thin rod shaped 
crystals. In addition, varying the crystallisation conditions for mouse 11β-HSD1 
produced several small rod-like crystals which diffracted to 2.71 Å and enabled a 
good quality crystallographic model to be constructed and refined. This will enable 
future soaking experiments with the novel inhibiting compounds from chapter 5 to 
be carried out with the anticipation of a co-complex structure. 
Ammonium sulphate screens for both mouse and human 11β-HSD1 were carried 
out, and it was observed that mouse 11β-HSD1 will begin to nucleate at a slightly 
higher concentration of (NH4)2SO4 than human enzyme. The mutation at residue 272 
in the human 11β-HSD1 (C272S) did not facilitate crystallisation in this research, and 
did not affect the solubility curve of the enzyme; however did stabilise the protein at 
lower pH. Crystallisation trials with this variant of human 11β-HSD1 are ongoing to 
produce larger single crystals. 
Future work would involve further screening; potentially not dissimilar to published 
conditions, addition of the novel inhibitors to stabilise the overall structure from an 
earlier stage (potentially prior to or during purification) or would involve the 
mutagenesis of one or more residues (following the example from Bristol-Myerrs 
Squibb, PDB accession code 3CH6, Wang et al 2008) such as leucine 262 to arginine, 
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CHAPTER 7 
 MATERIALS AND METHODS 
 
7.1 Cloning and Expression Methods 
The methods employed with all three species of 11β-HSD1 are identical, except 
where noted in the text.  
 
Murine and Human 11β-HSD1: Expression Vectors 
The base pairs 70 – 876 (amino acids 23 – 292) of human 11β-HSD1 DNA and base 
pairs 70 – 876 (amino acids 23 – 292) of murine 11β-HSD1 were cloned into the pET-
28b expression vector (Novagen). These expression plasmids in addition to the 
bacterial expression plasmid pGro7 encoding GroEL and GroES (Takara, Japan) were 
a generous gift from Dr. Scott Webster at the Endocrinology Unit at the QMRI, 




Figure 7.1: Simplified plasmid map for (a) the bacterial expression vector pET28-b and the 
placement of the human, mouse or rat 11β-HSD1 gene in the multiple cloning site (dark 
orange), the kanamycin resistance gene (Kmr), the origin of replication and the lac operon, 
and (b) pGro7 plasmid showing the location of the polycistronic chaperone protein genes 
GroEL and GroES, the araB promoter and the chloramphenicol resistance gene (Cmr). 
Illustrations prepared using ChemDraw 11.0.  
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The full DNA sequences of human and mouse 11β-HSD1 are shown in figures 7.2 
and 7.3. The segment of the 5’ end in red corresponds to amino acids 1 to 23 (in 
human and mouse, base pairs 1 - 69) which were truncated to facilitate expression. In 
black is the DNA sequence used in this research. 
   1  ATGGCTTTTA TGAAAAAATA TCTCCTCCCC ATTCTGGGGC TCTTCATGGC 
  51  CTACTACTAC TATTCTGCAA ACGAGGAATT CAGACCAGAG ATGCTCCAAG 
 101  GAAAGAAAGT GATTGTCACA GGGGCCAGCA AAGGGATCGG AAGAGAGATG 
 151  GCTTATCATC TGGCGAAGAT GGGAGCCCAT GTGGTGGTGA CAGCGAGGTC 
 201  AAAAGAAACT CTACAGAAGG TGGTATCCCA CTGCCTGGAG CTTGGAGCAG 
 251  CCTCAGCACA CTACATTGCT GGCACCATGG AAGACATGAC CTTCGCAGAG 
 301  CAATTTGTTG CCCAAGCAGG AAAGCTCATG GGAGGACTAG ACATGCTCAT 
 351  TCTCAACCAC ATCACCAACA CTTCTTTGAA TCTTTTTCAT GATGATATTC 
 401  ACCATGTGCG CAAAAGCATG GAAGTCAACT TCCTCAGTTA CGTGGTCCTG 
 451  ACTGTAGCTG CCTTGCCCAT GCTGAAGCAG AGCAATGGAA GCATTGTTGT 
 501  CGTCTCCTCT CTGGCTGGGA AAGTGGCTTA TCCAATGGTT GCTGCCTATT 
 551  CTGCAAGCAA GTTTGCTTTG GATGGGTTCT TCTCCTCCAT CAGAAAGGAA 
 601  TATTCAGTGT CCAGGGTCAA TGTATCAATC ACTCTCTGTG TTCTTGGCCT 
 651  CATAGACACA GAAACAGCCA TGAAGGCAGT TTCTGGGATA GTCCATATGC 
 701  AAGCAGCTCC AAAGGAGGAA TGTGCCCTGG AGATCATCAA AGGGGGAGCT 
 751  CTGCGCCAAG AAGAAGTGTA TTATGACAGC TCACTCTGGA CCACTCTTCT 
 801  GATCAGAAAT CCATGCAGGA AGATCCTGGA ATTTCTCTAC TCAACGAGCT 
 851  ATAATATGGA CAGATTCATA AACAAGTAGG 
 
 
Figure 7.2: The DNA sequence of human 11β-HSD1, 876 base pairs in length (translates to 
292 amino acids full length). Truncated base pairs are coloured red. 
   1  ATGGCAGTTA TGAAAAATTA CCTCCTCCCG ATCCTGGTGC TCTTCCTGGC 
  51  CTACTACTAC TATTCTACAA ATGAAGAGTT CAGACCAGAA ATGCTCCAGG 
 101  GAAAGAAAGT GATTGTCACT GGGGCCAGCA AAGGGATTGG AAGAGAAATG 
 151  GCATATCATC TGTCAAAAAT GGGAGCCCAT GTGGTATTGA CTGCCAGGTC 
 201  GGAGGAAGGT CTCCAGAAGG TAGTGTCTCG CTGCCTTGAA CTCGGAGCAG 
 251  CCTCTGCTCA CTACATTGCT GGCACTATGG AAGACATGAC ATTTGCGGAG 
 301  CAATTTATTG TCAAGGCGGG AAAGCTCATG GGCGGACTGG ACATGCTTAT 
 351  TCTAAACCAC ATCACTCAGA CCTCGCTGTC TCTCTTCCAT GACGACATCC 
 401  ACTCTGTGCG AAGAGTCATG GAGGTCAACT TCCTCAGCTA CGTGGTCATG 
 451  AGCACAGCCG CCTTGCCCAT GCTGAAGCAG AGCAATGGCA GCATTGCCGT 
 501  CATCTCCTCC TTGGCTGGGA AAATGACCCA GCCTATGATT GCTCCCTACT 
 551  CTGCAAGCAA GTTTGCTCTG GATGGGTTCT TTTCCACCAT TAGAACAGAA 
 601  CTCTACATAA CCAAGGTCAA CGTGTCCATC ACTCTCTGTG TCCTTGGCCT 
 651  CATAGACACA GAAACAGCTA TGAAGGAAAT CTCTGGGATA ATTAACGCCC 
 701  AAGCTTCTCC CAAGGAGGAG TGCGCCCTGG AGATCATCAA AGGCACAGCT 
 751  CTACGCAAAA GCGAGGTGTA CTATGACAAA TCGCCTTTGA CTCCAATCCT 
 801  GCTTGGGAAC CCAGGAAGGA AGATCATGGA ATTTTTTTCA TTACGATATT 
 851  ATAATAAGGA CATGTTTGTA AGTAAC 
 
Figure 7.3: The DNA sequence of mouse 11β-HSD1 which is 876 base pairs in length 
(translates to 292 amino acids full-length), truncated base pairs are red. 
 
Transformation 
The expression vectors pET-28b-mHSD1 for murine (or pET-28b-hHSD1 for human) 
and pGro7 were co-transformed into chemically competent BL21(DE3) Escherichia coli 
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cells (Calbiochem) by the following method. The cells were always sourced 
commercially. Cells were thawed on ice for 10 minutes, after which 1 μl of pET-28b-
mHSD1 and 1 μl of pGro7 were added to the cells. The cell mixture was left on ice for 
a further 10 minutes, and then heat-shocked at 42oC for 45 seconds in a heat block. 
The cell mixture was then returned to ice for a further 5 minutes. LB media (1 ml) 
was added to the cells followed by incubation at with shaking 37oC for a 45 minute 
recovery period. The transformed cells are then spun down gently (3000 rpm, 5 
minutes) and plated on room temperature LB agar plates containing both 50 μg/ml 
kanamycin and 50 μg/ml chloramphenicol (both Sigma-Aldrich Inc., U.K). The plates 
were then incubated overnight at 37oC. 
 
Starter Culture 
One colony was picked from the inoculated LB-agar plate and grown in 25 ml LB 
media with 50 μg/ml kanamycin and 50 μg/ml chloramphenicol. The cultures were 
incubated at 37oC, shaking at 250 rpm until reaching an OD600 of 0.6, then stored at 
4oC until further use. This culture was then used to inoculate a larger scale culture at 
a 1 % v/v ratio.  
 
Expression Trials 
Expression trials were carried out in either a 50 ml falcon tube containing a volume 
of 5 ml culture media, or alternatively in 250 ml glass expression flasks, containing 50 
ml of culture media to ensure adequate aeration of the cultures, which were shaken 
at 250 rpm (i.e. the flasks were filled 10 – 20 % of the total volume capacity with LB 
media). The final culture was centrifuged to pellet the cells, which were then lysed 
and the soluble and insoluble fractions separated through centrifugation. These 
samples and a whole cell fraction were then run on 12 % SDS-PAGE.  
 
Large Scale Grow-ups 
Larger scale E.coli cultures of 4 – 8 L were carried out as follows. In a 2 L glass conical 
flask, 500 ml of LB (with 50 μg/ml kanamycin and 50 μg/ml chloramphenicol) were 
inoculated with 5 ml of starter culture. The culture was incubated at 37oC, shaking at 
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250 rpm until the bacterial culture reached an OD600 of 0.6. At this point, the 
incubation temperature was reduced to 20oC and 0.1 % v/v L-arabinose, 1 % glucose, 
and 1 % sucrose was added to the culture to induce the expression of the molecular 
chaperones. After 1 hour incubation, a final concentration of 100 μM carbenoxolone 
(Sigma, prepared in 100% ethanol) and 1 mM IPTG (Melford Laboratories) were 
added to the culture. They were then left for 16 hours at 20oC to over-express 11β-
HSD1. The cultures were then harvested the following day by collection of the cells 
via gentle centrifugation (Beckman Coulter Avanti j-26 XPI centrifuge, JLA 8.1000 
rotor) at 15,000 rpm at 4oC for 45 minutes. The cell pellet was either snap-frozen in 
liquid nitrogen and stored at -20oC for later use, or resuspended in lysis buffer (50 
mM Tris pH 8.0, 150 mM NaCl, 20 mM imidazole, 0.01 % v/v thesit) and the cell lysis 
procedure carried out. 
 
Cell Lysis and Clarification 
 Cell pellets were resuspended in lysis buffer (50mM Tris pH 8.0, 150mM NaCl, 
20mM imidazole, 0.01% v/v thesit) by vortexing and inversion, with one EDTA-free 
mini-protease inhibitor tablet (Roche Diagnositics, U.K) per 500ml culture added. 
Once completely resuspended and smooth, the cell suspension was filtered crudely 
prior to using a cell disruptor (Constant Systems Ltd, U.K) at a pressure of 20 – 25 
KPsi. This disrupts the cell membranes and liberates cytoplasmic proteins. The cell 
lysate was then clarified through centrifugation at 50,000 rpm, 4oC for 30 minutes 
(Beckman Coulter Avanti J-26 XPI centrifuge, JA25.50 rotor). The clarified lysate was 
filtered through a 0.22 μm filter unit (Millipore, Co. Cork, Ireland) and applied to a 
chromatography column for purification. 
 
Rat 11β-HSD1: Cloning and Expression 
Source and Expression Vectors 
The rat 11β-HSD1 DNA was purchased from Codon Devices (Codon Devices Inc, 
Cambridge, MA), a company which synthesises specified genes. The gene sequence 
was provided (from GenBank NM_017080.2) for Codon Devices where it was codon 
optimised for E. coli and synthesised. The sequence is shown in figure 7.4. 
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   1  ATGAAAAAAT ACCTCCTCCC CGTCCTGGTG CTCTGCCTGG GTTACTACTA 
  51  TTCTACAAAT GAAGAGTTCA GACCAGAAAT GCTCCAGGGG AAGAAAGTGA 
 101  TTGTCACTGG GGCCAGCAAA GGGATCGGAA GAGAAATGGC ATATCATCTG 
 151  TCAAAAATGG GAGCCCATGT GGTATTGACT GCAAGGTCGG AGGAAGGGCT 
 201  CCAGAAGGTG GTGTCTCGCT GCCTTGAACT CGGAGCAGCC TCTGCTCACT 
 251  ATATTGCCGG CACTATGGAA GACATGGCTT TTGCAGAGCG ATTTGTTGTT 
 301  GAGGCAGGAA AGCTCTTGGG TGGACTGGAC ATGCTCATTC TCAATCACAT 
 351  CACACAGACC ACTATGTCTC TCTTCCACGA TGATATCCAC TCTGTGCGAA 
 401  GAAGCATGGA GGTCAACTTC CTCAGCTATG TGGTCCTGAG CACAGCAGCC 
 451  TTGCCCATGC TGAAACAGAG CAATGGCAGC ATTGCCATCA TCTCCTCCAT 
 501  GGCTGGGAAA ATGACCCAAC CTCTGATTGC TTCCTACTCT GCAAGCAAGT 
 551  TTGCTCTGGA TGGGTTCTTT TCCACCATTA GAAAAGAACA CTTGATGACC 
 601  AAGGTCAACG TGTCCATCAC TCTCTGTGTC CTCGGCTTCA TAGACACAGA 
 651  AACAGCTTTG AAAGAAACCT CTGGGATAAT CTTGAGTCAA GCTGCTCCCA 
 701  AGGAGGAATG CGCCCTGGAG ATCATCAAAG GCACAGTTCT GCGCAAAGAT 
 751  GAGGTATACT ATGACAAATC ATCTTGGACT CCACTTCTGC TTGGGAATCC 
 801  AGGAAGGAGG ATCATGGAAT TTCTTTCATT ACGGTCATAT AACAGGGACC 
 851  TATTTGTAAG CAACTAG 
 
 
Figure 7.4: The rat DNA sequence, taken from GenBank, 867 base pairs, which translates to 
289 amino acids. Shown in red are the base pairs which are not present in the cDNA used 
in this research (base pairs 1 to 57, corresponding to amino acids 1 - 19). 
 
 The sequence was designed to contain the consensus sequences for the restriction 
enzymes NdeI at the 5’ end and XhoI at the 3’ end to facilitate cloning, as shown in 
figure 7.5. In addition, the sequence had been codon-optimised by Codon Devices, to 
facilitate expression in E. coli. Cloning was required to exchange expression vectors 
from the pUC19 vector in which it was supplied, into the pET28b vector desired. 
Cloning was carried out using enzymes and recommended reagents from New 
England Biolabs Inc. The first 19 membrane-anchoring residues of the rat enzyme 
were truncated (similar to the human and mouse sequences) to improve the 
solubility profile of the enzyme. 
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Figure 7.5: Expression plasmid pUC-19 (Fermentas, left) and the location of the rat 11β-
HSD1 gene. Expression plasmid pET28-b (Novagen) is shown on the right, with the 
location of the rat 11β-HSD1 gene shown. Picture prepared with ChemDraw 11.0. 
 
Cloning: Preparation of the receiving vector pET28-b 
An aliquot of DH5α chemically competent cells (Invitrogen) was transformed with 
the pET28-b vector (approximately 10 ng) and plated out on 50 μg / ml kanamycin 
LB-agar plates. A 10 ml overnight culture from one colony was prepared for DNA 
extraction using a mini-prep kit, following manufacturer’s instructions (QIAprep 
spin miniprep kit, Qiagen Ltd, U.K). The DNA extracted from the transformed 
bacterial cells was sent for sequencing at the Edinburgh University Sequencing 
Service. Once verified, this expression plasmid was run on a 1 % agarose gel 
containing ethidium bromide and visualised with an ultraviolet light box. The 
amount of DNA was quantified from the gel. A double digestion was set-up for the 
remaining pET28-b vector. This consisted of: Xho1 (1.4 μl: equivalent to 28 enzyme 
units), Nde1 (1.4 μl: equivalent to 28 enzyme units) and buffer 4 (10 mM Tris-HCl, 50 
mM KCl, 1 mM DTT, 0.1 mM EDTA, 200 μg / ml BSA, 50 % glycerol) provided by 
NEB (total volume: 14 μl reaction, 2 hours at 37oC). After 60 minutes, the DNA was 
dephosphorylated with CIP (calf intestinal phosphatase, 0.5 units per 1 μg DNA, 
NEB Inc.) which removes the 5’ phosphate groups from the newly cleaved 
expression vector, and was incubated for a further 60 minutes at 37oC. The final 
reaction mixture was run on a 1 % agarose gel to purify the products and the 
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corresponding band (at 5.3 Kbp) was excised from the gel and extracted (Gel 
Extraction Kit, Qiagen Ltd, U.K). The cleaved vector was stored at -20oC until use. 
 
Preparation of the Synthesised DNA Insert (Rattus Norvegicus 11β-HSD 1) 
The online tool ‘Webcutter’ (http://rna.lundberg.gu.se/cutter2/) was used to ensure 
the codon optimised sequence would not be digested by restriction enzymes except 
at the two specified regions. Chemically competent DH5α cells (Invitrogen) were 
transformed with pUC19-rattus-11bHSD1 (approximately 50 ng). The lyophilised 
gene supplied from Codon Devices was resuspended in sterile ddH2O giving a final 
concentration of 5 μg / 50 μl (100 ng/ μl). The transformed cells were plated out on 
100 μg / ml ampicillin LB-agar plates. One colony was picked and inoculated in an 
overnight culture for DNA extraction with a MiniPrep kit (Qiagen Ltd, U.K). The 
extracted DNA was doubly digested with Xho1 (1.4 μl) and Nde1 (1.4 μl), buffer ‘2’ 
(10 μl) (total volume: 14 μl reaction, 2 hours at 37oC). The products were gel-purified 
as before and extracted from the gel as described previously.  
 
Ligation of the Expression Vector and DNA Insert 
Ligation reactions were attempted with the Rapid Ligation Kit (Roche) and with T4 
DNA Ligase (NEB), varying the insert to plasmid ratio and varying the incubation 
times and temperatures according to each manufacturer’s recommendations until a 
ligated product was detected. The successful reaction consisted of 1 μl of T4 DNA 
Ligase (NEB) in a total reaction volume of 20 μl, overnight at 18oC. The insert (100 ng 
/ μl) to plasmid (also 100 ng / μl) ratio was 10:1. The ligation products were run on a 
1 % agarose gel to separate the reaction components and the corresponding gel band 
(the pET28-b + rat 11bHSD1 gene) at 5.4 Kbp) was extracted as described previously. 
This DNA was transformed into chemically competent DH5α cells and plated out 
overnight on 50 μg / ml kanamycin LB-agar plates. Several colonies were picked and 
used to inoculate separate overnight cultures (5 ml LB media) for DNA extraction. 
The extracted DNA from the transformed DH5α cells was then doubly digested, as 
described previously. Running the reaction products on an agarose gel (1%, with 
ethidium bromide, as before) ensures that both components are present. A band for 
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the digested vector is clearly seen in addition to a smaller band for the digested gene 
insert. The DNA was also sent for sequencing. 
 
Expression Trials 
The pET28-b-rat-11bHSD1 plasmid was transformed into chemically competent 
BL21(DE3) cells in addition to the pGro7 plasmid (for GroEL/ES expression). Initial 
expression trials with the rat variant determined that it was present in the insoluble 
fraction, thus it was decided to attempt re-solubilisation of the protein.  
 
Extracting Insoluble Rat 11β-HSD1 through Denaturation 
For this experiment, BL21(DE3) cells containing expressed rat 11β-HSD1 were 
harvested and spun for 45 minutes at 8000 rpm in a centrifuge (Beckman Coulter 
Avanti J-26 XPI centrifuge). To the resultant cell pellet (equivalent to 1 L of bacterial 
cell culture) 50 ml of the denaturation solution (8 M Urea, 100 mM Tris pH 8.0, 300 
mM NaCl) was added and the cells resuspended, then filtered under vacuum 
(Whatman No.1 filter paper). Ideally, the supernatant will contain a host of 
denatured and previously insoluble proteins. Due to the presence of the hexa-His tag 
on the N-terminus of the rat enzyme, the protein should still bind to an IMAC 
column, as it does not require an intact structural integrity unlike tags such as GST 
(glutathione-S-transferase). The filtrate was spun again at 8000 rpm (Beckman 
Coulter Avanti J-26 XPI centrifuge) and the supernatant was then loaded onto an 
equilibrated IMAC column (both 1 ml HiTrap Chelating Column, (GE Healthcare) 
and a 3 ml Superflow Ni-NTA gravity column (Qiagen)) charged with Ni2+ ions. 
Elution from the IMAC column was achieved through step-wise variation of the 
buffer pH; decreasing the pH will cause protonation of the histidine weakening the 
binding of this residue to the chelated metal until it detaches, as shown in figure 7.6.  
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Figure 7.6: Diagram illustrating the binding mechanisms of 2 residues of a 6 x histidine tag 
to the IMAC Ni2+
 
 chelated NTA molecule, with varying pH. The pH is selected to allow 
protonation of the pyrrole NH in order to weaken the interaction between the histidine tag 
and the Ni-NTA. (A) shows binding when the pH is 7.4 : above the pKa of the pyrrole NH 
(pKa 6.04). Lowering the pH (below 6.04) results in protonation of the histidine residues, 
the lower the pH – the more residues will be protonated, as observed in B and C. 
Free, unbound histidine has three pKa values which correspond to the carboxylic 
acid (pKa1 1.82), the pyrrole NH (pKa2 6.04), and the ammonium NH (pKa3 9.17). As 
it is the pyrrole nitrogen which binds the divalent metal atom, it is pKa2 that the pH 
is varied around. At a pH 7.4, almost all of the histidine residues will be uncharged 
and able to interact with the divalent nickel atom (figure 7.6A). Reducing the pH to 
5.9 results in approximately half of the residues having a positive charge, which 
weakens the interaction between the tag and the nickel atom considerably, but is 
enough to remain attached while non-specific binding artefacts will detach from the 
solid matrix and rejoin the mobile phase (figure 7.6B). At pH 4.5 effectively all of the 
histidine residues will be positively charged, and the histidine tag no longer interacts 
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with the IMAC matrix (figure 7.6C). The buffers were freshly prepared prior to use 
due to the large pH drift that may occur with 8 M urea. 
With this method, the column is equilibrated with buffer pH 7.4, a wash step with 
buffer pH 5.9, and an elution step at pH 4.5. The resultant fractions were run on 12% 
SDS-PAGE. However, attempts to purify the denatured enzyme with this technique 
were not successful as the rat 11β-HSD1 was found to elute at pH 5.9 alongside other 
contaminating proteins or in the flow-through fractions. It was concluded that Ni2+
 
-
NTA chromatography was not a suitable technique for the purification of denatured 
rat 11β-HSD1, however it was used for the other species’ purification. 
7.2 Purification  
First Step Purification for Mouse and Human 11β-HSD1: Immobilised Metal 
Affinity Chromatography (IMAC) 
All chromatography procedures were carried out using ÄktaTM explorer and FPLCTM 
machinery (GE Healthcare Life Sciences). Murine, human and rat 11β-HSD1 all 
contain an N-terminal hexa-histidine tag, by virtue of the pET28-b expression vector 
encoding a His-tag upstream of the multiple cloning site. Exploiting the affinity of 
the amino acid histidine for divalent metal cations is a classic, efficient and simple 
first step procedure in purification. Several different metal cations are employed in 
IMAC, notably Ni2+, Zn2+ and Co2+.  
Uncharged columns composed of fast-flow (FF) sepharose beads (GE Healthcare) 
were washed with 10 column volumes (C.V) of H2O and charged using 100 mM 
NiSO4 for 3 C.V. The average column volume for the first step procedure (for an 
initial E. coli culture volume of 2 L) was a 1 ml column. Buffers used in this 
purification step were binding buffer (50 mM Tris pH 8.0, 150 mM NaCl, 20 mM 
imidazole, 0.01 % v/v thesit) and elution buffer (50 mM Tris pH 8.0, 150 mM NaCl, 
500 mM imidazole, 0.01 % v/v thesit). Once the column is charged with divalent 
cations, it was washed with 5 C.V of binding buffer and then a ‘ghost run’ 
performed, where the concentration of elution buffer is gradually increased from 0 – 
100 % over a short time period. The column was again washed with binding buffer 
until a steady UV baseline was achieved. The clarified, filtered lysate - filtered under 
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vacuum with 0.22 μm filter paper (Whatman, GE Lifesciences) - was automatically 
applied to the column slowly (0.5 ml / min), followed by a protracted wash step of 25 
C.V. Applying the lysate too quickly results in a lower yield eluted from the column. 
Although recommended flow rates for the FF IMAC 1 ml column can be up to 1 ml / 
min, for the purposes of purification of 11β-HSD1, slower application flow rates 
were found to be optimal. In addition, a lengthy wash step after application of the 
clarified lysate ensured less chaperone proteins were present in the final eluate. To 
elute 11β-HSD1 from the Ni2+ IMAC, the concentration of elution buffer was 
increased step-wise and through a steady gradient. This will elute as many of the 
non-specific binding material to the column as possible, without disturbing the hexa-
histidine – Ni2+ interaction and therefore eluting the protein of interest. At 
approximately 20 – 30 % elution buffer (which corresponds to 100 – 150  mM 
imidazole) 11β-HSD1 was eluted from the column; imidazole replaces the histidines 
bound to the sepharose bead. 
The relevant fractions were pooled (determined by visualisation on 10 – 12 % SDS-
PAGE) and dialysed overnight into dialysis buffer (50 mM Tris, 50 mM NaCl, 0.01 % 
v/v Thesit) using a dialysis membrane (SpectraPor Dialysis Tubing, Spectrum Labs) 




A rapid desalt 26/10 column (GE Healthcare) was employed to quickly and simply 
remove ions and other contaminating chemicals from the protein suspension. A 
volume of 10 ml sample is applied at one time, with one full run taking 
approximately 20 minutes. Dialysis buffer (50 mM Tris, 50 mM NaCl, 0.01 % v/v 
Thesit) was used to equilibrate and elute from the column. A lower salt concentration 
than 50 mM NaCl caused protein precipitation. The relevant fractions were pooled 
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Anion Exchange Chromatography 
This purification step was used only if the fractions from IMAC required further 
purification. Cation exchange (using a 1 ml SP-sepharose chromatography column 
(GE Healthcare)) was attempted and deemed unsuitable for reasons described in 
chapter 2. Anion exchange was selected as the enzyme was stable at higher pH 
values. An anion exchange binding buffer (100 mM Tris pH 9.0, 0.01 % Thesit v/v, 10 
mM NaCl) was used to equilibrate a 1 ml Q-sepharose column (GE Healthcare). 
Samples from IMAC were desalted prior to loading onto the Q-sepharose column to 
eradicate imidazole and other salts which prevent the enzyme binding to Q-
sepharose. Loading was followed by a wash step with low salt (20 mM NaCl). A salt 
gradient of 0 – 500 mM NaCl was used to elute the protein from the column, at 
approximately 75 mM (murine 11β-HSD1) or 100 mM (human 11β-HSD1). Fractions 
were run on 12% SDS-PAGE gels to ascertain which fractions contain 11β-HSD1. 
These fractions were then tested for enzyme activity. 
 
Concentration and Storage of Protein 
Once purified, the protein must be concentrated for crystallization trials. The buffer 
solution is exchanged through dialysis for one with a low Hepes / Tris concentration 
(20 mM), minimal salt (20 mM) and a low volume of detergent. The crystallization 
buffer is 20 mM Tris pH 7.8, 20 mM NaCl, 1 mM EDTA, 1 % glycerol. Alternatively, 
the protein was buffer exchanged into assay buffer (20 mM Tris pH 8.0, 50 mM 
NaCl). Protein samples were concentrated using either one of two methods.  
1. A Vivaspin (Sartorius Stedim Biotech, Germany) concentrator with a 10,000 
MWCO (molecular weight cut-off) which is an ultra-filtration technique. Problems 
arise with protein sticking to the filtration membrane, with subsequent loss of yield. 
To prevent this, the Vivaspin is left on ice after concentration in a centrifuge to allow 
the gentle resuspension of the sample before using a needle and syringe to remove 
the protein sample.   
2. Polyethylene Glycol flakes with a molecular weight of 20,000 daltons (PEG 20K, 
Sigma-Aldrich) were applied to the external side of a dialysis tubing membrane 
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(SpectraPor Dialysis Tubing, Spectrum Labs) which contained the enzyme 
preparation and soaked up liquid which passed through the membrane. 
 
Gel Filtration Chromatography 
Gel Filtration is a technique used to separate proteins on the basis of size and 3-
dimensional shape. Unlike other methods of chromatography, the proteins being 
separated do not bind to the solid phase, but instead are ‘retained’ in the column for 
varying amounts of time dependent on the protein size and the type of matrix used 
in the gel filtration column. For this purpose, a Superdex 200 10/300 column (GE 
Healthcare) was used to separate out the various oligomeric species of human or 
mouse 11β-HSD 1, as the column has a molecular weight separation range of 10 KDa 
to 600,000 KDa and will therefore separate the expected monomeric (31 KDa), 
dimeric (62 KDa) and tetrameric (124 KDa) forms of human 11β-HSD 1. Superdex is 
a composite of dextran and cross-linked agarose with a bead size of approximately 
13 μm. The buffer used was (50 mM Tris pH 8.0, 50 mM NaCl, 0.01 % v/v thesit). 
Runs were carried out with 200 μl of concentrated 11β-HSD1 sample at one time 
(typically 37 mg/ml). Calibration was carried out using the Amersham Biosciences 
Calibration Kit for gel filtration.  
 
MALDI-TOF 
Mass spectrometry was carried out either on full-length protein samples or on gel 
bands excised from SDS-PAGE gels followed by a trypsin digest procedure. For full-
length samples, 1 μl (typically 10 mg /ml protein) was spotted on a gold or stainless 
steel mass spectrometry plate on top of which 1 μl of 20 mg / ml sinapinic acid (3,5-
dimethoxy-4-hydroxycinnamic acid) was applied as a matrix. The protocol for a 
trypsin digest was supplied by Dr. Andy Cronshaw at the University of Edinburgh. 
For peptides the matrix used was 5 mg / ml CHCA (α-cyano-4-hydroxycinnamic 
acid). A Voyager DE-STR MALDI-TOF (Applied Biosystems) instrument was used, 
with analyses carried out on Voyager software. 
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Dynamic Light Scattering 
Assays were carried out in a total volume of 100 μl. For assays with detergent, 1.6 μM 
enzyme and assay buffer (20 mM Tris pH 8.0, 20 mM NaCl) was used. 
 
7.3 Assay methods 
Fluorescence 
Fluorescence assays were carried out on a Molecular Devices SpectraMax M5 
Multimode plate reader instrument using SoftMax Pro v 5.2, Excel and Kaleidagraph 
to analyse the data. The excitation and emission wavelengths were 340 and 458 nm, 
respectively. Conditions were initially optimised and chosen with no more than 20 % 
of substrate conversion. Measurements were carried out in the linear range of 
product formation versus reaction time and enzyme concentration. Where 
applicable, background controls were run alongside reactions each time. For the 
dehydrogenase reactions, the relationship between the increase of fluorescence and 
the rate of NADP+ reduction was initially established by generating a calibration 
curve using freshly prepared solutions of NADPH (Sigma-Aldrich). Samples of 
NADPH were prepared in assay buffer (50 mM Tris pH 7.7, 50 mM NaCl) and sterile 
filtered. The concentrations ranged from 0 to 500 μM although only the lower 
concentration points were necessary. Each concentration point was carried out in 
sextuplicate. The graph is shown in figure 7.7 overleaf. The calibration plot enabled 
the conversion of RFU obtained in activity and inhibitor assays to a concentration of 
NADPH produced in the reaction. 







0 1 104 2 104 3 104 4 104 5 104 6 104
NADPH Calibration Curve
1 - 5 uM NADPH
y = 0.039063x 
R
FU
NADPH, nM  
Figure 7.7: A plot of the Raw Fluorescence Units (RFU) versus the concentration of 
NADPH (nM) in each well, at a wavelength of 458 nm. 
 
Activity Assays 
Dehydrogenase activity assays were carried out immediately following purification 
and identification of fractions containing 11β-HSD1 by SDS-PAGE. A typical assay 
was set-up in a black 96-well microplate (Thermo-Fischer Scientific (Nunc GmbH), 
Germany), where each well contained a total volume of 300 μl. This consisted of 500 
μM NADP, 1 μM 11β-HSD1, 2 μM cortisol (or a set volume of 30 μl with varying 
cortisol concentrations) and topped up with assay buffer (50 mM Tris pH 7.7, 50 mM 
NaCl, sterile filtered). All components except the cortisol were incubated for 15 – 20 
minutes on ice. Prior to aliquoting the reaction mixture into the 96-well plate, cortisol 
was added. This is achieved quickly and efficiently by using a multi-channel pipette 
and troughs for the sample. The 96-well plate was then inserted into the fluorometer 
and read.  
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Active Site Titration 
The specific activity of the dehydrogenase reaction was measured with fixed enzyme 
(10 μg, 3.13 μM), cortisol (50 μM) and NADP (500 μM) concentrations in a 96-well 
black plate with a total reaction volume of 100 μl. This was in the presence of 
increasing concentrations of carbenoxolone (Sigma Aldrich, U.K) at concentrations 
between 1 nM and 200 nM. Data were then fitted by non-linear regression to 
equation 9.2. 
 
Initial Inhibitor Screens with Recombinant Enzyme (Chapter 5) 
 Each inhibitor compound was diluted to 10 mM in DMSO allowing for final 
concentrations of 100 μM and below to be achieved with a final concentration of 1 % 
DMSO per reaction. The initial screens were carried out in a 96-well plate with each 
well containing a different inhibitor at 100 μM; wells were in triplicate. A mastermix 
of the enzyme (10 μg), NADP (final 500 μM) and assay buffer (50 mM Tris pH 8.0, 50 
mM NaCl) was pre-incubated for 20 minutes at room temperature. Substrate was 
added to the mastermix immediately prior to transferring into each well. Controls 
with carbenoxolone (100 μM) and blanks were also run adjacent to inhibitor wells. 
Blanks contained all components excluding enzyme. Reactions were run for a time 
period of 20 minutes at 25o
 
C.  
Inhibitor Assays: Dose-Response Curves (Chapter 5) 
Assays were carried out at room temperature (i.e. ~22oC, set temperature) in an assay 
buffer (50 mM Tris pH 8.0, 50 mM NaCl). A typical reaction was as follows: In each 
well of a black 96-well plate (Nunc) a reaction was set-up with a total volume of 300 
μl. This was composed of: 30 μl of inhibitor (of varying concentrations, in 10 % 
DMSO, which gave a final 1 % DMSO v/v concentration), 30 μl of 5 mM NADP (final 
concentration 500 μM), 30 μl of 2 mM cortisol (final concentration 200 μM) and 20 μg 
of enzyme (60 μl of 160 μg/ml). The enzyme, assay buffer and NADP were incubated 
together at room temperature for 20 minutes prior to adding the substrate, at which 
point the mixture was then immediately transferred into each well. Each well 
contained a different inhibitor or concentration of inhibitor. Each reaction was 
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carried out in triplicate. The reaction was initiated by addition of the mastermix to 
each well, at which point the 96-well plate was placed in the fluorometer 
immediately for detection to begin. Each compound had a blank run carried out, 
with no enzyme. This was to ensure that the compound itself did not fluoresce at the 
particular wavelengths used. The pH of each reaction well was also checked with pH 
paper to ensure the pH remained between pH 7 – 8.  
 
Ki determination 


































1  Eqn 7.1 
Where [E]o and [I]o are the active enzyme and inhibitor concentration, respectively. 
Kiapp is the apparent inhibition binding constant, Vi and Vo are the rates of cortisone 
reduction in the absence or presence of inhibitor, respectively (Morrison, 1969).  
 
SPA 
SPA was carried out with pure recombinant protein (mouse or human) and also with 
mammalian cells; HEK293 cells which were transiently transfected with either 
human 11β-HSD1, mouse 11β-HSD1 or rat 11β-HSD1. Confluent cells were prepared 
by Dr. Karen Sooy or Ms. Margaret Binnie at the Queens Medical Research Institute 
(QMRI) at Edinburgh University. 
Assays were run in a total volume of 100 μl, including 0.5 μg purified enzyme, 10 μl 
diluted compound (with a final 1% DMSO concentration), 10 μl [3H]-cortisone (40 nM 
final), 10 μl NADPH (1 mM final) and 25 μl assay buffer (50 mM Tris pH 8.0, 50 mM 
NaCl) and 25 μl SPA buffer. The assay was initiated by the addition of the enzyme 
(final concentration 20 nM) which had been incubated with cortisone at 37oC prior 
for 10 minutes, followed by 20 minute incubation with NADPH. Assay plates (96-
well) were incubated on an orbital shaker for 1 hour at room temperature. At this 
time, 0.5 μl of 1:50 diluted anti-cortisol antibody (HyTest, Finland) and 5 ml of 15 
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mg/ml SPA beads in 5 ml SPA buffer were prepared. 25 μl of this preparation was 
added to 25 μl of each well solution. Plates were incubated for a further 2 hours at 
room temperature, then a radiometric quantification was carried out using a Perkin 
Elmer TopCount instrument. 
 
Initial Inhibitor Screens: Cell-based Assays 
Cell-based screens were carried out as described for recombinant protein except 
HEK-293 cells transiently transfected with 11β-HSD1 were added to the wells in 
place of recombinant protein. 
 
7.4 Crystallography Methods 
Murine 11β-Hydroxysteroid Dehydrogenase 1 was prepared for crystallography at 
16 mg/ml in a crystal buffer (20 mM Tris pH 7.8, 20 mM NaCl, 1 mM EDTA, 1 % 
glycerol) and taken as 95 % pure from SDS-PAGE densitometric analysis. Human 
11β-HSD1 was concentrated to 24 mg/ml - as determined by a Bradford Protein 
Assay - using a 1 ml or 20 ml Vivaspin concentrator (Sartorius) with a molecular 
weight cut off of 10,000 Daltons. The enzyme was concentrated in a buffer of 500 μM 
NADPH, 0.01 % Thesit, 1 mM EDTA, 50 mM Tris pH 7.7, 50 mM NaCl and 2 % 
glycerol. Both enzymes were assayed prior to crystallisation trials for dehydrogenase 
activity to show that the enzyme was active. In addition, the protein samples were 
centrifuged at 13000 x g, for 5 – 10 minutes at 4oC to remove any dust or precipitated 
protein. 
 
Hanging Drop Method 
For the hanging drop method; a 24 well plate was greased using a 50:50 preparation 
of paraffin wax and petroleum jelly. Into each well, 0.5 – 1.0 ml of the reservoir 
solution was pipetted. A volume of 0.5 – 1 μl of protein sample was pipetted into the 
centre of 22 mm siliconised circular cover slips, and immediately 0.5 – 1.0 μl of 
reservoir solution pipetted into the protein drop. A ratio of 1:1 resevoir to protein 
was used unless otherwise stated. The drop was not mixed and the coverslip was 
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immediately inverted over the well containing the corresponding reservoir solution 
and twisted 45o to ensure a good seal. The crystal trays were then incubated at 17oC.  
 
Crystal Freezing 
Crystals of mouse 11β-HSD1 were frozen in liquid N2 with a solution of the mother 
liquor and increasing amounts of glycerol (v/v) ranging from 5 – 40 %, prior to being 
mounted and screened.  
 
Crystal Seeding 
Micro-crystals were crushed gently before being removed from the original drop and 
diluted significantly. This prevented too many crystal seeds from being added to a 
fresh drop. To a fresh protein-crystallisation trial, 1 μl of the diluted seeding sample 
was added.  
 
11β-HSD1 Crystallography Screens using a Crystallography Robot 
A multi-channel pipette was used to transfer the crystal screen (Emerald Biosystems) 
from the 96-well plate into the 96-well microplate for robotic crystallography trials. 
The crystal screens used were diluted 1:1 with ddH2O. Once complete, these were 
inserted into the crystal robot (Oryx-8, Douglas Instruments) set-up, and the 
manufacturer’s instructions followed. Drops were 0.1 μl protein, 0.1 μl reservoir. The 
plates were then sealed with crystal tape (Crystal Clear, Manco Inc., Ohio). 
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APPENDIX 
8.1 Additional Information 
Alternative names: HDL; 11-DH; HSD11; HSD11B; HSD11L; SDR26C1; 
MGC13539; 11-beta-HSD1; HSD11B1 
EC number: 1.1.1.146 
 
Table 8.1: Additional information for 11β-HSD1 
 
 Human type 1 Human type 2* Mouse Rat 
RefSeq RNA NM_005525 NM_000196 NM_008288 NM_017080 
RefSeq Protein NP_005516 NP_000187 NP_032314 NP_058776 
 
Table 8.2: Sequence information for human, mouse and rat 11β-HSD1 and human 11β-HSD2. 
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8.2 Gel Filtration: Calibration Charts (Chapter 2) 
The Superdex 200 10/30 column (GE Healthcare) was calibrated prior to use using a set 
of proteins with a known molecular weight, oligomeric state and a regular spherical 3-D 
structure. From the elution volumes of this known set of proteins, the size of the test 
protein may be estimated. The kits for calibration are supplied by GE Healthcare Life 
sciences. The calibration proteins are shown in table 8.3. 
 
Protein: Size (KDa) : 







Ribonuclease I 13.7 
 
Table 8.3: Molecular weights of calibration proteins for gel filtration chromatography. 
 
These calibration proteins were run over the Superdex 200 according to the 
manufacturer’s instructions (figure 8.1). The KAV (the diffusion co-efficient) was 








)(           Eqn 8.1 
Where KAV is the diffusion coefficient, Ve is the elution volume of the peak of interest, Vo 
is the void volume and Vt is the total column volume. The KAV values were then plotted 
against the Log molecular weight to produce the calibration plot in figure 8.2. This 
allows an accurate estimation of protein molecular weight from a gel filtration column. 
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Calibration Curve for Superdex 200 10/300




Figure 8.2: A plot of KAV versus Log molecular weight (MW) for proteins eluted from the 
Superdex 200 10/300, prepared in Kaleidagraph. 
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From this calibration curve, it was possible to determine the approximate sizes of the 
eluted 11β-HSD1.  
 
8.3 Trypsin Digest MALDI-TOF Results 
A tryptic digest on mouse, rat and human 11β-HSD1 was carried out following the 
protocol provided by Dr. Andy Cronshaw. The results of the mouse digest are shown 
here in figure 8.3. Each peak represents a particular peptide mass from digested 11β-
HSD1. This technique was carried out to validate the identity of the protein. The 
combination of peptides obtained, known as a protein fingerprint, will be unique for 
each protein, allowing an accurate identification to be made. The results from the mass 
spectrometer were then fed into the search engine MS-Fit, which searched through the 
unique fingerprints of several million proteins and quickly finds a match in the 
SwissProt database (expasy.ch/sprot/). The top matches are shown overleaf. 
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Figure 8.3: Trypsin digest fingerprint of murine 11β-HSD1. The results from the database 
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8.4 Candidate Ligands for the Inhibition of 11β-HSD1 
The following tables show all 60 compounds which were initially selected as candidate 
inhibitors of 11β-HSD1. Eight of these candidate compounds were selected manually, 
and are labeled as such in the tables. The remaining 52 compounds were discovered 
through the use of virtual screening with UFSRAT. The compounds are binned into 6 
structural classes;  
1. Ureas (table 8.5) 
2. Tetrazines and Triazoles (table 8.6) 
3. Thiols (table 8.7) 
4. Benzamides and amides (table 8.8) 
5. Cycloheptanones, cyclohexanones and keto-groups (table 8.9 and 8.10) 
 
8.4.1 Ureas 
Table 8.5 (on next page): Clustering of urea–type compounds (N-(C=O)-NH) from VS. The 
table describes the molecular weight, solubility in water (MLogP), Supplier and the query 
molecule it was generated from. An asterisk denotes the compound was selected and available 




















MLogP Supplier Query Molecule 
 
27* 204.1 1.82 ChemBridge 2-
anilinothiazolone 
 
28* 246.1 3 ChemBridge 2-
anilinothiazolone 
 
29* 232.3 2.1 ChemBridge 2-anilinothiazolone 
 





31* 234.3 0.875 ChemBridge 2-
anilinothiazolone 
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2D Structure # 
M.W 
(g/mol) MLogP Supplier Query Molecule 
 










38 250.4 0.335 Maybridge 2-
anilinothiazolone 
 







44 231.2 0.199 TimTec 2-
anilinothiazolone 
 




53* 222.3 1.5 Specs Manually 
Selected 
 
55* 303.4 5.2 TimTec Manually Selected 
 
59* 304.4 1.6 Specs Manually Selected 
 
60* 302.4 1.6 Specs Manually 
Selected 
Table 8.5 continued from previous page. 
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8.4.2 Tetrazines and Triazoles 
Table 8.6 (continued on next page): Clustering of compounds with a tetrazine or triazole ring 
(with or without a thiol group) from VS. Table describes the molecular weight, solubility in 
water (MLogP), Supplier and the query molecule it was generated from. An asterisk denotes 
the compound was selected and available for further analysis. 
 
2D Structure # M.W 
(g/mol) 
MLogP Supplier Query 
Molecule 
 
7* 386.4 2.21 InterBioScreen CBX 
 
9 385.4 2.62 Ambinter CBX 
 
10* 371.4 1.56 InterBioScreen CBX 
 
11 354.4 2.44 Asinex CBX 
 
12* 425.5 2.65 InterBioScreen CBX 
 
13* 395.4 3.17 InterBioScreen CBX 
 
14 382.4 1.94 Asinex CBX 








15 352.3 2.45 Asinex CBX 
 
16* 395.4 3.18 InterBioScreen CBX 
 
19 386.4 2.44 Asinex CBX 
 
20 370.4 3.02 Asinex CBX 
 
23* 423.4 3.39 InterBioScreen CBX 
 
24 395.4 3.17 InterChim CBX 
 
25 369.4 3.19 Enamine CBX 
Table 8.6 continued from previous page. 
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8.4.3 Thioethers 
Table 8.7: Loose clustering of compounds containing a thioether (R-(C=O)-S) group (but no 
tetrazole or triazole) from VS. Table describes the molecular weight, solubility in water 
(MLogP), Supplier and the query molecule it was generated from. An asterisk denotes the 
compound was selected and available for further analysis. 
 
2D Structure # M.W 
(g/mol) 
MLogP Supplier Query 
Molecule 
 
4 420.5 2.15 ChemBridge CBX 
 
5* 420.5 2.15 Specs CBX 
 
6 396.5 2.16 TimTec CBX 
 
8 361.5 1.94 Enamine CBX 
 
21* 330.4 1.07 ChemBridge CBX 
 
22* 358.4 1.55 InterBioScreen CBX 
 
26 358.4 1.55 TimTec CBX 
 
54* 356.4 5.4 TimTec Manually 
Selected 








56* 259.3 3 TimTec Manually Selected 
 
57* 269.3 3.7 TimTec Manually Selected 
Table 8.7 continued from previous page. 
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8.4.4 Benzamides and Amides 
Table 8.8 (continued on next page): Loose cluster of amide- or benzamide containing 
compounds from VS. Description of molecular weight, solubility in water (MLogP), supplier 
and the query molecule are shown. An asterisk denotes the compound was selected and 
available for further analysis. 
 
2D Structure # M.W 
(g/mol) 
MLogP Supplier Query Molecule 
 
40 292.4 3.91 InterBioScreen 2-anilinothiazolone 
 







42 261.3 2.85 Asinex 2-
anilinothiazolone 
 
43 260.3 3.05 Sigma Aldrich 2-
anilinothiazolone 
 
46* 345.3 3.01 InterBioScreen Adamantane 
 
47* 277.3 2.38 TimTec Adamantane 
 
48 286.3 3.06 Enamine Adamantane 
 
49* 262.3 1.16 Sigma Aldrich Adamantane 




(g/mol) MLogP Supplier Query Molecule 
 
50 286.2 2.22 Sigma Aldrich Adamantane 
 
51 358.4 -0.042 TimTec Adamantane 
 
52 278.3 0.616 Chembridge Adamantane 
 
58* 327.4 3.5 TimTec Manually 
Selected 
Table 8.8 continued from previous page. 
 
- 249 - 
8.4.6 Cycloheptanones, cyclohexanones and keto groups 
Table 8.9: Clustering of cycloheptanone / cyclohexanone / central ketone containing 
compounds from VS. Table describes the molecular weight, solubility in water (MLogP), 
Supplier and the query molecule it was generated from. An asterisk denotes the compound 
was selected and available for further analysis. 
 
2D Structure # M.W 
(g/mol) 
MLogP Supplier Query 
Molecule 
 
1 408.5 3.05 Sigma Aldrich CBX 
 
2* 394.5 2.84 Sigma Aldrich CBX 
 
3* 354.4 2.59 ChemBridge CBX 
 
18* 413.8 1.75 Specs CBX 
 
And one sulfonyl compound: 
 
2D Structure # M.W 
(g/mol) 
MLogP Supplier Query 
Molecule 
 
17 346.4 1.32 Ambinter CBX 
 
Table 8.10: One sulfonyl group was selected as a potential ligand for 11β-HSD1, shown here, 
with the molecular weight, solubility in water (MLogP), Supplier and the query molecule it 
was generated from. This compound was not selected for further analysis. 
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